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Introduction
Nearly one million babies have been born worldwide as the
result of assisted reproductive techniques (ART) since the
birth of the first baby conceived using in vitro fertilisation
(IVF) techniques in 1978.1
Infertility is regarded as a health problem2 and affects
approximately every 6th couple in the Western countries.
It is not, however, regarded as a public health issue in every
country.3 The number of infertile couples is increasing, not
least because of advanced maternal age. Also, the quality of
gametes has deteriorated, for instance, owing to lifestyle
habits and environmental factors.
The goal of infertility services (counselling, diagnostics,
treatments) is to help people with fertility problems or
genetic conditions by finding solutions to their reproduc-
tive plans, for example, by ART, which is now important
also for normally fertile couples whose children might
inherit a serious genetic disease or even for those who wish
to save a sibling’s life. Counselling is an essential part of all
the treatments.
Genetic causes have a considerable involvement in
infertility. Well-known examples are some chromosomal
translocations or sex-chromosomal abnormalities and Y-
chromosome deletions. Advanced maternal age has in-
creased sporadic chromosomal anomalies with conception.
Many of the reasons and their nature are, nevertheless, this
far unknown. Genetic conditions may be transmitted to
the offspring and hence create transgenerational infertility
or other serious health problems. The use of donated
gametes and embryos needs attention with respect of what
genetic tests should be performed before their use.
Preimplantation genetic diagnosis (PGD), in most cases
an analysis of the one or two biopsied cells of a 3-day-old
embryo, was developed in 19894 in an effort to avoid the
transfer of affected embryos from couples who carried
serious genetic disorders, such as haemophilia, cystic
fibrosis (CF) or chromosomal abnormalities. Using PGD,
unaffected embryos only can be selected for transfer before
pregnancy starts and thus the need for a selective abortion
after prenatal diagnosis (PND) can be avoided.5
There seems to be a general consensus among profes-
sionals that the use of PGD is acceptable for medical
indications if a high risk of a serious genetic disorder exists.
However, PGD has been used not only to diagnose and
avoid genetic disorders but also to select for certain
characteristics, such as matching tissue type to an existing
sibling for therapeutic purpose. In addition, the demands
to use PGD for fully nonmedical purposes are increasing
(ie, sex selection of embryos solely for social or cultural
reasons6). This extended use of PGD is controversial.
Preimplantation genetic screening (PGS), previously also
called ‘aneuploidy screening’, ‘low-risk PGD’ or ‘PGD-AS’,
is performed for different indications than PGD by using
different methods. PGS is carried out for infertile couples
undergoing IVF in order to restrict from transfer those
embryos clearly having numerical chromosomal abnorm-
ality, with a hope that it will improve poor pregnancy
outcomes. Although the use of PGS is steadily increasing,7
the importance and place of this technique is still being
debated.8,9 This discussion is particularly relevant where
this genetic method is applied at IVF clinics without the
necessary genetic expertise.
PGD and PGS are still rather rare procedures owing to
high technical demands, costs, relatively low pregnancy
rates and strict licensing procedures in many countries.
Very few studies have performed an integrated analysis of
technological, patient-related, ethical and economic as-
pects of PGD and PGS10.
In contrast to these hopeful improvements, there are a
number of reports on adverse outcomes in children born as
the result of ART. Numerically, multiple gestations are
clearly the major risk to the future child’s health.11 There is
also a growing concern for structural anomalies and long-
term health effects (eg, Bonduelle et al,12 Hansen et al13 and
Klemetti et al14). Several studies on the safety of the
techniques have been published, but they have been short
term or too small to give any certainty. However, large
reviews of these studies suggest a slightly elevated risk of
birth defects in children born following ART (eg, Hampton,
2004).15 Whether this is related to the ART procedure as
such, or the ‘disease of infertility’, is not known.16 Many of
the new ART techniques, such as biopsy in PGD and PGS
and microinjection in intracytoplasmic sperm injection
(ICSI) as well as culture media, are feared to be detrimental
for the embryo development.
The ART-related legal and ethical issues have been
debated at many levels both nationally and internation-
ally. The attitudes towards ART, PGD and PGS vary
substantially not only in different parts of the world but
also within Europe, owing to scientific, cultural and
religious differences. Some techniques are wholly or partly
prohibited by law or access to them is limited to married
couples or only for specific medical indications. However,
as infertility does not respect cultural or religious bound-
aries, where necessary, couples seek medical fertility
treatments outside their own countries. Similarly, couples
whose children are at risk of inheriting some severe genetic
disease might go to a country where PGD is allowed.
Additionally, crossborder transfer of gametes might be
needed when treating couples from different ethnic back-
ground, and appropriate gametes cannot be found in the
treating country. All this demands wider perspective when
considering regulation and guidelines.
Several of the existing or possible applications of ART, in
particular PGD, are at the interface between reproductive
medicine and clinical genetics. As ART was originally used
to improve infertility treatments, it is now becoming used
for genetic reasons. The development of reproductive
sciences and genetics has given a new dimension to ART:
as aptly stated in a United Nations Educational, Scientific
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and Cultural Organisation’s (UNESCO) report on PGD and
Germ-Line Intervention of 2003, ‘IVF aims at having a
child, PGD aims at having a healthy child and PGD/human
leukocyte antigen (HLA) testing aims at having a healthy
and helpful child’.
The Public and Professional Policy Committee (PPPC) of
the European Society of Human Genetics (ESHG) found it
necessary to create professional recommendations on how
to use IVF techniques safely and reliably from the genetic
point of view. It also held important to issue guidelines on
acceptable (genetic) goals of IVF treatment and on how
these expensive treatments should be prioritised in the
European healthcare systems.
Accordingly, the purpose of the present paper was to
outline a framework for development of guidelines for the
interface between genetics and ART.
Methodology
The approach to the topic needed collaboration with other
groups involved, especially infertility and reproductive
genetics professionals of the European Society of Human
Reproduction and Embryology (ESHRE). In addition,
collaboration with the Institute for Prospective Technolo-
gical Studies (IPTS), one of the seven scientific institutes of
the European Commission’s Joint Research Centre (JRC),
was considered as essential, because its mission is to
provide European policy makers with technoeconomic
analysis to support the policy-making process.
The method used in creating this background document
was at first to examine relevant articles and literature and to
collect existing laws, practices and professional guidelines
mainly from the European countries. The legal framework
is presented in Appendix A. These documents were
submitted for consultation to approximately 150 high-level
experts, such as gynaecologists; geneticists; representatives
of patients’ organisations for infertile couples and heredi-
tary diseases; as well as to psychologists, ethicists, lawyers,
health politicians, social scientists and others.
A group of 50 experts representing the aforementioned
different disciplines were later invited to Sevilla on March
31–April 1, 2005 to discuss the issue further. The results of
the Sevilla workshops have been adapted to this document.
PPPC drafted the recommendations in collaboration
with ESHRE and submitted them for acceptance by ESHG
and ESHRE. The aim was to reach recommendations that
both ESHG and ESHRE could adapt and convey to the
professional societies. The recommendations will be pub-
lished in European Journal of Human Genetics and in
Human Reproduction.
Goals of services
Possible applications of ART
Fertility treatment aims at achieving a successful preg-
nancy (¼ live birth of one healthy child) in the most
natural way possible.17 Infertility has been described as ‘a
failure to conceive after at least one year of unprotected
coitus’.18 The definition of the concepts of infertility,
subfertility and sterility has however raised discussion.
Subfertility means in general decreased fertility, whereas
sterility means total infertility. The European Classification
of Infertility Taskforce (ECIT) has been formed by ESHRE to
develop a set of infertility-related codes (descriptions,
interventions and outcomes) appropriate for computerisa-
tion (http://www.ecit.info).
ART is used also when a naturally conceived pregnancy
might carry serious risks to the offspring. Factors critical to
the success of the treatment are maternal age, embryo
quality and number of embryos transferred. The older the
woman, the lower is the success rate, the riskier is the
pregnancy for both mother and child and the more likely
the embryos are to contain sporadic chromosome anoma-
lies.
ART is applied to a variety of indications, most but not
all of which are medical. These indications can be divided
into the following categories, which, however, are partly
overlapping:
Non-genetic or multifactorial medical causes:
 genital, or genital tract anomalies,
 sequelae after previous diseases, traumas or operations,
 toxic agents (chemotherapy, environmental toxins,
several pharmaceuticals),
 infections,
 endometriosis, varicocele, etc
 endocrine/hormonal causes,
 sexual dysfunction (vaginismus, anejaculation. etc).
Genetic causes:
 monogenic causes of infertility,
 chromosomal causes (including Y-deletions),
 risk of conveying a genetic disease to a child.
Other reasons:
 premature menopause or postmenopause,
 same-sex couples,
 single females,
 treatment of a sibling (HLA matching),
 HIV discordant couples,
 therapeutic cloning.
Some of the above applications are nonmedical and/or
controversial and may not be acceptable to all. However,
most of them have already been applied.
IVF clinics and collaboration with genetic clinics
Reproductive medicine and genetics have long been over-
seen separately and with very different degrees of care.19
While the need for genetic services is increasing at IVF
clinics, they are not always appropriately provided.
Family history may indicate a presence of a genetic
condition underlying infertility and therefore careful
Assisted reproductive technologies and genetics
S Soini et al
590
European Journal of Human Genetics
family history should be collected routinely.20 – 22 The
potential transmission of a genetic disorder to their
offspring is a major problem for many at-risk couples
when planning a pregnancy. Therefore, some fertile
couples seek IVF treatments in order to avail themselves
of PGD, for instance, if they regard termination of
pregnancy after implantation as ethically unacceptable.
However, the use and interpretation of genetic tests
demand expertise and special counselling skills (see below
on Counselling), because the results of genetic tests may
have serious implications for an individual and his/her
family members.
For this reason, ART requires a multidisciplinary team-
work and adequate training of all the professionals
involved. Although professionals in genetics have the best
qualifications for specific genetic counselling of the
couples, also gynaecologists have a duty to give counsel-
ling on the possible genetic consequences of ordinary ART
techniques, PGS and other relevant issues in case the
problem of the couple is infertility without any known
genetic indications or consequences.
A European multicentre survey of 20 centres revealed
that although many of the activities (IVF, embryo culture
and biopsy) take place in IVF units, others (counselling and
diagnosis) are at the responsibility of genetic diagnostic
centres: in the PGS procedure, the intake of the patients
happened predominantly via an IVF unit, whereas for PGD,
the patients were often referred via a genetic clinic.
According to the survey, the number of monogenic
diseases for which PGD was offered varied considerably.
In comparison to PND, PGD appeared to be much more
expensive.23 For the latest figures, see.7
The ESHRE PGD Consortium was established in 1997 to
survey the practice of PGD worldwide. Since then, it has
published four reports that give an overview on PGD from
European centres as well as centres in the US, Asia,
Australia and Israel. It will continue this work and in the
future focus on centres that take care of the complete PGD
cycle. According to the latest report, new indications in
PGD and PGS appear with every new report. Noteworthy is
the increasing number of PGS cycles performed for male
indications and for previous aneuploid pregnancies. The
overall pregnancy rate (positive heart beat) per oocyte
retrieval was 16%. This relatively low pregnancy rate was
anticipated most likely to be a result of the low proportion
of embryos suitable for transfer.7 Theoretically, it could also
be owing to possible embryo damage from the procedure.
Only large PGD centres have enough time and resources
to research and develop the tests needed for PGD,24 as it is
very time-consuming (several weeks or months for each
disease) at the single-cell level. Depending on the nature of
responsible mutations, many genetic diagnoses that may
be available at standard conditions cannot be reproduced
at a single-cell level through the available technologies
either.
Licenses and surveillance
In general, all medical professionals work under specific
license and overseeing provisions. According to the Inter-
national Federation of Fertility Societies (IFFS) Surveillance
04, many countries have set up standards for ART clinics
and perform surveillance by requiring periodic reports
from clinics in order to obtain or maintain a licence.25
These procedures are stipulated either by laws or govern-
mental guidelines usually involving a licensing body. In
some countries, different clinics have different levels of
licences depending on the complexity of the techniques
used and the disorders being tested.
Informed consent
All medical interventions and counselling should be
voluntary, and require the informed consent of the
patients and donors. Information provision and consent
procedures that enable applicants to make informed
choices are crucial components of assisted reproduction
services. It is important to discern the information compo-
nent and the consent component of informed consent.26,27
It is especially important when genetic tests are recom-
mended, because they may have far-reaching repercussions
for the patients, and sometimes for immediate and
extended family, and because some uncertainty about the
results still exist.28
Information provision means that the patient under-
stands the risks, discomforts and benefits of the procedure
to be performed and is aware of various alternatives,
including the alternative of not performing the proce-
dure.29 There is a need to present accurate data of the risks
involved, without which the consent may be invalid.
Accumulated data increasingly suggest an elevated risk of
birth defects after ART (see below). Even where the data are
still uncertain, possible risks of ART should thus be
addressed when obtaining an informed consent before
starting treatment.30 – 34
However, patients seem to interpret the information
given within a personal frame of reference and recall it
selectively.35 Medical professionals are therefore suggested
to evaluate patients’ understanding, for instance, by asking
them to describe the procedure, its purpose, and its risks
and discomforts in their own words.29
The demand for informed consent and its contents is
generally valued and expressly stated in most laws, even
though it has been reported of some practical variations in
Europe.23 Several professional and institutional organisa-
tions provide guidance on this issue.
Genetic studies of IVF couples
Need for genetic testing
The reasons behind infertility are manifold, and often
remain unsolved. There are no general guidelines to what
extent the causes of infertility should be sought and
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practices vary. Sometimes the cause is not found owing to
inadequate diagnostic procedures. Testing will, however,
often help with the diagnosis, will give information for the
treatment and evaluation of the risks to the offspring and,
moreover, will enable informed decision-making.
In the absence of general practice guidelines, clinics
apply different methods and policies. ESHRE has addressed
the issue of ‘optimal use of infertility diagnostic test and
treatments’ in the Capri workshop.20 The Italian commu-
nity of professionals, supported by some international
societies, has created guidelines for the appropriate use of
genetic tests in infertile couples in 2002.36 European
Molecular Genetics Quality Network (EMQN) has provided
elaborated, disease-specific guidelines (www.emgn.org).
It might be considered advantageous to be able to
perform genetic counselling and offer a selection of genetic
tests before all IVF treatments, because many genetic
causes of infertility still remain unrecognised. In practice,
however, providing genetic services in each case is
unrealistic, although improvement in this field is needed
in any case. As a compromise, it has been recommended to
solve reproductive, medical and family history always
before initiating the treatments (K Aittoma¨ki, 2005,
personal communication) and to perform genetic investi-
gations, chromosome and gene analysis in selected cases.
In the case of a family history of a severe (hereditary)
disease, but where the couple does not want to use PGD,
genetic counselling should be offered before any type of
ART, and especially before the use of donor gametes.
Patients should be told that despite the testing procedures,
absolutely safe germ cells do not exist, whether from a
donor or a partner, as only a limited number of hereditary
diseases can be detected and other factors also may affect
the outcome.
Genetic diagnosis of male infertility
Approximately 15–20% of Western males are affected by
infertility. Although some reasons can be diagnosed, often
no clear cause can be found, and the condition is labelled as
‘idiopathic infertility’. The most likely explanation for this is
our poor understanding of the basic mechanisms regulating
the genetic networks causing human infertility.37
In men presenting with defects in sperm, only karyotype
and Y-chromosome microdeletion analyses are usually
being performed, which will not reveal the majority of
genetic abnormalities.38,39 Additionally CF transmembrane
conductance regulator (CFTR) mutations in cases of
congenital bilateral or unilateral absence of vas deferens
(CBAVD, CUABV) are often tested. By these analyses, it is
possible to identify a genetic cause of severe male infertility
in 10–20% of cases.36,40
Karyotype analysis and Y-chromosome microdeletion
screening have been recommended to be performed in
men with nonobstructive azoospermia, because as many as
10–15% of these patients have an identifiable abnorm-
ality.39,41,42 Aittoma¨ki et al22 suggest that these tests should
also be carried out in men with oligozoospermia below
5106/ml. Although it has been suggested that karyotype
analysis should, before ART, be performed even in
normozoospermic men, because some aberrations (such
as 47,XYY) can be found,36 this is not a general recom-
mendation. Y-deletions are very rarely found in men with a
sperm count above 5106/ml, but below this count, the
deletions are found in 8.2% of men.43 The deletions arise
usually de novo, but are transmitted to all male offspring in
ICSI.22
New findings have shown that not every steroid
sulphatase (STS) deletion in Y-chromosome causes male
infertility.37 The existence of a spermatogenesis-controlling
factor(s), called azoospermia factor (AZF), in the long arm
of the Y-chromosome was first based on identification of
large deletions of this chromosomal area in azoospermic or
oligozoospermic men.44 Later microdeletions (Yq) were
found to be another common cause of male infertility36
and might result in azoospermia or severe oligozoospermia.
At present, it is known that AZFa, AZFb and AZFc deletions
are caused by intrachromosomal recombination events
between large homologous repetitive sequences blocks
located in Yq11, AZFc being recognised as the most
frequently known genetic lesion causing male infertility.45
Owing to a possibility of three microdeletions intervals
with ‘complete’ or ‘partial’ appearance, an estimation of
the extension of male’s AZF deletion is recommended to be
confirmed by investigating testicular pathology, because
only complete AZFa and AZFb deletions are associated with
a specific testicular pathology, whereas partial AZFc dele-
tions may have no impact on male infertility.37
The most common chromosomal aberrations associated
especially with severe oligo- and azoospermia are sex
chromosome aneuploidies and chromosomal transloca-
tions.46 Consequently, occurrence of aneuploid embryos
will lower the success rate of the IVF treatment, and
offspring have a risk of an unbalanced translocation or an
aneuploidy.47 – 49 PGS may be useful for some of these
couples in making the IVF treatment more successful by
choosing the embryos with the best possible developmen-
tal potential.22 In aneuploidy of the sex chromosomes or
Klinefelter syndrome (KS), there are few, if any, spermato-
zoa in the ejaculate. Couples must either be treated
following testicular sperm retrieval (if successful) com-
bined with ICSI or use donor sperm to have children. In
general, men with KS produce a higher number of sperm
with aneuploidy, particularly of sex chromosomes, with
respect to normozoospermic fertile controls and nonge-
netic idiopathic severely oligozoospermic men. The total
amount of aneuploid sperm has been recently quantified as
20%. Men with mosaic KS produce about 5% of aneuploid
sperm.50 Testicular sperm can be found in almost one-half
of the patients with even nonmosaic KS, and most have
normal karyotypes.51 Various mosaic karyotypes may cause
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oligozoospermia and can also be treated with IVF using
ICSI.5
As has been shown by fluorescence in situ hybridisation
(FISH) analysis, men with a normal lymphocyte karyotype
may still have aneuploidy in their spermatozoa.52 – 54 The
frequency of chromosomal abnormalities in spermatozoa
of chromosomally normal men is about 10% (involving 7%
of structural aberrations and 3% of aneuploidies). The FISH
analysis of sperm from infertile men provides essential data
on the chromosomal status of sperm before use in IVF and
ICSI. When immature sperm retrieved by TESE (testicular
sperm extraction) is used, chromosome anomalies in the
embryos are more common than when using ejaculated
sperm.55 World Health Organisation (WHO) recommends
that methods need to be developed to detect aneuploid
spermatozoa so that they can be excluded from sperm
preparations used for ICSI.18
Congenital bilateral absence of the vas deferens (CBAVD)
is a form of infertility with autosomal recessive genetic
background in otherwise healthy males.56 The most
common cause is CFTR gene mutations. Striking genotype
differences are observed in CF and in CBAVD.56 The
majority of males with CF have obstructive azoospermia
owing to CBAVD.57 CBAVD or CUAVD may also occur as
the only manifestation of CF.58,59 This occurs as a result of
a combination of a common or severe CF mutation with a
mild CF mutation or with a specific intronic variant. As
genetic testing is not able to identify all causative
mutations, it follows that a negative test does not exclude
the existence of an unknown mutation. However, when a
patient tests positive, that is, has CBAVD owing to CFTR
mutations, there is a risk of both male and female offspring
to have CF and for male offspring to have CBAVD. The risk
for the offspring depends on whether or not the spouse is a
carrier, since one mutated allele will always be inherited
from the affected male.22
Even with the current state of knowledge, counselling of
the couples with CBAVD remains very difficult.56 The
genetics of CBAVD is more complex than in CF, as (i)
genetic analysis is able to prove but not to exclude the
diagnosis of a genital form of CF, and (ii) the risk of CF or
CBAVD in the offspring may be unpredictable when rare
mutations are identified in the male or the female (see
Claustres56 for thorough analysis and risk calculations).
The importance of screening for kidney abnormalities in
males with CBAVD has been pointed out, as unilateral
renal agenesis is sometimes associated with CBAVD (in the
absence of CFTR mutations) and renal malformations of
varying severity might be transmitted to the offspring.60 – 62
Screening for androgen receptor gene mutations in
azoospermic and severely oligozoospermic men is still
debatable, given the quite low frequency (about 2%) of
mutations found in these patients.36,40
As is known since 1983, males with a normal karyotype
may show synaptic anomalies that usually cause chromo-
somally abnormal sperm. These are detectable only
through the study of meiosis in testicular biopsies. It has
been suggested that meiotic studies should be used more
often in the study of infertile males.63 Synaptic defects are
especially frequent in males with a severe oligozoospermia,
or with previous IVF failures, even if normozoospermic. In
Spain, meiotic studies in testicular biopsies are included in
the protocol of study of infertile males.64
PGD has been regarded as useful for couples whose
infertility is owing to some male factors, such as meiotic
anomalies65 or CF and CBAVD.
A British article highlights the need for formal training
in andrology among those clinicians who are managing
infertility in the male, because infertility appears to be
treated mainly by gynaecologists who have often had no
teaching in the subject of andrology.66
The practice of chromosomal testing in connection with
ART varies between countries. To mention some practices,
in Norway, for instance, chromosomal analysis before ICSI
is offered to all couples, in Sweden, only to men with
nonobstructive oligo- or azoospermia, and in Finland, the
testing is offered to men with nonobstructive oligo- or
azoospermia and to their spouses.22 In case of agenesis of
the vas deferens, mutations in the CFTR gene are generally
studied, in both spouses when needed, to avoid transmit-
ting CF to the offspring.67 Some centres in Italy offer sperm
aneuploidy evaluation with FISH in patients with repeated
implantation failure and recurrent abortion, but this
application is still held as experimental.68
To summarise, special consideration is needed when
treating infertile men, since infertility may be caused by
abnormalities that may cause infertility and/or potential
serious diseases to the offspring.36,40,69 Counselling and
more thorough genetic testing should be carried out before
any ART treatments, to inform patients of the risks and to
find appropriate treatment in each case.
Genetic causes of female infertility
Also, a number of causes behind female infertility may lie
in chromosomal aberrations and gene mutations. The
possibility of single or multiple gene defects in common
clinical conditions, such as polycystic ovarian syndrome,
or premature ovarian failure, has been described. In case of
female infertility, several tests during the diagnostic work-
up can be relevant before ART, such as karyotype analysis,
CFTR gene and fragile-X.36 In addition, other genetic
causes like mutations in LH and FSH receptor genes as well
as structural abnormalities of the female genital organs
may cause female infertility. Repeated early miscarriages
owing to a balanced translocation, either in the female or
the male, may be connected to infertility. Often, the
treatment is based on donated oocytes or embryos and the
genetic risks thus need not to be considered. However, in
case of a congenital malformation with a very abnormal or
missing uterus, the only treatment might be ART with the
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female’s own oocytes and a surrogate mother. In such a
situation, there could be possible genetic risk of inheriting
female infertility. Nevertheless, no case has been shown
among the children born, though.
Indications set by American Society for Reproductive
Medicine (ASRM) for considering the use of donor oocytes
include women with hypergonadotropic hypogonadism
(premature ovarian failure); women with advanced mater-
nal age; women who have a diminished ovarian reserve;
women who are known to be affected by or are carrier of
significant defects or have a particular family history;
women with poor oocyte; and/or embryo quality or multi-
ple failures during prior attempts to conceive via ART.70
Tests to be carried out for couples who receive donated
gametes or embryos
ASRM’s guidelines on evaluation of oocyte recipients
include obtaining medical and reproductive history, phy-
sical examination, laboratory tests, psychological evalua-
tion and assessment of the uterine cavity. Also the partner
should undergo several tests and an evaluation process.70
General guidelines would also be needed in Europe, even
though some clinics follow the ASRM’s guidelines and a
few countries have their own.71 For instance, testing the
male partner (or sperm donor) for carrier status of some
relatively common autosomal recessive diseases in the
population concerned could be required to minimise the
risk of such diseases in the offspring.
Is success rate an issue?
It has been claimed that the practice of publishing success
rates of identified clinics has impacted on the range and
availability of treatments.3 It may also have undesirable
impact on the methods used, and, for instance, result in
multiple pregnancies. Presenting success rates to the public
requires responsibility and generally accepted standards to
avoid unjustified expectations and comparisons between
centres.
Some indications of infertility include an extremely low
success rate of pregnancy. Therefore, the patients may be
selected on the basis of potential success rate. Moreover,
embryo biopsy during PGD has been suspected to decrease
success rates of ART, whereas in some situations, it may
increase possibilities for a healthy life in the future child.
At the moment, success rates are presented in many
ways, for example, for some, a positive heart beat of the
embryo means success, whereas others may consider
success only the birth of a healthy child. Success rates
reflect different components of the treatment, such as
expressions ‘per transfer’, ‘per oocyte pick-up’ or ‘per cycle
started’. Other variables include that the probability of
success is higher in the first new cycles; younger women
are more fertile; multiple pregnancies increase reported
success rates; cancellation rates have a negative impact on
success rates; and the number of embryos transferred will
also impact on the reported result.3 Lately, many Scandi-
navian centres perform single-embryo transfer and score
success rates in terms of clinical pregnancy rates per oocyte
pick-up (including both fresh and frozen embryo trans-
fers72). There is evidence that a transfer of more than one
embryo at a time does not improve the likelihood of
pregnancy, but only increases the likelihood of multiple
pregnancies.73 The provision of ‘delivery of a single, term
gestation, live baby per cycle initiated’ has been introduced
as a new standard of success for IVF clinics.17 Also, preterm
singleton live births are proposed to be noted then.74
PGD and screening
PGD vs PND
PND is a diagnostic or presymptomatic test carried out on a
developing fetus through amniocentesis, chorionic villus
sampling (CVS), foetal blood sampling, collecting foetal
material in maternal circulation or ultrasound. PND is used
to detect a fetus with a chromosomal aberration, con-
genital malformation or disease, or that is at risk for a
disease and thus offers the parents the option to terminate
the pregnancy in order to prevent the birth of offspring
with genetic and/or congenital anomalies. Couples who
have not experienced prenatal testing before do not
generally opt for PGD, but first try to conceive sponta-
neously, and ask for PND. Those who have experienced one
or more terminations of pregnancy following PND are
more prone to choose PGD.75
PGD was introduced at the beginning of the 1990s as an
alternative to PND to avoid termination of pregnancy for
couples with a high risk of their offspring being affected by
a sex-linked genetic disease. At that time, embryos
obtained in vitro were tested using molecular techniques
to ascertain the absence of a Y-bearing sequence, and only
female embryos would be transferred. Since then, techni-
ques for molecular and cytogenetic analysis at the single-
cell level, including assessment of first and second polar
bodies from oocytes or blastomeres from cleavage-stage
embryos, have evolved considerably.24 The list of diseases
for which PGD has been used is slowly growing.
Techniques for genetic analysis
The two main techniques of obtaining nuclear material for
genetic analysis are the aspiration of one or two polar
bodies from oocytes or the removal of one or two
blastomeres from early embryos (cleavage stage
biopsy).76,77 The most commonly used biopsy method is
cleavage stage biopsy.7 A third, less used method, is
trophectoderm biopsy from blastocysts.78
Polar body biopsy The stem cells (oogonia) of the future
oocytes enter the process of first meiosis during early
oogenesis. The chromosomes are duplicated (‘replication’)
and chromosomal material from the paternally and
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maternally derived chromosomes is exchanged (the pro-
cess of recombination or crossing-over). The primary
oocyte is at this stage diploid with duplicated chromo-
somes, and remains fixed in prophase until triggered by the
preovulatory LH surge to complete the first meiotic
division. The first polar body is extruded as a by-product
of that division, which normally occurs inside the follicle,
before the oocyte is ovulated. The first polar body thus
contains the counterparts of the chromosomes of the
developing oocyte. As the oocyte is surrounded by the zona
pellucida (ZP), the polar body remains ‘trapped’ in the
space between the oocyte and the ZP. Following fertilisa-
tion and activation by the sperm, the oocyte enters the
second meiosis, when the duplicated chromatids of the
now haploid oocyte separate: one set of chromatids
remains in the oocyte, whereas the other is expelled with
the second polar body. Owing to the recombination of
chromosomal material during meiosis, the polar bodies
and the oocyte contain unique genetic material, but
should contain the reciprocal chromosomal constitution.79
For PGS for aneuploidy, both polar bodies can be removed
simultaneously from pronuclear zygotes, whereas in PGD
for single-gene disorders, they should be removed sequen-
tially.80,81
Polar body biopsy maintains embryo integrity as only by-
products of meiosis are used for analysis.82 The polar bodies
can be analysed at the chromosome and at the monogenic
level. The advantage is that the selection process can be
carried out at a very early stage of fertilisation (eg, early
pronuclear stage) when syngamy has not yet occurred.
Polar body biopsy is used in Germany, for instance, where
embryo biopsy for PGD on cleavage stage embryos is
forbidden.83
Polar body biopsy is a safe technique, if the drawbacks
are kept in mind and the risks are correctly estimated.81
The main drawback is that polar body analysis can only
detect maternally transmitted genetic or chromosomal
abnormalities, whereas paternally derived defects and
those originating after fertilisation during the first em-
bryonic divisions (postzygotic) cannot be diagnosed.82
Another significant disadvantage of polar body diagnosis,
as compared to blastomere biopsy, is that in the case of X-
linked or autosomal recessive disorders, the discarded
oocytes include those that could have developed into a
child unaffected by the disease, depending on the genetic
constitution of the sperm. Furthermore, the same oocyte/
embryo is manipulated three times, once for removal of the
first polar body, second time for ICSI and then for removal
of the second PB. This is very demanding. An important
limitation is also the low quality of polar body chromo-
somal spreading, which can significantly limit the accuracy
and the reliability of FISH analysis on this material.
In a large series of first and second polar body analyses
for single-gene disorders, a genetic disorder was correctly
detected in 98% of oocytes tested.84
Cleavage stage biopsy Cleavage stage biopsy, also called
blastomere biopsy, is the most commonly used biopsy
technique. Embryos are grown in vitro until they reach
their third division (eight-cell stage), which normally
occurs on the third day after insemination.24 At this stage,
the embryos are biopsied to obtain one or two individual
blastomeres for analysis. During analysis, the embryos are
kept in culture and continue dividing until transfer of the
unaffected embryo is performed.5
All the cells in a human embryo, at four- or eight-cell
stage, are believed by many to be totipotent, that is, none
of the cells is yet committed to a specific developmental
path. However, it is important to realise that all blasto-
meres at the four- to12-cell stage are not identical, but
express different regulatory proteins.85 The developmental
consequences of PGD in respect of functional polarisation
of blastomeres need more evaluation.
There is no consensus on the number of blastomeres that
can be removed safely during cleavage stage embryo
biopsy. The decision whether to remove one or two cells
is based on many factors including the embryo cell number
and the accuracy and reliability of the diagnostic test used.
If removal of two cells is contemplated, it is recommended
that only embryos with six or more cells are used.77
PGD at the cleavage stage has the advantage of testing
disorders of both maternal and paternal origin, and those
originating after fertilisation. Data from the clinical out-
come of biopsied embryos have demonstrated that
approximately one-quarter of the cycles end in a preg-
nancy, but because more than one embryo are transferred
per cycle, the implantation rate is lower.7,82
There is substantial evidence for significant chromo-
somal mosaicism in cleavage-stage embryos. Therefore, the
biopsied cells may not be representative of the whole
embryo.9,86
Blastocyst biopsy The blastocyst stage is the latest stage
at which an embryo can be biopsied. At this stage, 5–6
days after fertilisation in the human, the embryos contain
approximately 150 cells, consisting of inner mass cells and
trophectoderm cells. Removal of trophectoderm cells
during blastocyst biopsy is achieved by herniation through
the ZP followed by laser or mechanical excision. The
advantage is that more cells can be obtained; the
disadvantages being that usually less than 50% of embryos
reach that stage in culture, and that there is little time left
for the diagnosis, as embryos should be transferred before
day 5 or 6.24 The clinical application of this technique is
recent and only limited data has been reported. An
Australian study reports on the advantages of testing five
or six cells, leaving the inner cell mass intact and enabling
the embryos to be electively transferred one at a time,
without diminishing the chance of pregnancy compared
with cleavage-stage biopsy and testing.78 However, one US
study suggests that compared to day 3 embryo transfer,
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blastocyst transfer appears significantly to increase the
incidence of gestations with monozygotic twinning.87 The
applicability of blastocyst biopsy on a large scale needs
validation.80
Analysing methods Two methods have thus far been
used for genetic analysis: FISH, the most frequently used
for the analysis of chromosomes, and the polymerase chain
reaction (PCR) for the analysis of genes in cases of
monogenic diseases.24 The primary use of FISH was to
determine the sex chromosome content of the embryos
from couples at risk of various sex-linked disorders, such as
haemophilia, but has since been extended to PGD for
chromosomal abnormalities and PGS. Amplification of a
specific region of DNA by PCR allows for the analysis of
disease-causing changes in DNA or markers linked to the
disease (eg, microsatellites, SNPs).5 Comparative genomic
hybridisation (CGH) combined with PGD is a relatively
new and still experimental technique. The advantage of
CGH is that the whole chromosome complement is
analysed, although polyploidy and balanced translocations
cannot be detected. The disadvantage is that the whole
procedure takes about 72 h, which limits its use.24
Technical improvements are on their way to decrease the
time necessary to reach a diagnosis and to improve the
resolution through the use of microarrays.
The main indications for PGD
Monogenic disorders and chromosomal rearrange-
ments Couples have an increased risk of conceiving a
child with a genetic disease, if they are carriers of a
monogenic disease or of chromosomal aberrations.24 These
diseases fall into the following main categories:
 autosomal recessive (eg, spinal muscular atrophy, Tay–
Sachs, CF) with a 1:4 risk;
 X-linked recessive (eg, haemophilia A and B, Duchenne
muscular dystrophy) with a 1:2 risk in males;
 autosomal dominant (early onset, for example, myotonic
dystrophy, achondroplasia or late onset, for example,
Huntington’s disease (HD)) with a 1:2 risk;
 chromosome rearrangements (eg, reciprocal or Robertso-
nian translocations; inversions, etc) risk varying with the
type;
 mitochondrial, risk uncertain.
The most common indications for PGD for autosomal
recessive diseases have been CF, b-thalassamia and spinal
muscular atrophy. For autosomal dominant disorders, the
most common indications are myotonic dystrophy, HD,
amyloid polyneuropathy and Charcot–Marie–Tooth disease.
PGD for X-linked diseases has been performed for fragile-X,
Duchenne muscular dystrophy and haemophilia A.7
The number of PGD for reciprocal and Robertsonian
translocations has been on the rise, especially because
many of the patients who carry such a translocation are
infertile or experience repeated spontaneous miscarriages.
Robertsonian translocations carry reproductive risks that
are dependent on the chromosomes involved and the sex
of the carrier.88 PGD is especially valuable in those cases
where the translocation causes infertility, because PGD is
the only way that patients can avoid repetitive abortions.
For fertile couples, careful risk assessment and genetic
counselling should precede consideration for PGD.
Concerning PGD for reciprocal and Robertsonian trans-
locations when the carrier is a male partner, a pre-
examination could consist of the chromosomal sperm
analysis and the subsequent determination of the meiotic
segregation pattern of translocated chromosomes. This
assay gives an indication of both the frequency and the
types of imbalances in the sperm of the patient, and thus
could help with a decision about the relevance of PGD (F
Pellestor, personal communication). However, it should be
kept in mind that there is not a perfect correlation between
the frequencies in sperm and after fertilisation.
PGD for an autosomal dominant late-onset disease with
full penetrance of the mutation and the example of
HD Some critics argue that testing for late-onset disease is
unjustified, because the child will probably have several
decades of unimpaired living and the disease may become
treatable. This critique, however, is debatable in case of
HD, for example, since it is a serious, even lethal, disorder
and has complete penetrance of the underlying mutation.
A person found to have a mutation would inevitably get
the symptoms in the future. Symptoms may appear from
the late 20s, but more usually in the fourth or fifth decade.
Furthermore, the prospect of the fate of the children who
carry HD often imposes an extremely severe burden.27,89 – 91
HD is currently untreatable. A predictive test allows
asymptomatic at-risk adults to know whether they have
the Huntington mutation. The use of PGD for asympto-
matic individuals with the Huntington mutation and
excluding embryos with the mutation is generally regarded
as acceptable.76 New molecular tools have been developed
improving the diagnosis for HD using PGD.92,93
Theoretically, nondisclosure PGD could be a solution for
some families when the prospective parent at risk for the
late-onset disease does not want a predictive test to be
informed about his or her own carrier status, but wants to
have a child without the mutant gene, for example, in HD.
Embryos could directly be tested for the presence of the
mutation without revealing any of the details of the cycle
or diagnosis to the prospective parents.94 This method is
controversial and not generally approved by profes-
sionals.26,92,95 Nondisclosure tests put the practitioners in
an ethically difficult position, for example, having to
undertake PGD cycles even when the results of previous
cycles preclude the patient being a carrier, or having to do
mock transfers if no embryos are available. Therefore,
the ESHRE ethics task force76 discourages nondisclosure
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testing. For at-risk persons who do not want to know their
own status, they encourage preimplantation exclusion testing
using linked DNA markers to determine whether the HD
allele of the embryo from the at-risk parent is originated
from the affected or nonaffected grandparent. The muta-
tion itself is not analysed.92,93 However, exclusion PGD is
considered as ethically dubious by some because embryos
with the allele from the affected grandparent will be
excluded for transfer, although only in half of the cases the
allele will be affected. If the linkage analysis indicates
inheritance from the grandparent with HD, the embryo
has the same 50% risk of being affected with HD as the
intervening parent.91 Notwithstanding their respect for the
prospective parents’ autonomy, some professionals have
problems with the use of exclusion preimplantation testing
as well as nondisclosure PGD. The reason is that in both
situations an invasive IVF and PGD procedure – with some
associated risks – is used while at least half of the couples
have no risk at all for transmitting the mutation and could
know this with certainty should they use a predictive test.
(The same consideration applies to prenatal exclusion
testing for HD.)
Offering PGD for patients showing symptoms of HD is
presently considered controversial, although HD is a
regular indication for PND, which may result in terminat-
ing the pregnancy. For the time being, the decision as to
whether or not to allow PGD for a symptomatic parent
should be settled on a case-by-case basis with respect for on
the one hand, the future child’s circumstances, if a parent
is to die during childhood, and on the other hand, the
parents’ autonomy and reproductive freedom.91
An extension of PGD for the detection of susceptibility
genes for common late-onset diseases and their heredi-
tary subgroups Contrary to the monogenic late-onset
diseases discussed in in the previous section, in which the
mutated gene inevitable leads to the disease, susceptibility
genes increase the risk of developing the disease, but their
effect is also being modified by other genes and other
factors. It is a dilemma whether it is ethically acceptable to
test and select embryos because of an increased risk –
instead of a certainty – of developing a particular disease
later in life. One problem with susceptibility testing relates
to the type of test result that could be generated and the
validity of the risk figures, as much uncertainty remains.96
For the hereditary forms of breast cancer (owing to BRCA1
and BRCA2) and for some hereditary forms of colorectal
cancer (eg, familial adenomatous polyposis (FAP) and
HNPCC), the absolute risk figures are relatively high, but
there are preventive measures. Controversy surrounds the
use of PGD in this situation. Polymorphisms increasing the
relative risk for common multifactorial diseases are so
common that it is hard to imagine that they could be an
indication for PGD, because it would mean that an
‘indication’ for such a test would exist in most families.
Indications for PGS for aneuploidy
PGS (for aneuploidy) is a method used at present to
identify the most chromosomally normal embryo for
transfer in an IVF/ICSI cycle. Usually five to nine pairs of
chromosomes are examined.
The use of PGS has increased tremendously during recent
years in IVF cases without any previously known familial
risk of affected offspring, with the aim to improve IVF
results (i) in women of advanced maternal age, or (ii) in
whom the embryos have repeatedly failed to implant, and
(iii) in women who have recurrent miscarriages (not owing
to constitutional chromosomal aberrations).
Aneuploidy resulting from nondisjunction increases
with maternal age, whereas polyploidy and mosaicism
appear irrespective maternal age, and are associated with
poor embryo morphology.24,86 Maternal age as such is also
suggested to increase the incidence of mosaicism.97 Various
studies on spontaneous abortions have shown that more
than half are associated with chromosomal abnormalities.
Using a set of specific fluorescent-labelled DNA probes, the
most common chromosomal anomalies found are triso-
mies: trisomy 21 (Down’s syndrome), trisomies 13, 16, 18
and 22; and numerical abnormalities of the sex chromo-
somes X and Y.98 PGS can be enhanced by new technol-
ogies, such as CGH, to enable full karyotyping of single
cells.99
Strategies to improve prognosis of IVF/ICSI include, inter
alia, microscopic evaluation of the morphological quality,
the dynamics of the cleavage pattern up to the blastocyst
stage of the in vitro-cultured human embryo in vitro and,
lately, PGS to exclude aneuploid embryos.9
PGS may lead to confusion between embryo viability
screening and screening for chromosomal disorders during
pregnancy. Some chromosomal aberrations (tris 21, XYY,
etc) can also result in viable embryos. There is as yet no
agreement about the indications for such screening and
the legal status of the method varies between coun-
tries.100,101 Among the member centres of the ESHRE
PGD Consortium who contributed data for the last data
report,7 21 out of 38 performed PGS (K Sermon, personal
communication)
Experience of the efficacy, reliability and safety of PGS is
growing, but still limited.7,8,102 Therefore, some consider
this procedure still as experimental.25 PGS raises concern,
because of the risk of misdiagnosis in part owing to the high
rate of mosaicism in cleavage-stage embryos9 and technical
failures inherent in the FISH technique. Others suggest that
PGS would be particularly beneficial for poor prognosis IVF
patients.103 At present, the advantages of applying this
technique on a larger scale have not been demonstrated
and harder data are asked for.76 UNESCO/International
Bioethics Commission (IBC) regards aneuploidy screening
to be as ethically acceptable98 and also ESHRE and
Preimplantation Genetic Diagnosis International Society
(PGDIS) have included PGS in their guidelines.77,80
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The first large-scale prospective randomised controlled
clinical trial investigating in vitro blastocyst culture and
PGS for the selection of the embryos in couples of
advanced maternal age, that is, 37 years of age or more,
was performed during 2000–2003. As a conclusion, the
trial provided no arguments in favour of PGS for improving
clinical outcome per initiated cycle in patients with
advanced maternal age as such. On the other hand,
patients having a transfer after PGS may have an advantage
in countries with strict regulation on the number of
embryos to transfer.9
Differences between PGD and PGS
PGD was designed for an a priori fertile couple that has a
high genetic risk of having an affected child, whereas PGS
is provided for an infertile couple to detect certain
anomalies of the embryo, which might prevent a successful
pregnancy. Indications are hence totally different.
High genetic risk patients are usually selected through
genetic centres and might then undergo IVF treatment and
PGD, whereas PGS patients become subject to PGS via IVF
clinics.77
In PGD, the genetic defect is known and established in
the parent(s) who carries the defect, whereas PGS is
screening for aneuploidies, in case of a possibility of an
increased but unspecified risk.
PGD-HLA typing in families where an HLA-matched
sibling is desired
There are a few malignant and nonmalignant (usually
genetic) diseases, which are treated by means of bone
marrow transplantation.104 Allogeneic haematopoietic
stem cell transplantation (HSCT) is the only presently
known cure for most of these diseases. The method
requires the availability of a HLA matched donor who
may be an HLA-identical sibling or, alternatively, a
volunteer-unrelated donor. The chance that a particular
sibling is HLA identical is theoretically 25%. Where there is
failure to find a compatible relative as a donor, a search of
the worldwide registers for HLA compatible donors can be
made. A third possibility is that of obtaining compatible
stem cells from cord blood. These are collected at birth and
cryopreserved in cord blood banks on a voluntary or
commercial basis. The overall success rate of a HSCT in a
child with a sibling donor is substantially higher than
performed with alternative donors.105
PGD with HLA tissue typing is an additional step to
determine the tissue compatibility of unaffected embryos
with an existing sibling. There are cases of the use of PGD
for this purpose, and after birth, the new child’s cord blood
has been collected and stored, and subsequently used to
replace the marrow in the affected sibling, thus curing the
disease. Opinion is divided on this issue of having a
‘saviour sibling’. A number of groups have addressed the
issue,106 – 108 and the practice is on the rise (H Van de Velde,
personal communication). Consequently, it has been
suggested that application of PGD in combination with
HLA typing is a promising therapeutic tool for an affected
sibling.109
Before the existence of PGD, natural conception fol-
lowed by PND, and possibly termination of pregnancy, was
the only alternative, when trying to find a HLA-matching
future sibling.105,110
No unaffected or diagnosed embryos available for
transfer
It often happens that no unaffected embryos are available
for transfer. In such cases, transfer of affected embryos is
not recommended.77 It may also happen that a diagnosis of
some embryos cannot be reached. If PGD was performed to
detect monogenic diseases, transfer of undiagnosed em-
bryos is not recommended. In contrast, transfer may be
regarded acceptable after PGS and after PGD for certain
chromosome rearrangements where they would give rise to
nonviable pregnancies.77 However, transfer is not generally
recommended, unless no other options exist and the
couple is informed.80 Professionals performing PGD told
in Sevilla that none of them transfer embryos that are not
diagnosed.
A difficult situation occurs in particular, if none of the
embryos, healthy per se, tested mainly for HLA matching
has the right tissue type. Similarly, potential selection
against healthy embryos carrying some autosomal reces-
sive disorder, such as CF, to avoid transgenerational risk, is
not considered ethically justified by many. These issues
require further discussion.
Results and misdiagnosis
It has been estimated than more than 6000 clinical cycles
of PGD/PGS have been performed worldwide, with a
current estimate of 1000 cycles annually.111 In particular,
the use of PGS is on the rise7 and its possible but non-
proven potential to improve IVF results is gaining more
approval.9,103
The PGD pregnancy rates tend to be somewhat lower
than for IVF in general.7 Results from 10 years data
collection in the Netherlands did not report misdiagnoses
and none of the babies had congenital abnormalities, and
as a conclusion, PGD was suggested to be a reliable and
successful method, with pregnancy rates similar to those of
IVF or ICSI.112
A systematic New Zealand review of the quantifiable
harms and benefits of PGD observed that the incidence and
nature of obstetric and neonatal complications after PGD
were comparable to those reported after IVF alone, and
related mainly to the risks associated with multiple
gestations.113 The incidence of major birth abnormalities
was about 3.8%, which again is similar to that reported
after IVF alone. The review concluded that PGD is a
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promising approach, but it is important not to overstate its
potential.
According to the fourth ESHRE PGD consortium data
collection published in 2005,7 the clinical reports showed
three misdiagnoses out of 136 foetal sacs tested, making
the total misdiagnosis rate 2.2%. One misdiagnosis
occurred in PGS after FISH (45,X seen on PND) and two
after PCR for monogenic diseases (amyloid polyneuro-
pathy, born and CF, born). Consequently, the misdiagnosis
rate after FISH (1:114) was 0.9%, whereas the rate after PCR
(2:22) was 9.1%. In previous years, the total rate has been
2–3% (ESHRE data III, 2002).
Most PGD centres worldwide recommend the use of
amniocentesis or CVS in women who become pregnant
after PGD in order to safeguard against diagnostic error or a
serious unscreened-for foetal abnormality. There is good
evidence that these tests are reliable, although they
increase the miscarriage rate by 0.5–1% above the baseline
risk, which is estimated at 12% for the general population.
Mosaicism is said to be a common characteristic in
human embryos generated in vitro, which may lead to
misdiagnosis.9,82 The consequences of chromosomal mo-
saicism for human embryonic development are unknown.
Therefore, detecting and discarding mosaic embryos may
imply an important loss of potentially viable normal
embryos.9
For potential adverse effects, see below.
Patient’s attitudes
A study performed in the UK and Spain on the experiences
of PND and PGD by couples who have been exposed to
both forms of diagnostics suggested that the experience of
PND and subsequent termination of pregnancy can be an
unwelcome memory and hence needs an alternative
approach.114 According to the study, PGD was acceptable
to most patients and offered a valuable alternative to PND,
but undergoing IVF itself was associated with stress and
anxiety: 41% of patients found the PGD cycle extremely
stressful, especially the time waiting after embryo transfer
for a pregnancy result and time waiting after the initial
consultation before a treatment cycle. The patients re-
garded as the main advantage of PGD that only unaffected
embryos were transferred to the uterus and thus therapeu-
tic termination could be avoided. The low success rate was
considered the main disadvantage. More than 90% of
couples used and were satisfied with genetic counselling.
In all, 77% would choose PGD again in a further pregnancy
attempt. An Australian study115 also concluded that the
patients found PGD to be a highly acceptable treatment
and morally less problematic than abortion. The recom-
mendation of performing back-up PND once the preg-
nancy has started and the possibility of an abortion in the
event of a misdiagnosis raised most concern in nearly half
of the patients. The issues surrounding the transfer of
embryos, restrictions to PGD and the destruction of
embryos raised some different thoughts.115
Factors predicting couples to start with PGD are the
number of previous spontaneous or induced abortions, and
the absence of acceptable alternatives and openness about
the treatment.75 Couples tend to feel it as a duty to first
apply PGD to avoid termination of pregnancy and they
want to avoid recurrent abortions. Couples usually under-
estimate the burden of PGD beforehand.75
Sex selection for medical reasons
Many countries and organisations (UNESCO, COE and
ASRM) accept sex selection for genetic reasons to prevent
the birth of a child with a serious condition. Usually this
occurs in situations wherein the specific mutation at the
origin of an X-linked recessive disease cannot be detected.
A more controversial indication for sex selection is the
prevention of the birth of a daughter who is carrier of the
mutant X-linked recessive gene. Indeed, when the future
father has a recessive X-linked condition, all his daughters
will be carriers, but sons healthy. Thus, the couple might
want to have only male offspring to avoid the birth of a
carrier daughter and the problems that it brings along. It is
clear that in this situation sex selection is used to prevent
the implantation of a carrier embryo.
The situation described above has a lot in common with
the situation whereby direct mutation analysis is possible,
and whereby neither female carrier embryos nor affected
male embryos are implanted (because the parents only
want unaffected boys or daughters who do not carry the
mutation).
The evaluation of the situation is even more complex for
some X-linked diseases, because female carriers of the
mutant X-linked gene may also have an increased risk of
symptoms, although less severe than males carrying the
same mutation.
Sex selection for social or family-balancing reasons
Sex selection for other than health purposes has lead to
vivid debate recently.116 – 120 The mere fact that ESHRE
included sex selection in its report in the first place has
caused disapproval.121 However, the attitudes towards
preconception sex selection for social or family-balancing
reasons vary among cultures, which is noteworthy in the
pluralistic Europe. Still, the European Convention on
Human Rights and Biomedicine,122 Article 14, explicitly
bans sex selection for other than health purposes by stating
that, ‘The use of techniques of medically assisted procrea-
tion shall not be allowed for the purpose of choosing a
future child’s sex, except where serious hereditary sex-
related disease is to be avoided.’ However, some ethicists
question the general ban and fail to see the moral
wrongness of social sexing or family balancing (eg,
Dahl120), some referring also to the concept of ‘reproduc-
tive liberty’, the ignorance of which requires justifica-
Assisted reproductive technologies and genetics
S Soini et al
599
European Journal of Human Genetics
tion.117,118 Some argue that if family balancing were
allowed, fears of sexism would lack ground, because both
sexes were presented in the family.123 However, public
opinion has been reported to be against this.123,124
Regulation
PGD is totally banned in some countries, whereas most are
content to limit the indications for PGD to serious
disorders or conditions. This includes the detection of the
sex of the embryo in order to avoid serious hereditary X-
linked disease. According to a recent comparative study,
there is symmetry in both the substantive requirements (ie,
severity, only health indications) and procedural safe-
guards (ie, informed consent, counselling, confidentiality,
oversight and accreditation) surrounding reproductive
genetic testing. The degree of severity or probability of
the risk has not been defined further, though. Under the
survey, common feature is that the final decision is
medical.6
Germany offers an example of a strict regulation, as there
the Embryo Law is interpreted as to prohibit other PGD
than polar body diagnosis, However, this interpretation
has been debated.79,125 According to a recent survey, public
attitude is more liberal towards PGD than public policy.125
At present, German patients travel to Belgium or to Spain,
for instance, to get the treatment they desire.126
Some have argued in favour of tight regulation of PGD,
because they think that otherwise this new technique
might be brought into disrepute owing to its application,
for instance, to sex selection.100 These demands have been
supported by concern that PGD may be seen as eugenic,
either through its aim to reduce the number of people with
a genetic disorder or because it makes possible selection of
embryos on the basis of nonpathological characteristics,
leading to full-blown free-market eugenics.127 However,
ethicists often answer to these doubts by a question ‘what’s
wrong with eugenics’ (see later section ‘What is wrong with
eugenics?’). The fact that someone may use a specific
technique elsewhere for purposes that are illegal, unethical
or unsafe is not necessarily indicative of this being a
slippery slope to perdition down which we all are
inevitably doomed to slide.
The Human Genetics Commission (HGC) in the UK, for
instance, has given the following recommendations to the
HFEA: PGD should be limited to the detection of specific
and serious conditions; PGD should not be used for trait
selection or in such a way that it could give rise to eugenic
outcomes; consistency is needed between conditions
considered as appropriate for PGD and for PND. PGD to
detect carrier status for an autosomal recessive condition
should, where possible, be avoided. Guidance regarding
PGD to select and implant embryos that are affected by a
genetic condition has not yet been formulated.124
Guidelines and recommendations of the ASRM, ESHRE,
HGC, HFEA, PGDIS, UNESCO/IBC and WHO are now
amending the lack of generally accepted rules concerning
PGD. ESHRE and PGDIS, for instance, have published their
best practice guidelines in 2004.
Selection of donors based on genetic information
What type of tests are carried out?
When donors are chosen for oocyte or sperm donation,
many clinics have the practice of asking family history,
usually focusing on first-degree relatives, and routinely
performing some medical tests (ie, hepatitis, HIV and
venereal diseases) and genetic tests at least in cases where
family history indicates a risk of hereditary disease.
Upon WHO’s recommendation sperm donors should be
screened for hereditary as well as infectious diseases.18 This
was, however, not fully accepted by the workshop
participants in Sevilla, who mostly viewed that the genetic
testing of donors should not lead to selection of better
genes for donor-conceived children compared to genes
presenting among the general population.
There are no common European guidelines on testing
the donors. In the United States, the ASRM has issued
guidelines on gamete and embryo donation, which include
exhaustive lists of risks and tests as well as minimum
genetic screening criteria for gamete donors (also specified
by ethnic groups70). Some European centres (eg, one centre
in Belgium) follow ASRM’s guidelines for gamete and
embryo donation.
Although acknowledging that all reasonable tests should
be performed to prevent transmission of a genetic disorder,
the HFEA, for instance, notes that genetic testing should be
limited to the determination of a carrier status for inherited
recessive disorders in which abnormal test results carry no
significant direct health implications for a prospective
donor, either sperm or oocyte donors. Certain tests (CF,
Tay–Sachs, thalassaemia and sickle cell disease) are
recommended depending on the population the donor
belongs to.71 The HFEA states that centres are expected to
ensure that where prospective donors are genetically
tested, they have the same level of support and counselling
as recipients.128
A large international commercial distributor of gametes
(Cryos in Denmark) checks the karyotype (46, XY). Upon
consideration case by case and following its Medical
Standard Operation Procedure, Cryos will examine genetic
diseases of the donor candidate (sickle cell disease,
thalassemia, Tay–Sachs disease, CF, etc, the list is increas-
ing). The donor’s complete medical history (specifically
regarding possible heritable conditions) is recorded, and
the data are entered in a registry of donors. In Cryos’s
opinion, recipients generally want as extensive genetic
disease screening as possible, whereas donors, on the
contrary, are usually against genetic disease screening, as
it would be traumatic for them to receive positive results
and consequent rejection. Donor rejection should only be
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enforced when known risk of a genetic disease is greater
than that in the general population (www.cryos.dk).
According to the ‘IFFS Surveillance 04’ of practices in
different countries, genetic screening by history in sperm
or oocyte donors is widely practiced.25
In the European Union, several tests will be obligatory in
the future when procuring reproductive cells, if technical
requirements of the Tissue Directive come into force as
proposed (see Appendix A). The use of reproductive cells
shall meet certain criteria. Donor selection criteria and
laboratory testing is not needed in the case of partner
donation for direct use, that is, when cells are donated
within a couple and used without banking. The proposed
laboratory tests shall basically include HIV, hepatitis B and
C. Donors in connection with high incidence areas shall be
tested for HTLV-I antibody. Additional testing (eg, RhD,
malaria, CMV, T cruzi) shall be subject to the characteristics
of the tissue or cells donated or donor’s travel and exposure
history. In partner donation the clinician shall determine
and document, based on the patient’s medical history and
therapeutic indications, the justification for the donation
and its safety for the recipient and any child(ren) that
might result. In case of nonpartner donation, age, health
and medical history of the donor shall be ascertained by a
questionnaire and personal interview. Genetic screening
for autosomal recessive genes known to be prevalent in the
donor’s ethnic background and assessment of the risk of
transmission of inherited conditions known to be present
in the family shall be carried out as well.
What type of family history?
Generally agreed principles on the extent and quality of
the family history asked from a prospective donor do not
exist. A three-generation pedigree would provide enhanced
information for planning relevant testing.129 Family
history may contain monogenic, chromosomal or multi-
factorial diseases including malformations in many gen-
erations. There are no means to check whether the given
family history is true. In genetic counselling it is well
known that, in some populations, diseases are not very
openly discussed within the extended family and thus
family history may not be fully known. Many clinics do
not accept donors if hereditary (including multifactorial)
diseases have occurred among first-degree relatives. See
also donor- specific requirements of EU Tissue Directive
(Appendix A).
Choosing characteristics
Many clinics enable some selection regarding the appear-
ance of the donor, such as skin colour, height, hair, eye
colour, based on his/her resemblance with the prospective
parent(s). One generally accepted indication for selection
of a donor is the couple’s desire to have full siblings, in
other words, if donor gamete has already been used to
assist conception for the couple’s first child, the same
donor can be used to the following assisted conceptions in
order to try to have some similar characteristics.
The selection mechanism could be very delicate and very
comprehensive, and is applied in particular in the USA. In
Europe, the attitudes are cautious with respect to choosing
characteristics.
What type of counselling is provided to counter-
selected people?
If an individual is counter-selected and told that his/her
gametes cannot be accepted for donation owing to
hereditary diseases in the family, the message might be
that he/she should not have own children either. There-
fore, detailed genetic counselling should accompany
counter-selection to avoid unnecessary misinterpretations
and to give accurate information on the disease, reproduc-
tive choices in the future as well as to provide psycholo-
gical support and counselling to family members.
Carriers? Homozygosity? Limitations to use the same
donor?
Not all carriers can be detected by family history alone. The
donor himself/herself may learn about his/her severe, for
instance, late onset, disease tens of years after the gamete
was used. The question may arise as to whether genetic
screening should be applied when choosing gamete/
embryo donors and whether repeated use of the same
donor in a small community, narrowing of the gene pool,
might increase risk for certain autosomal recessive condi-
tions in future generations.
The couple may consider a sister or brother as a donor.
However, in case of genetic infertility like Fragile X, CF or
chromosomal translocation, it is possible that he or she is
also a carrier, which should be tested to avoid the risk of a
serious disease in the offspring. However, this could create
a conflict: brother or sister might like to donate gametes,
but may not like to know his/her carrier status.
According to the IFFS Surveillance 04, countries tend to
limit the use of the same donor’s gametes from five to the
maximum of 10 children.25 However, according to an
opinion on the basis of relevant studies, these limits do not
seem to be based on any valid population genetics
argument.130 However, after an incident in the Nether-
lands, where 18 children were conceived from sperm of
one donor, who later developed a serious hereditary
disease, the Netherlands decided to reduce the previous
limit of 25 offspring, and now the donors’ opinions are
asked. The practice so far shows that donors usually prefer
to have approximately five children. This may also relate to
whether the donation is anonymous or nonanonymous.
Knowledge of having a large number of children or half-
siblings may also be a psychological problem for some of
the children and donors (www.cryos.dk). In Cryos’ opi-
nion, the inbreeding risk criterion is not the total number
of children born, but the number of children created via
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donor insemination (DI) per capita in each community. In
cosmopolitan communities, a larger number of offspring
from the same donor would not create such consequences
as in smaller communities. Legal limits differ greatly from,
for instance, 5 in South Africa (total population approx.
45 000 000) to 1 per 32.000 in the USA. If the limit is set too
low, it will result in a price increase and/or a reduction in
the availability of DI, leading to reproductive tourism and
the Grey Market (www.cryos.dk). Several studies have
calculated the risk of consanguinity and have concluded
that the risk is very small.131
It has been argued that when limiting the number of
children per donor, it should be noted whether all or part
of the children have been born to the same mother, as well
as the geographic origin of the recipients. It is quite
different to have had five children with five women from
different countries than with five women from the same
middle-sized town.
Embryo donation
Embryo donation has become an acceptable practice in
many countries and may be used by a couple if both
partners lack gametes or have gametic failures, or after
several unsuccessful attempts of ART.132 It may also be
considered in parents at high risk of having a child with a
genetic disorder.
Embryo donation requires special attention, as donated
embryos usually originate from the parents who have been
subject to IVF treatment themselves. Consequently, it
cannot be excluded that these supernumerary embryos
are at increased risk of carrying a known or unknown
genetic defect relating to parental infertility.132 The
Genetics Commission of the French Federation of CECOS
has recommended that embryos with a well-defined
genetic risk for the future child should not be made
available for donation. The recipient couples should be
clearly informed of the risks.132
Counselling in the relation of genetics and art
Definition and purpose of the counselling
Counselling means ‘the provision of objective information
from the counsellor and its interpretation by a patient’.133
The purpose of counselling is, among other things, to
enable patients to make informed decisions, and also find
and accept other reproductive options, such as adoption,
gamete donation and refraining from offspring. Counsel-
ling has also an important goal in helping patients to
develop coping strategies to sustain and accompany
persons in adverse circumstances or after difficult or
traumatic experience. Counselling aims at empowering
counselees for decision-making that reflects their values
and not those of the counsellor. In genetic counselling
situations, counselling often extends to family members
and relatives.
Each act of counselling consists of a contract between
counsellor and counselee, and therefore it is of great
importance to clarify the contract, to formulate it as
precisely as possible and also to revise it regularly, because
the attitudes and goals of the patients may change during
the course of time, and other solutions than ART may
become equally or more attractive (eg, adoption). Also,
new techniques or cures may have become available.
Reproductive counselling
Reproductive counselling means consultation with a
fertility professional during which the patient is given
information on different forms of fertility treatment, their
advantages and disadvantages as well as risks, and any
diagnostic tests that need to be conducted to identify the
cause of infertility. If needed, patients should be referred to
a psychologist or a psychiatrist.
Ample time should be devoted to reproductive counsel-
ling, as it is an essential part of planning of ART. Fertility
professionals should have education on reproductive
counselling in their training. For different counselling
situations see ESHRE Guidelines for Counselling in In-
fertility (Guidelines for Counselling in Infertility Contents.
ESHRE Monogr, 2002:1. Oxford Journals).
Genetic counselling
Genetic counselling is a communication process that deals
with the occurrence, or risk of occurrence, of a genetic
disorder in the family. The process involves an attempt by
appropriately trained person(s) to help the individual or
the family to (i) understand the medical facts of the
disorder; (ii) appreciate how heredity contributes to the
disorder and the risk of recurrence in specified relatives;
(iii) understand the options of dealing with the disorder;
(iv) choose the course of action which seems appropriate to
them in the view of their risk and their family goals and act
in accordance with that decision; and (v) make the best
possible adjustment to the disorder in an affected family
member and/or to the risk of recurrence of that disorder.134
As genetic counselling is extremely important, it is
worrying that one-third of the genetic testing centres
surveyed (EMQN report) were not linked to clinical
genetics services.135 The importance of an appropriate,
nondirective genetic counselling is emphasised, for in-
stance, in Article 11 of the International Declaration of
Human Genetic Data of 2003. ESHG has addressed genetic
counselling in its previous review ‘Provision of genetic
services in Europe: Current Practices and issues’.134
A multidisciplinary expert group in the field of law,
philosophy, ethics and medicine, invited by the European
Commission, published in 2004 their ‘25 Recommenda-
tions on the ethical, legal and social implications of genetic
testing’. In this document genetic counselling is consid-
ered an essential requirement for genetic tests and the
importance of qualified professionals, education and
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standards is stressed. The need for Europe-wide general
standards for fundamental principles of genetic counsel-
ling by medical professionals is thus acknowledged.
Patients value counselling and demand accurate informa-
tion to avoid unnecessary fears as well as false optimism.114
Counselling has been noted to provide help in areas of
psychological assistance, technical explanations and dis-
cussing relationships.136 At best, genetic counsellors are
sensitive also for the burden of an infertility diagnosis and
the emotional impact – including anxiety and ethical
questions – of different treatment options. If needed,
patients should be referred to a psychologist or a psychiatrist
for emotional support or formal psychotherapy in which
these emotional issues can adequately been addressed.
Autonomy
The ideal of modern genetic counselling is not only to
avoid a directive approach (whenever suitable) but also to
concentrate on the medical, psychological and social
circumstances so that couples can make decisions that
are appropriate for them.
In the preparatory phase, the genetic counsellor should
first of all let the couple express their desires and
expectations. Some patients may not want to make an
autonomous decision, and some of them have already
made their decision and really want the counsellor to
validate it, etc.
Autonomy is problematic, though, because patients may
not have the capacity to deal with excess information.
Moreover, the specific context of ART and genetics needs
specific modified ethics doing justice to the responsibilities
and autonomy of professionals involved.
Traditional ethics of clinical genetics, in particular the
emphasis on respect for reproductive autonomy and on
nondirectiveness (ND), has been developed in the general
context of genetic counselling in various situations. In the
context of ART, however, the doctor involved has his own
responsibility to avoid serious harms to future children
(and his own professional autonomy), and because he is
directly involved in reproductive decision-making/repro-
duction, he cannot ignore the consequences of his acts
(professional duty of care). In view of this, it has been
suggested to be justified
(a) to give access to IVF/ICSI to couples at high risk of
having an affected child only on the condition that
they accept PGD (in order to eliminate/reduce this risk)
and
(b) to accept a shift in the locus of decision-making after
PGD from the patient to the doctor. It is indeed the
doctor who should decide which embryo(s) will be
implanted. (The situation is, from a moral point of
view, different in comparison with the traditional
context of PND, where the mother has decision-making
authority26).
Challenges of counselling
Counselling is challenging because counsellors and coun-
selees are shown to value different information and hence
understand and remember it differently. The high degree of
uncertainty relating to genetic counselling is in direct
contrast to the needs of clients.137 Thought should also be
given to the potential conflict between legal requirements
to disclose all information and the need of some indivi-
duals to avoid information (‘a right not to know’). One
solution proposed to avoid this conflict is to inform the
patient in the initial stage of counselling that he or she can
decide whether or not to be told about the subject under
discussion in more detail.137
The increase of crossborder-assisted reproduction services
disturbs the principles of counselling owing to cultural and
language problems and might create a need to agree on
uniform goals and practices of the counselling, including
the problem of directiveness vs ND. In addition, uniform
practices of the consent process should be agreed upon.
ND vs neutrality
Nondirective genetic counselling has been defined as ‘the
provision of accurate, full, and unbiased information in an
empathic relationship that offers guidance and helps
people work through their own decisions’.29 Applied to
genetic counselling, ‘the non-directiveness describes pro-
cedures that aim at promoting the autonomy and self-
directedness of the client’.138 It was in 1942 that Carl
Rogers presented the term ND to describe his personal
approach to psychotherapy and renamed it later as client-
centred therapy in 1951.139,140 The origins of the term lay
hence in psychoanalysis and psychotherapy.
ND is an active strategy requiring quality counselling
skills and assumes that most clients have the ability to
make their own decisions.138 Because genetic counselling
inevitably entails tensions between conflicting values, a
professional should be aware of them.96 The ND in the
sense of not influencing the clients may be considered as
negative and may remove opportunities for reflection from
clients who might find broader social and emotional issues
helpful in decision-making.96
The term neutrality should not be used as a synonym of
ND, because it lacks an essential component of genetic
counselling, namely the empathy and involvement of the
counsellor.141
Shared decision-making
The nondirective decision-making approach may some-
times prove unattainable, especially in situations where
there is significant ambivalence about the decision. ‘Shared
decision-making’ can then provide a complementary
approach when trying to balance the tensions between
evidence-based guidance and the need to respect patient
choice.142 In particular, in PGD, where the ambivalence
concerning the decision may be high, a model of shared
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decision-making is probably more appropriate.115 This
approach may balance chances for success and advantages
with risk, burden and other disadvantages.75
Risk communication/language of uncertainty
Probability information is essential in genetic counselling.
The meaning or interpretation of verbal uncertainties can
easily be influenced by characteristics of the context (eg,
desirability of an event, its perceived seriousness, its base-
rate). The way information is presented (eg, negative vs
positive framing; loss vs gain framing; numerical vs verbal
risk information; relative vs absolute risks; etc) can have
significant effects to the results. These different presenta-
tion models leave space for manipulation of the goal of risk
communication.143 People seem to prefer to receive
probabilities in a numerical mode, even though they
would handle uncertainty verbally.141 The vagueness of
verbal terms does not make verbal expression of uncer-
tainty inadequate in genetic counselling.
Understanding
There is a need to focus more on what the patients really
understand. It is doubtful whether the couples internalise
the risks of treatments, the potential of disappointments,
etc. Counsellors and counselees are shown to value
different information. A third of the information that the
researchers regarded as key points were not recalled by the
counselees some weeks after the consultation.35 A French
survey examined what pregnant women understood from
information given during prenatal testing for Down’s
syndrome. The findings showed that roughly half of the
participants had misunderstood or ignored the informa-
tion presented.144
Counselling and PGD
Genetic counselling in the context of PGD has to take care
of both communication and coping strategies. Women and
men considering the procedures of PGD have almost
always experienced difficult situations and may not have
been offered adequate counselling to cope with their
situation. Being told that one is carrying a gene or a
chromosomal aberration that may cause a serious condi-
tion for oneself or one’s offspring is a traumatic experience
to most people. It may disrupt personal identity and
provoke self-doubts or feelings of inappropriateness and
guilt. Nevertheless, parents should be told that all people
are carriers of several mutations, which only seldom
become obvious.
Multiple pregnancy losses are equally disruptive, dis-
empowering and traumatic experiences. Moreover, other
family members may need to be informed of their risks. All
this may adversely affect the couple’s relationship or the
relationships within families. Only infrequently will this
suffering be communicated spontaneously by one of the
partners or by the couple. Therefore, it is important to asses
carefully the couples’ psychological state, the stability of
their relationship and their coping strategies as well as
support structures and social networks before offering
PGD, as the procedure in itself is likely to put a
considerable strain on the couple, not least because of
the low success rate. Couple experiencing a failed PGD
cycle also should be offered professional support to help in
developing coping strategies. Genetic counsellors have
therefore an important diagnostic responsibility to differ-
entiate between ‘normal’ and ‘pathological’ grief reactions
in patients, partners and couples. If necessary, patients
should be offered appropriate help or be referred to a
psychiatrist/psychologist with experience in the field.
Genetic counselling before PGD for late-onset disease
should be given by a clinical geneticist or a counsellor who
has experience with predictive testing for the specific late-
onset disease and who is prepared to discuss the pros and
the cons of all options for prenatal and preimplantation
testing with the prospective parents.
ESHRE’s best practice guidelines for PGD and PGS of
2005 provide specific guidance on counselling, informed
consent, patient inclusion/exclusion criteria, various tech-
niques and diagnosis, etc.77 The guidelines recommend the
following steps in the PGD procedure for all couples at
high genetic risk owing to structural chromosome abnorm-
alities or monogenic diseases: a clinical geneticist or
genetic counsellor first counsel potential parents to discuss
the use of PGD for their particular disorder; thereafter, a
clinical fertility specialist should see and evaluate the
couple as for routine IVF.77 ESHRE advises to test only
embryos of couples who were ready for the results and
accept all the implications of the test.76
Indications for PGD and PND are often rather similar,
but the efficiency of the methods as well as the con-
sequences of the test and treatment may be different. If
couples are considering PND owing to a risk of certain
disease, they should be informed also of the possible
availability of PGD. With respect to PGD, couples should
be informed of residual risks and the uncertainty, which
may relate to the PGD techniques and be offered the
possibility of PND for confirmation. Couples who do not
want to experience pregnancy under uncertainty and wait
till PND with a possibility of a pregnancy termination may
prefer PGD. However, PND is used by some couples who
want information about their fetus, but who will not
contemplate a termination. PGD is being used for a
growing list of conditions where PND would rarely be
used, for example, late-onset cancer syndromes, or not
used at all, for example, HLA matching.
Prediagnosis genetic counselling before PGD A genetic
counselling session should be characterised by openness
for discussion. The counsellor should give the couple a
general understanding of the principles of ART (eg, ovarian
stimulation and IVF/ICS and potential risks). Limitations of
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the PGD method should be brought up. Important points
to be expressly communicated are the aim, the type and
the reliability of the test; the possibility of obtaining
unexpected or false results; explanation of nature and
severity of the inherited disorder and its recurrence risk;
the theoretical risks involved in the test (eg, possible long-
term negative effects, which are at present unknown);
possible psychophysical repercussions; reproductive op-
tions and alternatives to PGD. The risk that embryos may
not be suitable for biopsy, may not survive biopsy or may
not be able to be diagnosed after biopsy76 or may not be
suitable for transfer owing to genetic status or poor embryo
quality also has to be discussed.
Postdiagnosis genetic counselling after PGD Appropri-
ate genetic counselling includes also postdiagnosis counsel-
ling to verify that the information given is comprehensible
and understood; to interpret the results and evaluate and
discuss the consequences and available options; to provide
discussion for decision-making; to inform about possible
psychological impact; and ensure adequate means of
support, in particular if the treatments fails. This implies
that a psychiatrist or psychologist with interest and
experience in the field should be part of the team and that
the centre knows to whom patients can be referred to.
Research on counselling
Marteau et al145 studied the association between the
outcomes of pregnancies diagnosed with KS and the
specialty of the health professional providing pre- and
postdiagnostic counselling. According to the study, there is
an association between whether or not a woman termi-
nates a pregnancy affected by an unfamiliar fetal anomaly
and the professional background of the health professional
providing postdiagnostic counselling. The study raises the
possibility that decisions made after the diagnosis of a
foetal abnormality may reflect the knowledge or values of
health professionals: the affected pregnancy was more
likely to continue when postdiagnosis counselling in-
volved only a geneticist. In addition, remarkable differ-
ences between European countries were observed.145 More
research is needed on counselling and in particular on
framing effects of different ways of presenting risks;
heuristic and biases in risk perceptions; emotional and
motivational factors that influence risk perception and
interpretation; and means for avoiding undesired ef-
fects.141,143 In addition, conversational or discourse analy-
sis of genetic counselling in the field of ART might reveal
unrecognised problems and tensions in these situations.
Potential adverse effects of ART
Introduction
The question about possible adverse effects of ART to the
child or to the mother is still controversial.13 Risks may
relate either to the techniques (eg, biopsy for PGD or
microinjection in ICSI), drugs used during the treatment,
culture media during in vitro processes or underlying cause
of infertility per se,146 maternal age, etc.
Many studies on adverse outcomes have been performed,
but the methods and patient materials are often not
comparable and conclusions have been diverse. While
mentioning, for example, the technique used and maternal
age as background information, most studies have not
included the initial reason for using ART. Moreover, the
target groups have been too small to give accurate data of
rare conditions. For methodological challenges see later
section ‘Methodological challenges of research of the
effects of ART’.
Despite the ambiguity of the studies, recent reviews of
studies conclude, however, that children born following
ART are at increased risk of birth defects compared with
spontaneous conceptions.13,15
Multiple gestations
Multiple gestations are a major problem with ART and risky
for both the woman and the fetus.11 Risks to the mother
include inter alia hypertensive disorders, pre-eclampsia,
thromboembolism, urinary tract infection, anaemia and
vaginal–uterine haemorrhage (placental abruption, pla-
centa previa), and fluid overload in association with
parental tocolysis.147 Risk of stillbirth and early postnatal
deaths are increased. Obstetric, neonatal and long-term
consequences of multiple gestations for the health of ART
children are enormous, resulting mostly from premature
birth and low birth weight.147 Cerebral palsy is one of the
most significant neurological impairments associated with
multiple births, and increases in line with the number of
fetuses.147
ESHRE has set the reduction of the multiple pregnancy
rates as a high priority for assisted reproduction pro-
grammes in 2000.20 Moreover, Scandinavian experts have
debated for new strategies to avoid multiple pregnancies
and suggested that (i) clinics should endeavour to imple-
ment one-embryo transfers; (ii) two-embryo transfer
should be used only for those women who are at low risk
of multiple pregnancy; and (iii) ART results should be
presented as ‘birth per embryo transferred’ and this term
should be given the status of ‘the criterion of ART
excellence’.148 If a singleton pregnancy is the goal of the
infertility treatment, then a multiple gestation could be
viewed as a complication of the treatment.149
One of the most promising practices to reduce twin
pregnancies has been elective single-embryo transfer
(eSET).72,73,150,151 Cryopreservation is essential in conjunc-
tion with this application.72 An important issue is how to
select patients suitable for eSET and embryos with a high
putative implantation potential. The typical patient sui-
table for eSET is young (agedo36 years) and in her first or
second IVF/ICSI trial. Embryo selection is performed using
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one or a combination of embryo characteristics.72,73,151,152
In Sweden, where a practise of single-embryo transfer was
put into effect in January 2003, the rate of SET is now
approaching 70%, with the rate of multiple pregnancies
going below 10%.72 Although PGS does not seem beneficial
in an environment of transfer of unrestricted numbers of
embryos, it may prove to be of more value in single-
embryo transfer.9
Multiple gestations may not be totally preventable,
because some techniques (eg, assisted hatching) have been
associated with monozygotic twinning.153,154
Other risks to the woman
Among the patients who become pregnant after assisted
conception, around 4% of the pregnancies will be ectopic.
The embryos migrate to the ostial ends of the tubes after
transfer, or they may inadvertently be placed there when
they are transferred. Heterotopic pregnancy (a multiple
pregnancy with one embryo in uterus and one in the tube)
is extremely rare with natural conception, but the rate may
be as high as 1% in assisted conception. Careful ultrasound
monitoring after assisted conception detects these risks.155
Oocyte procurement also produces a risk to the woman,
because she has to undergo superovulation and oocyte
retrieval, which involve the risks of ovarian hyperstimula-
tion syndrome. In particular PGD demands many oocytes.
The risk of hyperstimulation could be avoided by using in
vitro maturation (IVM) of oocytes when treating inferti-
lity.156
The discussion of possible long-term effects of the
hormones and other medication to woman’s health has
initiated some studies to examine the connection between
ovulation-inducing drugs and gynaecologic cancers and
breast cancer. A review article31 has analysed these studies
and while not finding reasons for concern demands,
however, prospective, larger-cohort, multicentre studies
with longer follow-up periods. The article notes further
that gynaecologic cancers may be overdiagnosed among
infertile women, because of the careful follow-up during
treatments or because an already existing cancer might be
stimulated by the hormonal changes. According to a recent
French study, infertility treatments do not increase the
incidence of a breast cancer.157 More research is needed for
ovarian cancer risk, despite some reassuring results.158
Adverse effects to the child
Diverse studies Several studies and large reviews have
tried to evaluate the risk of adverse effects of ART to the
child, but the results are partly controversial. As mentioned
earlier in section ‘Multiple gestations’, multiple gestations
constitute clearly the major risk to the child. Many of the
other causes behind adverse outcomes are unknown,
although studies have suggested correlations with ART
and in particular ICSI.
Hansen et al159 concluded that infants conceived with
the use of ICSI or IVF have a twice as high risk of a major
birth defect as naturally conceived infants, even though
the absolute numbers are quite low.
It is not clear why also IVF singletons seem to do worse
than their naturally conceived counterparts in terms of
perinatal outcomes.160 Data on obstetric outcome and
neurological sequelae,161 obtained by crosslinkage with the
Danish national registries on 9557 born IVF/ICSI children,
642 survivors of a vanishing co-twin, 5237 singletons from
single gestations and 3678 twins from twin gestations
originating from clinical pregnancies detected by trans-
vaginal sonography in gestational week eight, showed
significantly increased risk of preterm birth, low birth
weight and a tendency towards increased risk of cerebral
palsy in survivors of a vanishing twin (A Pinborg, personal
communication). Thus, vanishing twins and poorer out-
comes in the surviving co-twin might explain some of the
difference between IVF and naturally conceived singletons
and may stimulate towards a general policy of single-
embryo transfer. A comparison of medical records on
malformations in 1139 infants consisting of 736 single-
tons, 200 sets of twins and one set of triplets born after ICSI
with all births in Sweden using data from the Swedish
Medical Birth Registry and the Registry of Congenital
Malformations,162 showed that the increased rate of
congenital malformations mainly was a result of a high
rate of multiple births. These data illustrate that factors
(double-embryo transfer) associated with ART rather than
the techniques themselves may lead to poorer perinatal
outcomes, and increased prevalence of malformations.
One Finnish study concluded that neonatal outcome
after IVF is worse than in the general population with
similar maternal age, parity and social standing, mainly
owing to the large proportion of multifetal births. The
higher prevalence of heart malformations did not, how-
ever, solely arise from multiplicity but also from other
unknown causes.163
A thorough US examination164 of all relevant articles
(2444 articles, out of which 169 were found eligible for
review) concluded that the evidence generally was sugges-
tive of no association between ART and the rates of the
serious malformations. According to the review, there is: (i)
enough evidence that ART is associated with some adverse
neonatal outcomes (low birth weight, perinatal mortality,
premature birth also in singleton births); (ii) suggestive
evidence of an association with ART and some congenital
conditions (Angelman, Beckwith–Wiedemann); and (iii)
suggestive evidence of no association with paediatric
cancer and adverse psychosocial and developmental out-
comes.
A new international multicentre cohort study12 was
designed to examine both birth defects and mental
development of children born after ICSI, IVF and natural
conception, consisting altogether of 1500 children from
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several European countries, who were followed up to age 5.
The study concluded that singleton IVF and ICSI children
were more likely to need healthcare resources than
singleton babies born after natural conception. Assessment
in general was reassuring, excluding higher rates of
congenital abnormalities among ICSI children.
A large Danish study observed equal frequencies of
childhood cancers, mental diseases, congenital syndromes
and developmental disturbances in 442 349 singleton non-
IVF and 6052 IVF children,165 and did not find support for
previous suggestion of an association between ART and
retinoblastoma.166 Lidegaard and colleagues observed,
however, an 80% increased risk of cerebral palsy among
IVF children.
A Swedish population-based study on possible excess of
congenital malformations came to the conclusion that
there is an increased risk for congenital malformations
after IVF, regardless of the technique used, and is mainly
owing to parental characteristics.62
Epigenetics Evidence has been presented from animal
systems that in vitro embryo culture and embryo mani-
pulation affect epigenetic mechanisms such as DNA
methylation and imprinting.167 The safety of ART at the
epigenetic level has not been well studied. Epigenetics
refers to the phenomena where modifications of DNA
methylation and/or chromatin structure underlie changes
in gene expression and phenotype characteristics. Epige-
netics cover a broad range of effects: DNA methylation,
imprinting, RNA silencing, covalent modifications of
histones and remodelling by other chromatin-associated
complexes. Disturbance of epigenetic reprogramming may
influence gene expression and phenotype characteristics.
Moreover, epigenetic changes that occur shortly after
fertilisation, before specification of the germ line, will
involve both somatic cells and germline cells, and may lead
to inheritance of an epigenetic trait resulting in transgenera-
tional phenotypes. An important property that distinguishes
epigenetic modifications from genetic modifications or
mutations is their potential reversibility.167
Environmental factors like superovulation and culture
medium may interfere with overall methylation repro-
gramming and embryonic development. A higher percen-
tage of aberrant genome-wide methylation patterns were
observed in two-cell embryos from superovulated female
mice and when specific synthetic media were used.168 DNA
methylation plays also an important role in the mechan-
ism of genomic imprinting.
Imprinting Imprinted genes exhibit a parent-of-origin
specific pattern of expression. Imprinted genes play key
roles in embryonic growth and behavioural development
and they are also involved in carcinogenesis.167 Such genes
have been shown to be targets of molecular defects
in particular genetic syndromes such as Beckwith–
Wiedemann (BWS) and Angelman syndrome. Several
recent studies suggest a possible link between ART and
genomic imprinting disorders.169 – 175 For instance, the
data resulting from studies of Marques et al175 suggest an
association between abnormal genetic imprinting and
hypospermatogenesis, and that spermatozoa from oligo-
zoospermic patients carry a raised risk of transmission of
imprinting errors.175 Moreover, a recent investigation
suggests that superovulation may be associated with
defects of genetic imprinting.16
BWS is an overgrowth disorder resulting from mutations
or epimutations affecting imprinted genes on chromosome
11p15.5. Angelman syndrome is characterised by severe
mental and motor retardation, lack of speech and a happy
appearance and is linked with a loss of function of the
maternal allele of UBE3A on chromosome 15. The
mechanism is often imprinting.176
Subfertility per se may be associated with an increased
risk of conceiving a child with an imprinting defect,
meaning that some couples may have a genetic defect
which predisposes to subfertility, and which also increases
the risk of an imprinting defect in the child. Moreover,
superovulation rather than ICSI may further increase the
risk of conceiving a child with an imprinting defect (B
Horsthemke in an interview, see).16,164
Nevertheless, a recent large-scale national follow-up
study in Danish children born after IVF did not reveal
any increased risk of imprinting diseases.165 Accordingly,
Danish register data do not support reports of an increased
risk of imprinting diseases after IVF.
ART includes the isolation, handling and culture of
gametes and early embryos at times when imprinted genes
are likely to be particularly vulnerable to external influ-
ences. Amino-acid concentrations, folate concentrations
and serum in the culture media can affect gene expression.
Additionally, it has been noted that the process of
extended culture in mice (eg, permitting extended embryo
development before transfer) can cause imprinting pro-
blems leading to abnormal development.172,177 Poor
culture conditions may also influence the human embryo,
but this has not been studied. Consequently, a need for
studies on the effects of the culture media was stressed in
the workshop in Sevilla.
Evidence of sex-specific differences in imprint acquisi-
tion suggests that male and female germ cells may be
susceptible to perturbations in imprinted genes at specific
prenatal and postnatal stages. Imprints acquired first
during gametogenesis must be maintained during pre-
implantation development when reprogramming of the
overall genome occurs. The understanding of genomic
imprinting has been developed, including the mechanisms
and timing of imprint erasure, acquisition and mainte-
nance during germ cell development and early embryo-
genesis, as well as the implications of this research for
future epigenetic studies in reproduction and ART.178
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One study found a clear sex-related growth difference in
human blastocysts originating from ICSI, but not in
blastocysts from IVF. The mechanism responsible for the
findings remains unknown so far, but according to the
study group’s hypothesis the ICSI procedure might inter-
fere with the process of imprinted X-inactivation.179
ICSI
Risk factors ICSI is a widely used microinjection techni-
que, practised since 1992, and has a high success rate,
particularly in cases with a male infertility factor. However,
there has been concern of genetic, congenital and devel-
opmental abnormalities in children born after transfer of
ICSI embryos (eg, Golombok,180 Braude and Rowell181 and
Bondulle et al182). The use of ICSI technique may overcome
natural barriers of conception. See above page 5 for more
information on male infertility and a risk of conveying
infertility and other diseases to the offspring. For imprint-
ing, see previous subsection.
PGD procedures using PCR require ICSI for technical
reasons to avoid DNA contamination, whereas conven-
tional IVF may be utilised for PGD where FISH is used.
Some opinions are in favour of adding PGD to the ICSI
procedure in case testicular spermatozoa is used owing to
the risk of aneuploidy presenting in the offspring (WHO18,
p 387).
In France, the French National Consultative Ethics
Committee for Health and Life Sciences (Le Comite´
consultatif d’e´thique national pour les sciences de la vie
et de la sante´, CCNE)183,184 has addressed the issue of ICSI
and referred to the considerable experience of the AZ-VUB
in Brussels.185 According to CCNE, the following informa-
tion was obtained regarding the studied risks, which fall
into two main categories:
(a) Risks linked to the ICSI method itself: For example, there
is the risk of introducing foreign material into the
oocyte (toxin, virus, DNA, particles, etc) or of a trauma
to the oocyte caused by the perforation. The literature
does not so far provide any publication confirming or
refuting such fears for humans. A recent study on
monkeys has, however, mentioned the possibility of
lesions to the meiotic spindle. Another study evi-
denced the incorporation of a fragment of foreign DNA
in the embryonic genome after ICSI.183
(b) Risks linked to parental factors: Male-factor infertility
differs from female-factor infertility in that there is a
more considerable involvement of chromosomal ab-
normality in its origins. Possible transmission of
infertility to the child and a risk of congenital disorders
exist.183
Adverse outcomes of ICSI First 5-year follow-up studies on
ICSI children’s physical health182 and psychological well-
being and cognitive development,186 published in 2004,
were mostly reassuring in stating that ICSI has not affected
the children’s well-being.
1. Chromosomal aberrations: Available data so far have
shown that there is a small but definite increased risk
of chromosomal abnormality (1.6%) to children born
after being conceived by ICSI.181 Several studies of
Bonduelle and colleagues and others have shown that in
ICSI children the incidence of de novo and inherited
chromosomal aberrations is approximately three times
higher than in the general population.159,187 Some
other studies have shown a higher incidence of
chromosomal abnormalities in TESE spermatozoa.55,69
2. Major malformations: A 5-year follow-up study of ICSI
children found increased incidence of major congenital
malformations, particularly in boys.12 It was recognised
that at least 30% of congenital anomalies are missed at
birth and so the higher rates of anomalies at 5 years was
not considered surprising. The higher rates of genitour-
inary defects were suggested to reflect paternal genetic
factors rather than the procedure itself. Ka¨llen et al62
found excess of hypospadias after ICSI compared to
other IVF. For imprinting, see subsection ‘Imprinting’.
Also, increased risk of musculoskeletal defects and
mental developmental delays has been detected.159
3. Growth and cognitive development: The potential impact
of ICSI on the cognitive development of children has
raised some concern.180 However, according to a newly
published psychological follow-up study of 5-year-old
ICSI children, ICSI does not appear to affect the
psychological well-being or cognitive development at
age 5, even though some lower scores in certain
performance tests, compared to a control group of
naturally conceived children, were found.186
4. Several issues, which need to be further addressed in
relation to different aspects of ICSI outcome have been
listed, including the role of prenatal testing during ICSI
pregnancies: the significance of malformations among
terminated pregnancies and stillbirths; the outcome of
ICSI pregnancies in cases where nonejaculated sperm has
been used; the incidence of abnormalities in children
after replacement of frozen–thawed ICSI embryos; and
the long-term follow-up of ICSI children.187
PGD Blastomeres at the four- to 12-cell stage are not
identical, but instead express different regulatory proteins.
Certain patterns of fragmentation can result in the partial
and nearly total loss of the regulatory proteins and the
development potential of the biopsied embryo may thus be
disturbed.85 Thus, removal of one or two cells from the
embryo might theoretically involve a risk of impaired
development of the embryo and a potential risk to the
offspring.
However, one study, published in 2004, has reviewed the
12-year experience of three of the world’s largest PGD centres
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and analysed the clinical outcome of PGD in USA and
Italy.111 The study comprised 754 babies as a result of 4748
PGD attempts. The incidence of birth defects rate compared
to that of the general population was almost equal.
The aforementioned New Zealand study noted that there
are suggestions of an increased incidence of rare epigenetic
disorders in babies born as a result of reproductive
techniques such as IVF and ICSI, which could apply
equally to babies born after PGD.113
The report of the first 5 years experience of PGD
suggested that PGD is a safe and feasible technique.188 It
rose, however, a question whether there is a causal
relationship between biopsy procedure and the occurrence
of monozygosity.
Polar body diagnosis has not been observed to have
detrimental effects on children born after the procedure.81
Other techniques related to ART
 Cryopreservation might affect gene expression or lead to
other molecular effects such as ‘telomere shortening and
replicative senescence, damage to plasma and nuclear
membranes, and inappropriate chromatin condensa-
tion’.177 It has also been shown that an increased
chromosomal aneuploidy rate can be found in frozen–
thawed embryos.189 However, Wennerholm concluded
in a thorough review that cryopreservation of embryos
has no apparent negative impact on perinatal outcome
and early infant development. The available data do not
indicate an elevated congenital malformation rate.162
The possibility of risks of cryopreservation of GV-stage or
metaphase-II-stage oocytes for health, developmental
potential and for predisposition to epigenetic or genetic
abnormalities is still being debated (eg, Boiso et al190 and
Chen et al191).
 IVM: Some patients may benefit from natural cycle IVF
with in vitro matured human oocytes.156,192 However,
research on the potential risks of in vitro maturation of
human oocytes for the health of the oocyte and embryo
is also still at its early stage. When oocytes are retrieved
from the ovary for IVM before the maternal imprinting
has been completed, a theoretical risk for congenital
abnormalities and genetic disease owing to imprinting
errors exists. Also, in vitro culture of human oocytes has
been associated with the premature separation of
homologous chromatids, which can lead to trisomy
formation (F Pellestor, personal communication). For
instance, in Italy, oocyte freezing has been imposed by
the law as the only possible way to overcome the need of
repeated ovarian stimulations. However, oocyte freezing
is an experimental technique and possible risks are not
adequately studied (some countries have banned its
clinical use at the moment).
 Assisted hatching (or any manipulation of the ZP) has
been associated with a higher incidence of monozygotic
twinning154 and an increased risk of twins carried in the
same amniotic sac, which can lead to malformation,
disparities in growth and pregnancy complications.153
 Ooplasm transfer: In practice, oocyte donation is the only
way to avoid passing mitochondrial disease from mother
to child. The indications for preimplantation genetic
treatment of mitochondrial disorders seem very remote,
but one such approach, ooplasm transfer, has been
discussed and even tried as a means to avoid mitochon-
drial disease in the fetus when the mother is a carrier of a
heteroplasmic mitochondrial mutation.193 Moreover,
ooplasm transfer has been used for women whose
fertilised ova do not develop normally, presumably
owing to a deficiency in their mitochondria. To remedy
this problem at the time of fertilisation, the oocyte is
injected with donor cytoplasm. The donor mitochondria
could be passed on to future generations through the
resulting child. The use of cytoplasmic transfer had by
the year 2001 led to 30 children born worldwide, but
unexpected results appeared (in two out of 30 pregnan-
cies the embryo’s karyotype was 45, X) and the possible
risks to the physiology of the early embryo are not
known.194,195 This treatment has now been disallowed
in the USA by the FDA because of safety concerns. An
alternative approach might be nuclear transfer into an
enucleated oocyte with normal mitochondria, as abnor-
mal mitochondria (ie, mutations) tend to overcome the
normal population of the cell ( J Egozcue, personal
communication). Whether ooplasm transfer should be
regarded as ‘a genetic manipulation of an embryo’,
which is illegal in many countries, remains unsolved.
 Gamete retrieval before cancer treatment: In case gametes or
testicular or ovarian tissue have been removed before
cancer treatment and are subsequently used for IVF,
there may be a risk of passing on mutated genes leading
to hereditary cancer. Therefore, the possible hereditary
aetiology of the cancer should be investigated.
Follow-up studies
Bonduelle et al196 – 198, in particular, have performed many
international follow-up studies of ICSI, but owing to the
relative novelty of the technique, ongoing follow-up is
needed. The ESHRE PGD Consortium will in the future
focus on the data from centres that take care of the
complete PGD cycle, from patient intake to transfer and
intends to extend the follow-up to the babies.7
Many countries and professional organisations have
stressed the need for systematic, long-term follow-up
studies on the children born after ART. The problem with
follow-up studies is, however, that only a minority of
parents want to inform their children about the use of ART.
If follow-up studies are conducted with these children
issues regarding informed consent and privacy will raise.
Parents should be encouraged to take part in follow-up
studies of health and development of their offspring.
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Methodological challenges of research of the effects of
ART
The research is challenged by multiple biases, such as
confounding effects (twins vs singletons; maternal and
paternal infertility; age); multiple steps (ovarian stimula-
tion, gamete manipulation, IVF, ICSI); and techniques
(ejaculated vs nonejaculated sperm; IVF vs ICSI; early
embryos vs cultured blastocysts). In addition, reliable
results would need larger samples to demonstrate a
potential increase of rare diseases (eg, the incidence of
Prader–Willi or Angelman syndrome is 1/15 000,167 but
ART births represent only a small percentage of all births.
Moreover, future lifetime effects may be difficult to
connect to ART. Transgenerational effects are so far mostly
unknown and very difficult to show. Prospective, large
cohort, lifelong, multigenerational multicentre studies
would be extremely important.
Quality and safety of procedures
Need for quality assessment for the ART process
So far, there have not been common European rules and
regulations to guarantee minimum standards. The risk of
transmission of diseases and other adverse effects has raised
concern, resulting in legislation and guidance at European
level. EC Directive 98/79/EC on in vitro diagnostic medical
devices defines the essential requirements that devices
must meet before being placed on the market and obliges
mainly the manufacturers. The first European initiative to
common standards for procurements, preservation, proces-
sing and distribution of organs, tissues and cells was
published by the Council of Europe in 2002 and was
revised in 2004 (Council of Europe, 2004), but it does not
concern gametes.
The quality and safety of the procedures of gamete
retrieval, preservation and processing will hopefully be
improved now that the European Union has in 2004
accepted the ‘Tissue Directive’ 2004/23/EL that will set
standards of quality and safety for the donation, procure-
ment, testing, processing, preservation, storage and dis-
tribution of gametes, when also its technical parts become
approved. For further details, see Appendix A.
Quality in the ART requires involvement of clinics,
laboratories and treatment procedures. Personnel should
be competent, committed, well informed and educated.
Attention should be paid to internal and external controls,
documentation and validation. Quality of culture media is
very important. A high-quality IVF clinic offers proper and
optimal treatment for the patient, which increases the
chance of having good quality embryos for analysis and
treatment, with good and stable results.
Workshop participants in Sevilla were unanimous
that European clinics should be certified or accreditated
and licensing systems should be developed by
professional self-regulation. Minimum quality standards
should be set. Transparency and patients’ rights should be
secured.
Professional guidelines
The ESHG is an international professional society founded
in 1967, which promotes research in basic and applied
human and medical genetics and facilitates contact
between all persons who share these aims. The ESHG has
issued several policy reviews and recommendations, for
instance, it has examined professional and scientific views
on the social, ethical and legal issues that impact on the
provision of genetic services in Europe, and was worried
about equal accessibility and effectiveness of genetic
services, quality assessment of services, professional educa-
tion, multidisciplinarity and division of tasks, as well as
networking.134
The main aim of the ESHRE is to promote interest in, and
understanding of, reproductive biology and medicine. It
does this through facilitating research and subsequent
dissemination of research findings in human reproduction
and embryology to the general public, scientists, clinicians
and patient associations; it also works to inform politicians
and policy makers throughout Europe. On a more applied
level, it aims to promote improvements in clinical practice
through organising teaching, training and continuing
medical education activities, developing and maintaining
data registries and implementing methods to improve
safety and quality assurance in clinical and laboratory
procedures. It has issued, for instance, best practise guide-
lines for clinical PGD and PGS.77 ESHRE has important
subgroups, for example, the ECIT (www.ecit.org), which is
planning a European-wide network for electronic data
collection from ART clinics.
The IFFS is an international democratic body whose first
objective is to create links among countries, peoples and
cultures in the field of Human Reproduction. The IFFS aims
at stimulating the quality of care and the spreading of
knowledge and awareness in the field. It also wants to
contribute to the standardisation of terminology and
evaluation of diagnostic and therapeutic procedures in
the field of reproduction. IFFS organises World Congresses,
workshops and issues consensus papers and official state-
ments in order to help national societies in their specific
objectives. It has conducted a survey of the current status
of ART procedures around the world.25
The PGDIS was established in 2002 and has published
guidelines for good practice in PGD in October 2004. The
guidelines contain consensus points of general application
that promote quality laboratory practice, enabling PGD
centres to offer a good clinical outcome to their patients. A
variety of aspects related to a safe working system have
been taken into consideration, based on the assumption
that a quality programme depends on everybody’s co-
operation (PGDIS).
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The EMQN started in 1998 to promote quality in
molecular genetic testing through the provision of external
quality assessment schemes and the organisation of best
practise meetings and subsequent publishing of best
practise guidelines. It is an independent nonprofit organi-
sation with a large network and has received funding from
the EU under the framework FP4. Best practise guidelines
on testing for individual diseases are available at the EMQN
website (www.emqn.org).199 The EMQN is based at the
National Genetics Reference Laboratory (Manchester), St
Mary’s Hospital, Manchester, The United Kingdom.
The International Clearinghouse for Birth Defects Re-
search and Surveillance (ICBDSR) and European Registra-
tion of Congenital Anomalies (EUROCAT) follow closely
ART issues, but they have not issued opinions or policies.
Liability Questions of medical responsibility usually arise
in situations which involve risk taking.200 A child may be
born affected after the use of ART for several reasons. To
begin with, some adverse effects on the child may be
connected to ART (see Chapter 8). The question may arise,
whether someone is liable for a birth of an affected child in
such cases. In this contex, it is extremely important that
professionals pay attention to informed consent procedure,
and present the anticipated risks before decision-making.
Secondly, in case of a negligent medical action, the birth
of an affected child may be regarded as damage, for which
parents may present claims of ‘wrongful birth’ against a
genetic counsellor or doctor. The parents may claim that,
as a result of the fault, they have been deprived of the
opportunity to eliminate or terminate the pregnancy and
they are burdened with a sick or handicapped child. The
counsellor may have failed to inform of the risk of a genetic
illness in a child; to inform about the available new
techniques (eg, PGD) and/or of risks and uncertainty of the
outcomes; or to carry out tests and interpret the results
correctly, which would have disclosed abnormality in the
fetus.201,202 Both false-positive and false-negative test result
as well as false interpretation of the consequences of the
result might be equally serious and lead to, for example,
unintended family planning decisions, such as giving birth
to an affected child or a termination of pregnancy based on
misinterpretation of the results.
Also, a child might bring a claim in respect of its
‘wrongful life’ on the basis of his/her impaired existence or
‘prenatal injury’ thorough the negligence of the medical
expert. Such court cases have been taken place especially in
the USA. A high proportion of such cases result from
laboratory errors, which are in general clearly recognisable
as negligent. The claims are usually rejected on the grounds
that it is not better to be dead or aborted than alive with
deficiencies.202
In the continental legal tradition, the general rules of
liability require both fault (negligence) and a causal
connection between the fault and the consequence. In
case of negligence, one ought to have acted otherwise. The
fault is in causal connection, if in its absence the damage
could have been prevented. Lesions to meiotic spindle
during ICSI could be considered malpractice, for instance.
In case of a wrongful birth or wrongful life, the physician
cannot be held responsible for causing the illness, handi-
cap, etc; the damage to which he contributed is the birth of
the affected child, to the extent of having disabled the
pregnancy or its termination. Different arguments can be
reasoned when considering the compensation of the
damage in such cases.201 The legal tradition is different in
the Anglo-Saxon world, though.
If the clinical procedures, including informed consent,
have been appropriate, diligent and in accordance with
professional standards, and the parents have made a
voluntary autonomous decision on starting the treatments
and pregnancy, grounds for successful wrongful birth
actions should not exist. It has been argued that the
nondirective method of clinical geneticists may protect
professionals from overinvolvement with clients and
perhaps also from litigation.96
Research frameworks
Need for long-term monitoring
When new techniques have emerged in the field of
infertility treatment, they have often been taken into
routine clinical use without appropriate research with
case–control studies, etc. The chance that even the oldest
and best established methods of IVF would create problems
in the children in older age, for example, owing to
imprinting errors, is not known, as the oldest children
are not more than 27 years old. Animal studies on this
subject are not feasible because of the huge differences in
species in this area. The experience and knowledge about
the safety of the techniques have accumulated just by
using them. It has been possible to investigate the
techniques only retrospectively by research groups and
professional organisations like ESHRE. As the couples
coming to infertility treatment are often very well aware
of the possible techniques to be applied, it would be
extremely difficult at present to collect control material for
the existing, but not thoroughly investigated techniques in
use.
Consequently, there is a clear need for more experience
and data, as well as basic research in many aspects of IVF, in
particular follow-up studies of long-term effects on artifi-
cially conceived children. Moreover, empirical data on the
psychosocial consequences of ART, counselling and of
infertility/subfertility, is lacking. Long-term monitoring of
developmental and psychological outcomes for parents
and offspring, and their inter-relations is hence needed.
Long-term studies are complicated by the lack of register
and monitoring systems, partly owing to the parents’ wish
to keep the nature of conception secret from their children,
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who subsequently are not aware of the use of artificial
means resulting in their birth. Also, personal data protec-
tion requirements set limits to such research requiring
separate consent procedures.
In this line, ‘The European IVF Monitoring (EIM)
Programme’ was initiated in 1999 with the aim to start a
collaborative IVF data collection programme for all
European countries. The data includes regional informa-
tion for Europe on direct clinical results, but also on side
effects, follow-up of children’s well-being and also on the
availability and the structure of services in the different
countries. ESHRE collects, audits and publishes the data on
an annual basis. Thus, the reports allow for comparisons
between different countries in Europe and other regions of
the world.
Research needs on some of the techniques
Among the techniques that seem particularly to require
closer monitoring is ICSI, which is a widely used and
clinically accepted micromanipulation technique in many
countries.25 The effect of ICSI treatment on the risk for
congenital malformation should continue to be moni-
tored. Further animal studies are needed to evaluate the
safety of some procedures. Some stress the need to develop
methods to detect aneuploid spermatozoa so that these can
be excluded for ICSI (WHO18, p 387). The collection of
information on congenital abnormalities of IVF and ICSI
births needs to be more rigorous including data from
neonatalogists, epidemiologists, statisticians and child
development specialists (President’s Council on Bioethics
(PCBE)203, p 73).
Reports have raised a question on whether abnormalities
seen in ART are epigenetic rather than genetic,204 or
whether in fact they relate to the aetiology of the
infertility.16 Research is hence needed to find out the role
of ART in abnormalities, that is, imprinting errors, and
what specific step of ART is responsible for the connection,
if any.
Also, the safety of PGD needs to be confirmed in even
larger series. PGD is fairly accurate, but the possibility of
misdiagnosis does exist and it has been reported.7 Further
research is needed on the sensitivity, specificity and
predictive value of PGD for the detection of aneuploidy
(WHO, p 389). In detection of single gene defects where
amplification of specific gene sequences is carried out by
PCR, accurate and reliable diagnosis can be hampered by
amplification failure, contamination and allele drop out,
and therefore new PCR strategies are continuously being
evaluated.205 The problem of mosaicism might require
further research as results show that only a minority
(o35%) of human embryos derived from IVF have a
normal chromosome complement in all the cells and the
nucleus of one cell may not be representative of another.
The effects of removing some blastomeres from the early
embryo would also need closer evaluation.85 Initial
evaluation has shown that PGD has no adverse conse-
quences on early development,81,206although it has been
shown that in PGD after ICSI, a significantly higher rate of
inherited chromosomal anomalies related to a higher rate
of constitutional chromosomal anomalies is found, mainly
in the fathers.197 An interesting research question would be
whether constitutional chromosome anomalies increase
the risk of de novo chromosomal anomalies. The hypothesis
of a higher risk of postzygotic events as a consequence of
the ICSI procedure leading to a higher proportion of
chromosomal mosaicism requires further investigation. It
can not be excluded that the technique itself plays a role in
the formation of those abnormalities.207 In any case, ICSI is
considered a highly invasive technique, and its use should
be limited to strict indications. Attention may also be paid
to consider circumventing the need to use ICSI when using
PCR for PGD (M Pembrey, personal communication).
The latest techniques involving oocyte freezing and
oocyte culture starting from ovarian biopsy are still
experimental and their results should be systematically
collected and followed. This applies to testicular biopsies as
well.
Assisted hatching is a rather widely used micromanipu-
lation technique, but conclusive data attesting to its
usefulness are lacking. In the case of cytoplasmic transfer,
foreign mitochondrial DNA seems to be maintained in the
infant, which has caused some concern, although abnorm-
alities attributable to this foreign DNA have yet to be
identified.25
The possible safety of analysing the first and/or second
polar body instead of one or two cells of the embryo in the
cleavage stage or later has not been proven in large studies.
Further research on societal issues
Many of the aspects of ART are not known and should
hence be systematically studied. What are the ways of
selecting oocyte, sperm and embryo donors? Are genetic
criteria applied, and if they are, are they based on the real
understanding of genetic risks or misconceptions and
prejudices? Do individuals with a genetic cause for their
infertility choose such ART that prevent them from
transmitting the infertility to their progeny or can we
foresee that genetic infertility will become more common
in the future? What type of information and counselling is
offered to couples and how it is understood? Which
professionals are in charge in different stages? What is
the impact of counselling (or the lack of it) to the decision-
making process?
Further research on the selection of patients and on the
cost–benefit ratio are needed for the evaluation of SET.208
A European wide study of ELSI (ethical, legal and social
implications) of ART is needed to detect social drivers
within the community as patients and services move cross
borders.
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Funding of the research
Some of these issues have clear implications on public
health as children born using ART constitute already a
considerable part of the new generations. It is estimated
that in some European countries, 5% of all births are owing
to ART.18 Thus, public funding on national and EU level
should be made available for studies like ELSI, for instance.
At the beginning of 2005, the Commission will present its
proposal on FP7, including its suggestions for thematic
research priorities.
Cautious attitudes towards an embryo research prevent
funding, even though it would result in more information
of the first moments of human life and serve the safety of
the techniques, as preclinical studies are essential for
examination of the safety before introducing the techni-
ques in clinical practise.
Collaboration between different professional groups is
important to avoid parallel work. An encouraging example
is cooperation between the ESHRE and the New Zealand’s
respective group.113
The European Group on Ethics in Science and New
Developments (EGE) has in its opinion of 14 November
2000, ‘Ethical aspects of human stem cell research and use’,
considered that stem cell research can be funded by the
Framework Programme of research of the European Union,
if it complies with ethical and legal requirements as
defined in the programme. In the context of European
pluralism, EGE leaves the issue of allowing or prohibiting
the embryo research for each member state. The EGE also
sees that stem cell research based on alternative sources
(spare embryos, foetal tissues and adult stem cells) requires
a specific Community research budget. It recommends that
the EU should insist that the results of such research are
widely disseminated and not hidden for reasons of
commercial interest.
Regulation of embryo research
Research of embryos, children and pregnant women is
strictly regulated in many countries and is also addressed in
international conventions. Research on embryos is highly
controversial in some countries. Nevertheless, great im-
provements have been achieved by research on preimplan-
tation embryos, for example, with variations in culture
media. Also much is learned about chromosomal abnorm-
alities.25 Embryo research may hence be considered
essential for improvement of ART, but there are sensitive
issues, such as procurement of research embryos; whether
to use surplus embryos or embryos created on purpose;
destruction of embryos; and the possibility to implant an
embryo that has been a subject to research. The time limit
for how long embryo culture and research in vitro is allowed
needs to be defined. Generally countries seem to have
adopted a 14-day rule.25
Research on embryos usually requires informed consent
of the couple or donors and many countries also require a
licence from a specific governing body and/or an ethical
body.
Article 18 of the Convention on Human Rights and
Biomedicine122 concerning research on embryos in vitro
requires adequate protection of the embryo, if the research
is nationally allowed in the first place. The convention
hence leaves this issue of allowing or prohibiting embryo
research for the member countries to decide upon.
However, according to the Convention the creation of
human embryos for research purposes is absolutely
prohibited, and thus only surplus embryos are allowed to
be used for research.
There is an ongoing debate in many countries about the
ethics of creating embryos for research purposes. Many
ethicists think that both the research use on spare embryos
and the creation of embryos for research purposes can be
acceptable, as the moral status of these embryos is the same
and the embryos are instrumentally used in both cases.209
Most European countries have prohibited the creation of
human embryos for research purposes, excluding Belgium,
Sweden and the UK. The following European countries
allow research on stem cells from surplus embryos:
Belgium, Denmark, Estonia, Finland, France, Greece,
Hungary, Latvia, the Netherlands, Slovenia, Spain, Sweden,
Switzerland, and the UK.210 – 213
A new additional protocol to the Convention on Human
Rights and Biomedicine concerning biomedical research
was introduced in June 2004. The protocol covers a full
range of research activities in the health field involving
interventions on human beings. It does not apply to
research on embryos in vitro, but it does apply to research
on fetuses and embryos in vivo. General provisions include
that research may only be undertaken if there is no
alternative of comparable effectiveness.
The CIOMS’s International Ethical Guidelines for bio-
medical research of 2002 recommend that research proto-
cols on pregnant women should include a plan for
monitoring the outcome of the pregnancy with regard to
the health of the woman and the short term as well as a
long-term health of a child.214
The Charter on the Fundamental rights of the European
Union was approved by the European Council in Biarritz
on 14 October 2000 and was adapted to the EU Constitu-
tional Convention in June 2004. The provisions prohibit
different kinds of practices possibly related to embryo
research, namely ‘eugenic practices, in particular those
aiming at the selection of persons and the reproductive
cloning of human beings’.
Public health dimension/public policy
Public health care
The concept of health includes also reproductive and
sexual health according to WHO.2 The problems relating to
justice and equal access to medical services are often raised
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in this context. A fair healthcare system can be regarded to
provide equal access to an adequate level of health care
with a reasonable reimbursement system provided by the
society. It has been argued that medical reasons have
priority on nonmedical reasons and nonmedical reasons of
a personal nature do not qualify public funding.215 In
Europe, genetic services are mainly paid by the public
healthcare system,134 while public funding of infertility
treatments is diversified. There are also health insurance
systems, such as in Germany and Switzerland, for instance.
In addition, both genetic and ART services may also be
provided by the private sector at the person’s own expense.
According to European Organisation of Rare Diseases
(EURORDIS),216 80% of rare diseases have identified
genetic origins (www.eurordis.org) and concern between
3 and 4% of births. The medical community knows
relatively little about rare diseases. An accurate diagnosis,
if made at all, is often made very late, and support is
generally poorly provided by the public health system,
including lack of effective treatment. Some of the rare
diseases can be prevented by PGD.
Increased funding of IVF treatment has been considered
as a key factor in reducing costs related to multiple
pregnancy through increased use of eSET, single-embryo
transfer.151
Access to health care, reimbursement and regulatory
challenges in the EU
According to the Treaty of European Union, health services
are left to national regulation, and therefore harmonisa-
tion of ART is not possible. Tissue Directive of 2004 sets
requirements for safety of some of the procedures. The
access to health care is affected by many factors, such as
preconditions for treatment; availability and acceptability
of different services and techniques; and costs and
reimbursement from the public funds.
A common European approach to the right of health care
and to the individual patients’ rights is becoming more and
more apparent. Patient’s rights fall into two categories: the
so-called individual rights and social rights, the latter
including protection of health and access to health care.217
The right of all European citizens to health protection
can be derived from the Treaty of European Union, whereas
access to health care has not been explicitly mentioned in
the Treaty. The Treaty enables citizens to seek health
services in other member states. In several cases, the
European Court of Justice has ruled that the provisions of
free movement of goods and services shall not be contra-
vened. The free movement of services concerns also health
services meaning that a clinic may operate in another
member state on a temporary basis, even though such
operation would not be allowed by the country in
question. If certain action is legal in the community level
and in one member state, another member state may not
prevent such action on the basis that it is illegal there. This
means, for instance, that a country prohibiting abortion
cannot deny access of a so-called abortion ship to its area.
In case of permanent establishment of healthcare services,
however, the regulation of the member state in question is
to be applied. Respectively, citizens are allowed to seek
PGD and other ART services in another state.
The reimbursement issues in this respect are more
complicated. The cost of infertility treatment may vary
considerably from one European country to another.126
The European Court of Justice has in its practice created
principles concerning the reimbursement. In the case of
Decker and Kohll (1998), the Court held that the home
country had an obligation to reimburse a medical device
and an ambulatory service obtained in another member
state on the basis that it otherwise contravenes the
provision of free movement. In the case of Vanbraekel
(2001), the Court decided that reimbursement of hospital
services shall be based on the insurance coverage in the
treating country, not on the patient’s home country to
guarantee the free provision of services. Establishing prior
national authorisation for obtaining medical services
abroad are allowed, but in the case Geraets-Smits and
Peerbooms (2001), the Court decided that the expression
‘normal treatment’ as a national precondition for obtain-
ing authorisation shall mean normal treatment according
to the state of international medical science and medical
standards generally accepted at the international level.
Authorisation can be refused on the ground of lack of
medical necessity only if the same or equally effective
treatment can be obtained without undue delay at an
establishment having a contractual arrangement with the
insured person’s sickness insurance fund. In respect of
‘undue delay’, only the individual patient’s medical
condition should be taken into account. The case Geraets-
Smits and Peerbooms is interpreted to pave the way towards
harmonisation of the right to health services in Europe.217
In the case Mu¨ller–Faure´/van Riet (2003), the Court
confirmed this jurisprudence. Until now, there are no
known cases relating to infertility treatments in the
European Court of Justice.
A consultation process performed by the Commission
revealed that the Member States have different interpreta-
tions of the jurisprudence. Consequently, the situation of
patients varies accordingly. Patient mobility is considered
negligible according to the report (Commission staff
working paper, 2003, report on the application of internal
market rules to health services). To meet this controversy,
the Commission has proposed a Directive on Services in
the Internal Market. The Directive aims to remove, on the
basis of the case law of the European Court of Justice,
unjustifiable and in particular discriminatory restrictions
on the freedom of establishment and the freedom to
provide services for a variety of activities, including health
services. It does not aim to harmonise Member States’
regulation or modes of delivery of health or social services.
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The proposed Directive does not in any way interfere with
the way Member States organise and finance their health
and social systems. It is for Member States to decide to
what extent and under what conditions private operators
such as private hospitals receive funding from the public
budget or the social security system (Commissions web-
page, internal market, FAQ). This directive has raised many
concerns about provision of health services. Nevertheless, a
recent motion in 2005 has suggested leaving healthcare
services outside the scope of the proposed Directive on
Services.
The Commission has carried out a follow-up on patient
mobility and healthcare developments in the European
Union (COM (2004) 301 final) for a high-level reflection
process. On 15 July 2004, the European Commissioner for
Health and Consumer Protection, David Byrne, launched a
reflection process on EU health policy. This process will
help shape the future EU health strategy. The reflection
paper ‘Enabling Good Health for all’ outlines Commis-
sioner Byrne’s view of the key principles that ought to
guide the development of EU health policy over the
coming years.
While dissimilarity in national regulation and practices
among the Member States as well as crossborder treatments
might stimulate an initiative for drafting uniform stan-
dards, best practice guidelines, etc, the task might be too
difficult owing to European pluralism. However, the nature
and consequences of ART are such that they invoke public
concern and at times stimulate government intervention
in some areas. The key issues are protection of human
dignity; respect for the unborn child and the parental self-
determination in the countries; freedom of research,
freedom of contract and movement between European
countries; and the efficiency of medical care. Conse-
quently, international guidelines should be based on broad
principles, respecting the various national social, legal and
religious aspects.218
Recently, issues connected with gamete/embryo dona-
tion have been subject to vivid discussion. The conflict of
interests between recipients, physicians, donors, society in
general and the future children are not fully recognised in
many societies. Legal regulatory intervention leads to a
decrease in supply, which in turn leads to reproductive
tourism and the ‘Grey Market’, which is made up of
(unauthorised) sperm banks or private persons offering
their services at a lower or nonexistent level of screening,
with the risk of sexually transmitted diseases and possible
legal complications (www.cryos.dk). The worldwide web
provides a number of services available to those who wish
to circumvent limitations of public regulation.
If society wishes to prevent or reduce free market forces,
positive eugenics, low supply, higher costs, reproductive
tourism and Grey Market, it should observe these mechan-
isms. A large international provider of donated sperm,
Cryos, with a practical view on the present situation,
considers it medically and ethically appropriate to have
defined and agreed minimum screening standards. If the
society wants to prevent positive eugenics, it should set
limits with respect to the degree of genetic testing. If the
recipients want a higher level of genetic testing they must
do it themselves (carrier status) or by prenatal screening
(www.cryos.dk).
Economic factors play a central role in the decision-
making process concerning, for instance, diagnostic work-
up of the infertility, PGS, etc, as access in public sector may
be limited, and a considerable part of ART is performed in
the private sector. Out of an ethical point of view, one
could question how to deal with economical considera-
tions. Also, the principles of patient autonomy are, in
practice, easily jeopardised by social, family and economic
pressures on the woman, especially where there is a risk of
remaining without a child; a severe disease in a family; or if
an abnormality in the embryo or fetus is discovered. Some
argue that genetic counselling should clearly be separated
from public health policies.96 On the other hand, doctors
are nowadays seen to have a dual responsibility219 and are
expected to pay attention to social implications as well.
Crossborder treatments The main reasons for cross-
border flow of gametes and patients seeking treatment
abroad are limitations in access to and availability of ART
including: (1) shortage of local donors (usually owing to
regulations about donor identity); (2) too specific selection
criteria for donors or patients for IVF; (3) restrictive
regulation and practices; (4) long waiting times; (5) high
costs; and (6) lack of services or expertise. It is anticipated
that new European member countries will be attractive to
many couples owing to easier access and a lower price for
many treatments.
Crossborder flow of patients Changes in legislation or
other restrictions may increase reproductive tourism. An
example is the Italian law of 2004 on ART, which falls into
the category ‘very restrictive’. Donation of embryos and
gametes is banned, as well as cryopreservation. A max-
imum of three oocytes can be fertilised and every embryo
has to be transferred regardless of its quality or the age of
the woman. PGD is absolutely prohibited. Hundreds of
couples at high genetic risk have started to seek PGD
abroad.126,220 Similar tendencies have been observed in
other countries where PGD is banned. Also, local restric-
tions concerning oocyte donation and compensation for
donors have invited patients to Spain, where in 2004,
almost one-third of ART couples were foreign (German,
Italian, British and Irish, Swiss, Portuguese and some from
South America and Asia, El Pais, 24 January 2005).
Crossborder flow of sperm and oocytes In general,
various countries throughout the world have difficulties
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to produce enough donors and donor gametes to meet the
demand owing to restrictive regulations (especially non-
anonymity, low payment, limitation of offspring). A fresh
example of expected changes in the crossborder need of
gametes is stated by Cryos, which is said to have recruited
50 additional sperm donors to cover the expected shortage
of donor sperm when rules on donor identity changed in
April 2005 in the UK. Semen donated before April 2005
from anonymous donors may be used for treatment until
April 2006 in the UK.
Removal of donor anonymity has reduced sperm dona-
tions a great deal initially, for instance, in Sweden, the
Netherlands and the UK. However (at least in Sweden,
where anonymity was removed in 1985), a new generation
of donors have come forward, who are willing to donate
also nonanonymously. Also, need for sperm donation is
somewhat reduced owing to the possibility today of having
biological children from IVF/ICSI. The EU Tissue Directive
introduces a requirement that tissues and cells must be
traceable throughout the Europe, even though it is not
meant to be a tool for a child to detect its biological parent.
It is not yet clear how traceability will be provided, but
nevertheless, the information remains existing.
Perception of normality
The concept of genetic counselling in connection with
family planning has been questioned in so far as it
increasingly involves the systematic selection of fetuses,
and hence approaches children as consumer objects
subject to quality control. The increasing need for genetic
counselling can be seen as being based on the increasing
number of disorders, which can be diagnosed. There is a
risk that before long, the definition of fetal imperfection
will come to mean any condition that can be diagnosed.
One often used argument against different screening and
tests on the fetus, the embryo or sperm before birth is that
selection unfairly discriminates and will lead to disrespect
of people with disorders, that is, their dignity and human
value would thus be questioned.
With respect to this issue, it is noteworthy that only the
rare Mendelian disorders can be regarded as truly mono-
genic. The majority of genetic disorders result from multi-
factorial traits, which are believed to be the result of not
only the direct effects of one or several genes but also
owing to combinations of genetic and environmental
factors. Furthermore, even in the case of monogenic
diseases, symptoms may vary depending on how the gene
is expressed. This makes decisions about the selection of
the embryos or fetuses based on the intended child’s future
health extremely difficult. As mentioned above, the
increased use of preimplantation diagnostic methods may
lead to tendency to expect, and require perfect babies.
Pregnancy and birth always involve uncertainty and
unpredictability; a child might have a genetic problem,
be damaged in uterus or at birth. The question may thus
arise as to whether the future parents have capability to
cope despite intense prepregnancy planning. Wrongful life
and wrongful birth claims could become more common.202
In trying to create guidelines and a list of indications or
diseases, there is, besides the problems of fixed lists as such,
the problem of concepts. Not even the best determinations
can satisfactorily resolve the problems relating to terms,
such as ‘essentially’, ‘adverse’, ‘severe’, etc. Moreover, a
severe condition may also, in the progress of medicine,
later become treatable and hence be alleviated or even
cured.
Ethical questions
ART from an ethical point of view
The faith and potential destruction of the surplus embryos
resulting from ART appeals to the moral sensitivity of many
people. Some arguments against ART oppose any form of
technical interference in the ‘natural process’ of procrea-
tion. The latest arguments concern the potential weaken-
ing of the gene pool and increasing infertility in the
society. In particular, PGD brings together three areas of
biotechnology each of which have engendered their own
ethical debates: IVF, genetic testing and PND (for the
purpose of selective continuation of pregnancy, or for the
establishment of an unaffected pregnancy). In making the
case for the development of PGD, the contribution of PGD
to the services for families threatened by genetic disease
needs to be set in the broader perspective of all PND
techniques and the associated genetic services.221
The central ethical questions relating to PGD are the
moral and legal status of the embryo and its potential
eugenic dimension.127,222 For some critics, PGD is seen as
‘eugenic’, because it may enable ‘frivolous choices’, that is,
facilitate the selection of children with certain desirable
physical characteristics or intelligence.127 Technologies are
developing rapidly and our knowledge of genetics and the
causes of genetic diseases, or even characteristics, increases
all the time, which easily leads to demands for new
applications.
What is wrong with eugenics?
Some of the consulted ethicists have posed the question
‘What is wrong with eugenics?’ and declined to see the
moral wrongness of aiming to reduce the number of people
with a genetic disorder. The argument of slippery slope is
rather vague. The possibility of abuse is not a sufficient
argument to outlaw the use of a technique. Practices that
some consider as eugenics are not viewed similarly by
others (eg, thalassemia carrier screening in Cyprus before a
marriage licence).
The WHO has issued the following working definition of
eugenics: ‘A coercive policy intended to further a repro-
ductive goal, against the rights, freedoms, and choices of
individual’.29 Upon the WHO’s statement, ‘Under the
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above definition, knowledge-based, goal-oriented indivi-
dual or family choices to have a healthy baby do not
constitute eugenics’, and furthermore, ‘Eugenics is directed
against the whole populations, whereas the work of today’s
clinical geneticists is directed towards individuals and
families’.
On the other hand, it has been suggested that selection
for nondisease genes should be allowed, even if this
maintains or increases social inequality, and pose a
principle of ‘procreative beneficence’, in which couples
select the child of the possible children they could have,
who is expected to have the best life, or at least as good a
life as the others, based on relevant available information.
The arguments used for this is that some nondisease genes
affect the likelihood of leading the best life.223 This
approach is rather controversial. It can be argued that
creating perfect children cannot be the goal of ART and
would mean practising ‘euphenics’, that is, the improve-
ment of the phenotype by biological means.
Even an extensive screening of donors might de facto lead
to euphenics, with or without the aim of enhancing the
gene pool. One could argue, based on equality, that genetic
screening of donors should not exceed what is normal in
the general population before natural reproduction.
Choosing characteristics
It has been reported that parents with a certain genetic
condition, such as deafness or shortness of stature, have
demanded PGD for selection of embryos carrying the same
mutation as them, so that the child would better integrate
into the family. The IBC of UNESCO, for instance,
considers this approach unethical, because it does not take
into account the many lifelong and irreversible disadvan-
tages that will burden the future person.
An UK survey by the HGC in 2001 has found public
support for using genetic information to detect disabling
conditions before birth, but with clear opposition to sex
selection or to selection of mental and physical character-
istics of children (Ref. www.servicefirst.gov.uk/2001/panel/
hgc/index.htm). For more details on sex selection, see
section ‘Sex selection for medical reasons’.
PGD-HLA
Choosing an embryo that may provide stem cells for an
existing person, ‘a saviour child’, leads to ethical discus-
sions regarding instrumentalisation and the best interests
of the future child, concern over reduced genetic diversity,
unnecessary destruction of embryos and moral disapproval
of society.223,224 Compared with many other persons, who
are conceived by accident or without any conscious
thought at all, a saviour child, however, already has a
reason to exist.105 Although some regard the creating of
children as saviour children as acceptable, other arguments
do not support the use of PGD for the selection of embryos
for ‘nonmedical’ reasons.26,27 In particular, the faith of the
embryos that are healthy per se, but not HLA compatible,
needs consideration.225
This question has drawn a lot of public attention,
especially in the United Kingdom over some controversial
decisions made by the HFEA.226 There is considerable
ethical debate concerning this issue among professional as
well (eg, BMJ Autumn 2004). No clear professional guide-
lines exist specifically related to the use of PGD for the
benefit of an existing person. A common objection is that
these children would not be valued for their own existence.
Some professionals suggest that in countries were PGD
already is allowed, using PGD solely for choosing a HLA-
compatible embryo to provide stem cells for treating an
existing person should also be permitted.223,224 France,
Denmark and Norway have adapted new statutes allowing
PGD for HLA matching with a sibling in 2004, and Spain is
preparing amendment in the law in 2005. Also, the HFEA
in the UK has eased its previous strict policy. Moreover, the
IBC has taken a positive attitude to HLA typing as an
additional step to PGD, if it is primarily performed to avoid
an affected embryo (‘selection in two stages’). In contrast,
the IBC considers it unethical to perform PGD with the
only goal of HLA typing and selecting embryos fit for
donorship ‘since the embryo becomes instrumentalised for
the benefit of others’.98
A case report of a 6-year-old girl suffering from Fanconi
anaemia, an autosomal recessive disorder,227 gives the first
example of selection in two stages. PGD was directed to
finding those embryos that did not have Fanconi anaemia
in order to avoid another affected child, but at the same
time HLA typing was used to select for those unaffected
embryos that would be a match for the sibling affected by
Fanconi anaemia.105
A possible criterion to determine acceptability of PGD-
HLA is a so-called ‘postnatal’ test: it is ethically acceptable
to make a child for a certain reason, if it is acceptable to use
an existing child for the same reason. Optimal conditions
might include no cure without transplantation; high
success rate of transplantation; considerable advantage of
using an HLA-identical sibling compared with alternative
donors; and slow progression of the disease, resulting in
sufficient time to wait for the birth of the donor child. A
more general discussion of this solution is needed in order
to determine whether a similar approach would be justified
for other conditions.105
Select or protect? What is the obligation of the
medical profession?
Most societies grant physicians a considerable autonomy in
deciding what is to be regarded as the best way of
implementing a medical procedure.200 One of the most
important norms for medical professionals to apply is the
medical principle of beneficence. The principle of ND
relates to genetic counselling. The future child’s interest
should be considered too. How to resolve these sometimes
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controversial aspects in medical profession? Especially, the
principles of professional duty of care vs patient autonomy
may sometimes be hard to combine.
The WMA has addressed the issue of ‘dual loyalty’ of
physicians in its new Medical Ethics Manual of 2005.
Although the WMA International Code of Medical Ethics
states that ‘A physician shall owe his patients complete
loyalty’, WMA acknowledges that there may be exceptional
situations where a physician might have to consider other
interests as well, such as those of other patients, society,
third party. This statement could be easily interpreted as to
cover offspring of the patients as well. The physician’s role
is nowadays considered to include a more social concep-
tion.219 The ethical challenge is to decide when and how to
protect the patients.
An important question in the context of reproductive
genetics is whether and under which conditions medical
professionals are allowed to withhold treatment in case of a
high risk of having an affected child or to start treatment
only if couples undergo PGD/PND? Furthermore, with
respect to nonmaleficence, is a doctor allowed to deny
transfer of affected embryos in case it would result in the
birth of a seriously affected child? On the other hand, with
respect to the patient autonomy, is it possible to let the
parents decide on giving birth to a child that is known to
carry some hereditary disease, which involves suffering
and/or premature death? What about the decision-making
authority if some milder chromosomal aberrations (XYY or
XXY) are found and people want to have these embryos
transferred, because there are no other embryos available?
According to the ESHRE’s statement, the clinic has the
right to refuse participation in the reproductive project, if
it considers the risk of the future child being affected as too
high, despite PGD.76 This may happen, that is, in the case
of PGD, when no unaffected or diagnosed embryos are
available for transfer. Parents then might reconsider their
intentions and require transfer of affected embryos,
especially if they otherwise were faced with a situation of
‘no child at all’. ESHRE PGD guidelines state that ‘it is
acceptable for health care providers to object conscien-
tiously to transferring embryos that are likely to result in
the birth of an affected child. In such cases, providers
should consider referring the couple to colleagues who are
prepared to offer transfer of such embryos’.77
Some argue that the parents have an obligation to
protect their future child from preventable impairments
and should take this into consideration when planning a
child.19
It is a challenge for a genetic counsellor to find out what
the couple really wants. The couple is under a lot of stress
during the cycle and therefore may not be fully capable of
evaluating the situation. Their desire for a child may
overweigh a potential genetic disease in a child.115
One could also argue that it is not in the best interests of
the national healthcare system and its resources to further
birth of seriously ill children, nor does it accord with the
medical principle of nonmaleficence. Moreover, the goal of
genetic counsellors is not to guide their patients to certain
decisions, but to help them to make their own decisions
(ND). It has been argued that genetic counselling should
clearly be separated from public health policies.96 How-
ever, as argued previously, the new understanding of the
physician’s role includes a social and third-party perspec-
tive as well.219
One ethical dilemma concerns patients with susceptible
capability of parenthood owing to drug abuse, unstable
psychological character or social conditions, risk of child
abuse, or involving other risks to the well-being of a child.
Furthermore, to offer ART to couples where a parent may
have a terminal genetic condition and would not be around
to parent the child (eg, HD) is also problematic. ASRM has
addressed the issue of offspring welfare and stated that
fertility specialists are allowed to consider the patients’
child-rearing ability and the home conditions of the
potential child, and they can select patients and withhold
services, as long as such decisions are not discriminative
and are based on empirical facts derived from careful
inquiry.228– 230,70 This topic is highly sensitive and con-
troversial, and although it is part of the HFE Act in the UK,
it still is open to public consultation to revisit this part of
the Act. There are always those who will limit the access
based on individual properties of the people, but a valid
method has not been found to evaluate who will be a good
parent and who will not. Often those who have a high
desire to have children are also likely to be good parents.231
Psychological issues
In Western society, parenthood is experienced as one of the
most important role transitions in adult life for both
women and men. Hence, the experience of sub- or
infertility can therefore be characterised as a ‘nonevent
transition’. Infertility can be defined as a nonevent that
alters the individuals perception of self and of the world
that demands a change in assumptions or behaviour, and
that may lead either to growth or to deterioration.232 The
psychological impact of infertility as such cannot be
underestimated especially in the context where children
are being experienced as an emotional capital (see section
‘Evolution of the emotional significance of children’).
Apart from the psychological impact of the diagnosis of
infertility, ART treatments pose emotional challenges for a
couple attending treatment. The process of a cycle itself is
stressful, for example, the frustration and disappointment
of several unsuccessful attempts, the concern for the health
of the future child and so on. The situation is uncontrol-
lable and unpredictable. Furthermore, the presence of a
genetic defect may first have been detected unexpectedly
during the treatment process. It is not surprising that
psychological support may be needed.
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Some fear that the donor-assisted conception may lead
to dysfunctional patterns of parenting owing to the
difficulties experienced by the mothers and fathers in their
quest for a child, or that parents may feel or behave less
positively when they are not biological parents of a child
and may not fully accept the child as their own. A further
issue is that the majority of adults and children conceived
in this way remain unaware that the person they believe to
be their father (or mother) is not their biological parent. In
recent years, there has been growing unease about the
secrecy that surrounds families created by DI.231
Studies of IVF families where the mother and the father
are the biological parents of the child have generally found
that the parents are well adjusted and have good relation-
ships with their children.231 ART mothers did not differ
from the adoptive or natural conception mothers in
expressed warmth, and sensitivity towards the child nor
in affection. ART mothers showed greater emotional
involvement with their child, and enjoyed motherhood
more than the natural conception mothers. Also, the ART
fathers showed greater expressed warmth and emotional
involvement than both the adoptive and natural concep-
tion fathers, and enjoyed fatherhood more than the
natural conception fathers. ART children reported less
criticism or rejection from both their mother and their
father than the natural conception and adopted children.
No differences were identified between the IVF and DI
families for any of the variables relating to parenting or the
psychological well-being of the child. This suggests that
the absence of a genetic link between the father and the
child does not interfere with the development of a positive
relationship between them.231
With respect to PGD-HLA, the child may feel proud of its
role in attempting to save its sibling’s life. For instance, it
could be considered more devastating for one’s self-
concept to be told that he or she was an ‘accident’. On
the other hand, it could be argued that a heavy burden is
placed on the donor child. The transplantation may fail
and this may give the child a fundamental sense of
unworthiness and deficiency and a feeling of not being
able to live up to the expectations. The child may be
required for further donations of blood, marrow or other
organ’s. Furthermore, the consent issues may be compli-
cated. Consequently, the psychological impact of bone
marrow donation among siblings should not be under-
estimated.233
Children from DI may remain ignorant of their biologi-
cal parents. Firstly, it has been traditionally considered as a
family matter and left for parents to decide, whether they
disclose the conception method to their children or not,
even though the legislation would allow to detect donor
identity. From a psychological point of view, it is not clear
which of both positions (disclosure or nondisclosure) is
better for the child and/or his parents. In clinical practice,
however, it is important to confront clients with this
question in order to enable them to gain insight in the
meaning of the necessity to use donor material.
Secondly, some jurisdictions support anonymity of
donors. This may be thought to violate a right to know
one’s genetic history. This is not unique, or even a new
phenomenon, although, as adopted children may have the
same situation and many children throughout the history
have been conceived by other than their social father.
Arguments relating to the emotional and social needs of a
child are numerous, some in favour, some against the
identification (eg, The Danish Council of Ethics234). Until
recently, most countries’ practices or laws kept the identity
of both the sperm donor and the recipient confidential.
However, at the time of writing this paper, many countries’
decisions emphasise the child’s best interest and allow the
child access to some background information whether
identifying or nonidentifying. Identifying information is
provided, for example, in Sweden already since 1985,
Switzerland in 2001, Germany, the Netherlands in 2004,
Norway and UK in 2005.
Scenarios for the future: main drivers
Support groups needing PGD
The quality and the amount of information to the patients
on PGD and its indications, risks, etc should be increased.
In the UK, for instance, the Genetic Interest Group (GIG)
is a national alliance of organisations with a membership
of over 130 charities, which support children, families and
individuals affected by genetic disorders, most of which are
rare diseases. The GIG has strongly argued in favour of
PGD, keeping PGD and research involving embryos
‘central to our members’ interest’. The GIG has supported
the use of tissue typing in conjunction with genetic testing
to enable a family to have a child who is both free of a
genetic disorder and also able to be a stem cell donor to a
sick sibling (GIG’s submission to House of Commons
Science and Technology Committee Inquiry May 2004).
Future aspects of quality, safety and efficacy
Efficacy, measured in terms of success rate, will be a main
driver for the use and development of new and improved
technologies. Optimal treatment implies good chance of
pregnancy with a minimal risk for mother and child.
Ironically, the social and psychological consequences of
infertility for the couple have increased with the advance-
ment of ART. Given the increased expectations, the higher
economic and emotional cost for the couple and the
greater physical demand on women, the failure of ART
leads to greater psychological and social consequences for
the couple than the unavailability of these technologies.235
IVM may in the future become more generally used,156
which would prevent the drawbacks related to super-
ovulation, such as side effects and costs of the hormone
therapy.
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As there is a clear link between certain genetic abnorm-
alities and spontaneous abortions, PGS could become a
solution to detect anomalies and to improve chances of
successful pregnancies, especially in patients over 36 years
of age.
The 24-colour FISH painting technique, known as M-
FISH or spectral karyotype, allows the simultaneous and
distinct identification of all the chromosomes. Adaptation
of CGH-array will probably modify the conception and
practice of PGD and PGS.236
Some believe that CGH could boost success rate even
further by allowing a complete analysis of all the chromo-
somes,99 but time constraints that involves embryo freez-
ing and therefore reduces the potential of improved
implantation is at present a considerable drawback of this
technique. Faster techniques that obviate the need for
embryo freezing are necessary to unleash the full potential
of PGD.111
Besides efficacy, the standards for quality (and with it the
safety) of the procedures will also drive the level of
implementation of these medical procedures. International
quality standards already apply to IVF laboratories, such as
the ISO 15189:2003 for medical laboratories with particular
requirements for quality and competence in IVF.237 In
Europe, the new Tissue Directive of 2004 sets minimum
quality requirements (see Appendix A) and requires labs to
be accredited, designated, authorised or licensed by a
competent authority of the Member States not later than 7
April 2006. It is expected that ‘tissue-specific’ technical
requirements will be included in a series of further
directives in the near future. The Directive will bring a
great deal of effort for hundreds of centres, but this effort
will contribute substantially towards ensuring high stan-
dards of quality and safety. There is still a risk that many
clinics may find new requirements hard to attain and
hence availability of services might be reduced.
Acceptability of genetic testing and screening
Another important driver will be social acceptability.
Generally, clinics only test or screen untreatable conditions
and usually those that manifest early in life or affect
children, such as spinal muscular atrophy and CF, but the
trend is to enlarge the scope to diseases that may have a
later onset, for example, HD. Some pressure groups have
shown discontent to allowing screening for late-onset
diseases or for significant disease traits, for example, FAP
because they see it as a slippery slope to screening for genes
with lower penetrance or those that merely increase risk,
without being a guarantee that the disorder will develop,
for example, mutations in cancer predisposition genes like
BRCA1.238 However, others argue that having a child with
inherited susceptibility to cancer could be a major source of
suffering for parents and child.239
If genetic tests for nonmedical multifactorial traits such
as strength, intelligence, sexual orientation or other factors
become available, the impact of PGD might be important.
However, such tests, with a few exceptions, are unlikely to
become available.240,241 To begin with, the number of
eight-cell stage embryos available for testing is limited.
Secondly, PGD enables to analyse only one to two defects
from single cells. Therefore, design babies are not feasible
(Outi Hovatta, personel communication).
Concerns about the potential misuse of embryo screen-
ing should be addressed.
Economic constraints will be heavier
These techniques are costly and insurance coverage will be
a key issue in their future development. One restriction to
the availability of genetic diagnosis might arise from
commercial patents, which could raise the costs too high
or even totally refuse licensed use. Reimbursement takes
place mostly at public level, but infertility is not included
in private insurances as there is a reluctance to consider it a
disability or a medical condition, but rather an elective
procedure.3 It is conceivable that health plans that do or
will cover IVF might someday require PGD for selection
against potentially costly diseases.203 On the other hand,
widespread use of PGD, as long as not subsidised, might
widen social inequalities as access to both PGD and IVF is
restricted to those who can afford it.
Scenarios for genetic testing include social, technologi-
cal, economic and political drivers. As medical use of
genetics is seen in a positive light by citizens and patient
groups, and as they are also constantly more aware of
developments in that field, there is a trend that patients are
acting as enlightened consumers, which may lead to
demands for the use of the latest medical achievements
and increased costs of health care. Four scenarios for
genetic testing are presented by IPTS in view of high or low
impact on genomics and favourable or poor economic
outlook: (1) Rationing of New Technologies; (2) Centra-
lised cost–benefit rationing; (3) High demand, Diverse
Supply; and (4) Diverse Supply, Diverse Utility.135
Possible prevention of infertility
Trends indicate that the decline in birth rates in Europe is
long lasting and shows no clear sign of levelling off. This
reflects mostly the family planning decisions involving
fewer children, but at the same time infertility is increas-
ing. Couples face increasingly more trouble to get a child.
Advanced maternal age, environmental factors, smoking
habits, stress, etc all may affect fertility in Western
countries (eg, Klonoff-Cohen242). Developed countries
have experienced unprecedented declines in fertility rates
over the last half of the 20th century with a prevalence of
subfertility close to 10%, mostly owing to genital track
infections. It is possible that the need for infertility services
will increase.
The proliferation of infertility might be somewhat
retarded by promoting younger motherhood by public
Assisted reproductive technologies and genetics
S Soini et al
620
European Journal of Human Genetics
means, for example, supporting parents economically and
socially, and in particular women to combine work and
family. Giving more information about the negative
influence of smoking, drinking, etc to fertility might bring
some help. Perpetual attention should also be paid to
prevent genital track infections, which often lead to
infertility. Hence, the use of condoms should be promoted
more intensively, even though their use is forbidden in
many cultures.
Evolution of cultural groups
Cultural pressure can make a difference, mainly in PGD for
sex determination. A distinction should be made between
child sex selection and the so-called ‘family balancing’. Sex
selection is not circumscribed to developing areas; there is
demographic evidence that choosing the sex of children in
the US – largely by using sonography and abortion – is
happening, but there is, however, no monitoring of such
demographic effects.203 It is clear that the use of other
technologies (ultrasonic screening and abortion) has lead
to sex disparities in China and India.241 Although PGD is
currently too expensive and inaccessible to be used on a
wide scale for sex selection, and although PGD would affect
only marginally the societal sex ratio balance, it is a
potential driver that should be kept in mind.
Evolution of adoption systems
In many European countries, attitudes towards delivering
an unwanted baby and then giving the baby for adoption
are not very positive. Instead, early abortion is seen as more
acceptable. These attitudes may change, to one direction or
the other. Many infertile couples might opt for adoption if
only the process were faster and easier. At the same time,
some countries in the third world have adapted stricter
policies concerning foreign adoption, and thus the amount
of babies available for adoption may be decreasing. In
consequence, adoption may become even more difficult
than today.
Evolution of the emotional significance of children
In recent history, the significance of children has shifted
from an ‘economical’ to an ‘emotional’ capital. Together
with this shift in importance of children, the advent of oral
contraceptives has created the ‘illusion’ of the possibility to
create our own children, if we want and when we want. The
development of IVF techniques – now further developed
with PGD – only strengthen people in their belief that
children can be created and that nothing stands in their
way in doing so. This kind of reasoning and the strength of
this belief are reflected in an increase of the psychological,
emotional and relational burden created by the inability to
conceive own children. In the near future, it will be
important to further develop the availability of counsellors,
psychologists or psychiatrists who can help patients to cope
with the psychological, emotional and relational burden in
order to help in IVF and genetic centres where PGD is being
performed (P Enzlin, personal communication).
Evolution of policies toward disabled people
Some have argued that wider use of PGD or PND may lead
to more discriminative attitudes towards disabled people.
However, if the number of the disabled people decreases,
this might theoretically lead to more resources for treat-
ment and rehabilitation of the individuals with disabilities.
Furthermore, it has been feared that ART might in fact lead
to dysgenics, altering the gene pool of populations and
expanding the need for infertility treatments. Nevertheless,
it should be noted that PGD and PND can only take away
the extra risk of the disease known to be running in the
family. The population risk of genetic and congenital
abnormalities remains and is not reduced by these tests.
Besides, other (nongenetic) medical reasons and accidents
cause the majority of disabilities.
Developments in the field of stem cells
Stem cell research is expected to be equally important for
basic science, as well as for the understanding of how
diseases develop, and for the development of safer and
more effective drugs and other treatments. Although
countries such as France, Spain and the UK have expressed
their support for stem cell research, others, including
Austria, Germany and Italy, have voiced opposition. These
differences in opinions resulted in an 18-month freeze on
EU-funded research in this area under the Sixth Framework
Programme (FP6) expired at the end of last year without
agreement between Member States on how to proceed. It
has been left up to the Commission to steer a principled
course in deciding which projects to fund. Incoming
Research Commissioner Janez Potocnik has said that he
would seek to set aside funds for such research under the
upcoming FP7.
Developments in the germline modification
techniques
At present, genetic modifications affecting the germ line
are forbidden. If, however, such modification would turn
out to be safe and efficient, they might be allowed and
families with hereditary conditions might want to use such
techniques. This would mean that, instead of PGD or PND
or, on the other hand, donated gametes, genetically
modified own gametes would be used.
Development in donor attitudes
One of the most significant factor decreasing donors is the
past trend to remove donor anonymity in many countries.
Donated oocytes are scarce owing to the difficulties in
procuring and preserving them. The procedure for this type
of donation is surgically invasive and includes some risks.
Donation of oocytes from women is usually not compen-
sated. Some clinics offer ‘egg-sharing’ schemes, where a
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woman who needs fertility treatment receives it at a
reduced price in return for donating some of her oocytes
to another woman or couple. Synchronising the cycles of
two women to get fresh oocytes is difficult, but would
increase chances of success, since frozen oocytes do not
have as good fertilisation potential as fresh do. Unpleasant
situation occurs, if the donor does not become pregnant,
whereas the recipient does. The use of oocytes and/or egg
sharing is forbidden in some countries. The HFEA in the
UK issued a public consultation128 on this and other issues,
such as the regulation governing the import of gametes
and the limits of oocytes per donor.
The EGE has in its opinion of 14 November 2000,
‘Ethical aspects of human stem cell research and use’,
stressed the necessity to ensure that the demand for surplus
embryos and oocyte donation does not increase the burden
on women, as women who undergo fertility treatment are
already subject to high psychological and physical strain
(EGE 2000). In Spain, without specific regulation on oocyte
donation, women receive between 600 and 900 euros to
compensate time and effort provided. The oocyte donation
programme has made Spain an attractive place for
reproductive tourism, as mentioned earlier (El Pais, 25
January 2005).
Embryo donation, although it is widely regarded as a
cost-effective use of a valuable resource, confronts a large
emotional barrier to relinquishing couples that usually do
not want to consider full siblings living with other families.
Raising embryo donation as a possibility using educational
programmes and media coverage are depicted as a
potential positive influence on embryo availability.243 It
is noteworthy, however, that supernumerary embryos
available for donation may be at increased risk of carrying
a known or unknown genetic defect related to parental
infertility, as the main source of donated embryos are
couples being subject to ART themselves.132
Regulation
National and international regulation may have a great
impact to ART and stem cell research in the future, one way
or the other. ART and research develop at a pace faster than
legislation and to an unpredicted destination. Courts and
authorities might be challenged with demands of licensing
new interventions, but are not the right place to settle the
basics of these issues. Excess bureaucracy and endless
licensing policies will certainly lead to inefficiency and
retard development in this field. Regulation should
guarantee a satisfactory, flexible and reasonable research
framework, whereas protecting research subjects and
requiring good scientific results.
Conclusions
The interface between ART and genetics comprises several
sensitive and important issues that affect infertile couples,
families with genetic diseases, potential children, profes-
sionals in ART and genetics, health care, researchers and
the society in general.
Many representatives of the European IVF clinics
reported in Sevilla that almost half of their IVF patients
are over 36 years old. Advanced maternal age increases not
only infertility, but also the risk of sporadic chromosome
anomalies and complications. Society should hence sup-
port younger motherhood in order to decrease the need for
ART and complications to both mother and child.
Ample reproductive counselling should be available to
all couples coming for treatments. In addition, proper
counselling in all genetic testing services, including in the
field of ART, is considered extremely important. At the
moment, it does not seem to be provided in the best
possible way. Any person involved in the procedure of
counselling (whether reproductive or genetic) should be
adequately trained. Moreover, a multidisciplinary ap-
proach and close cooperation between professionals would
be extremely important. Centralisation of the most com-
plex genetic counselling situations is needed.
Practice guidelines would be needed on adequate
diagnostic procedures to solve aetiology of infertility in
each couple. Unexplained infertility may lead to problems
in pregnancy and for the future child. Moreover, the causes
of possible morbidity in the child might be suggested to be
a consequence of ART even when they actually relate to the
cause of infertility. Thorough investigation of the reasons
behind infertility is hence desirable.
The workshop participants in Sevilla had different
opinions on the extent of genetic testing of donors, but
felt generally that testing should not lead to selecting
better genes for donor-conceived children compared to
those presenting among the general population.
PGD has become widely practiced throughout the world
for various indications, and it helps to restore the
reproductive confidence. PGD can substantially decrease
the eventual risks of passing a genetic undesired condition
to the offspring. Nevertheless, its extension to some new
and nonmedical indications has raised ethical concerns.
PGD is an invasive and expensive technique with a rather
low success rate and involves psychological stress to the
couples. One disadvantage in connection with PGD is the
need to use IVF/ICSI, which might lead to other risks. The
complications of multiple pregnancies should be avoided by
transferring only one embryo. All the aspects and risks of
PGD and other options should be weighed and balanced.
PGD offers thus an alternative to PND, but cannot replace it.
Although widely used, PGS is still considered as an
experimental procedure and its clinical utility is not fully
proven. PGS may improve the success potential of a single-
embryo transfer and thus help decreasing multiple preg-
nancies with high risks to both mother and child. In
addition, need for termination of pregnancy after PND
might be reduced.
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The need to shift towards a single-embryo transfer has
been stressed to avoid risks of multiple pregnancies.
Potential other side effects, either related to medical
procedures of ART or parental factors, need to be envisaged
further, as the studies carried out so far cannot give
adequate knowledge of the impact of the ART procedures.
High-quality clinical research should be performed before
introducing new techniques into clinical practice. More
preclinical and follow-up studies are hence needed.
The information given to patients should be evidence
based. The concept of success rate needs evaluation and
standardisation.
Reproductive autonomy vs professional duty of care
constitutes an ethical challenge for professionals. Their
dual responsibility requires focusing also on the future
child’s interests.
Diverse levels of access and provision of services within
the EU Member states has led to crossborder reproductive
treatments. However, considering the pluralism in Europe
and the fact that legal harmonisation is impossible and
even undesirable, a general legal framework is not a
solution. Instead, patients treated in different European
countries should be entitled to access of the same standard
of care through professional guidelines and systems of
accreditation. Adequate counselling in connection with
crossborder treatments should be secured as well.
Both ESHG and ESHRE feel that professional recommen-
dations on the very sensitive interface between ART and
genetics are urgently needed. Everything that is possible
should not be carried out. It is clear, however, that any
recommendations on this quickly developing field must be
reviewed regularly.
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Appendix A
LEGAL FRAMEWORK
Countries have adopted very different legal approaches to
regulation of ART as well as to the jurisdiction of authority,
the nature of enforcement and other particulars. Some
have enacted very restrictive laws (Austria, Germany, Italy,
Norway, Switzerland), some have adopted middle course
regulation (Canada, France, the Netherlands, the UK,
Spain) and some have rather permissive laws or no legal
regulation at all, but ART issues are regulated by profes-
sional standards (Belgium, Finland, USA).
The autonomy of the professionals to practise ART varies
from country to country, as well as access to treatments
(see Chapter 11 of the background document). In some
countries, practise of forbidden ART may lead to criminal
sanctions.
Regulation at its best creates guidelines and is flexible to
welcome new technologies, when they are scientifically
justified. At its worse, the regulation prevents adoption of
novel techniques, shifts decision-making in ART issues to
courts, limits autonomy of patients and access to treat-
ments, and leads to import and export of ART services.
Professional self-regulation is often a good solution, but
some of the potential applications of ART need clear
guidelines, for example, limits for the use of PGD.
For regulation to be effective, there must be an authority
responsible for licensing and controlling medical facilities
that provide ART treatments. A frequently cited model for
an effective structure of regulation is the Human Fertiliza-
tion and Embryology Authority (HFEA) in the United
Kingdom.6 However, it has been argued also that the
system is bureaucratic and inefficient.
Whereas national regulations are very miscellaneous,
the numerous different international organisations,
national committees and professional associations
have addressed the bioethical issues, given recommenda-
tions, guidelines and policies regarding concepts,
methods and practises. Although lacking certain legal
authority, this ‘soft law’ is still widely applied and seem
to provide rather similar views on what can be considered
acceptable. Soft law has significant relevance in bioethics
and medical law. However, it may be difficult to recognise
its potential legal status and hierarchical order of applica-
tion.
These different approaches and international along with
national professional and ethical guidelines will be pre-
sented below. This appendix does not aim at being
exhaustive, but rather collecting mostly central European
international guidelines and policies, as well present
different national approaches on how issues relating to
ART are being settled in various countries. The selection of
countries presented is based on practical factors, mainly
access to information, but not on prioritising any country
over another. Therefore, also the contents of information
regarding different countries vary.
INTERGOVERNMENTAL ORGANISATIONS
1. United Nations (UN) UN Convention on the Right of the
Child (1990), Article 3 states that in all actions concerning
children, whether undertaken by public or private social
welfare institutions, courts of law, administrative autho-
rities or legislative bodies, the best interests of the child
shall be of primary consideration. The convention has
been ratified almost universally; however, not by USA.
According Article 7, paragraph 1: The child shall be
registered immediately after birth and shall have the right
from birth to a name, the right to acquire a nationality
and, as far as possible, the right to know and be cared for by
his or her parents. Article 8, paragraph 1: parties undertake
to respect the right of the child to preserve his or her
identity, including nationality, name and family relations
as recognised by law without unlawful interference. Article
8, paragraph 2: where a child is illegally deprived of some or
all of the elements of his or her identity, Parties shall
provide appropriate assistance and protection, with a view
to re-establishing speedily his or her identity.
The physical, psychological and social well-being of
children produced by ART has raised lots of discussion. In
particular, the right to know one’s genetic background has
been debated. The donor identification has gained stronger
position in the Western legislation. Whether the para-
graphs of the UN Children’s convention support a child’s
right to know its genetic background or not has been
subject to different and sometimes opposite interpreta-
tions.
World Health Organisation
 Reproductive Health Strategy from 2004 mentions inferti-
lity services as a part of the five core aspects of
reproductive and sexual health. Among the specific
targets are reductions of maternal mortality ratio and
under-5 mortality rate, as well as halting of HIV/AIDS.2
 Review of Ethical issues in Medical genetics of 2003
contains guidelines on ethical issues in medical genetics
and genetic services, the items including genetic screen-
ing and testing; autonomy and informed consent;
presymptomatic and susceptibility testing; disclosure
and confidentiality; PND and PGD and prior and post-
test counselling.29
 Based on a WHO meeting in 2002 ‘Current practises and
controversies in Assisted Reproduction’, the participants
agreed upon six recommendations on the following
topics: (1) infertility and ART in the developing world;
(2) infertility and ART from a regional perspective; (3)
recent medical developments and unresolved issues in
ART; (4) social and psychological issues in infertility and
ART; (5) ethical aspects of infertility and ART, and (6)
national and international surveillance of ART and their
outcomes.18
United Nations Educational, Scientific and Cultural Organi-
sation (UNESCO) has also aimed to create standards in
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bioethics. It has already contributed to the formulation of
basic principles in bioethics through, in particular the
Universal Declaration on the Human Genome and Human
Rights of 1997 and the International Declaration on Human
Genetic Data of 2003. The Member States should take
appropriate measures to promote the principles set out in
the Declarations and encourage their implementation.
Upon the Article 17 of the Declaration on the Human
Genome and Human Rights, ‘States should respect and
promote the practice of solidarity towards individuals,
families and population groups who are particularly
vulnerable to or affected by disease or disability of a
genetic character. They should foster, inter alia, research on
the identification, prevention and treatment of genetically
based and genetically influenced diseases, in particular rare
as well as endemic diseases which affect large numbers of
the world’s population’.
The importance of genetic counselling is emphasised in
Article 11 of the International Declaration of Human
Genetic Data, according to which it is ‘ethically imperative
that when genetic testing that may have significant
implications for a person’s health is being considered,
genetic counselling should be made available in an
appropriate manner. Genetic counselling should be non-
directive, culturally adapted and consistent with the best
interest of the person concerned’.
International Bioethics Committee (IBC) is a permanent
committee of UNESCO established in 1998. It has pub-
lished several reports relevant to the subject such as:
 Report on Genetic Screening and Testing 1994.
 Report on Human Gene Therapy 1994.
 Report on Genetic Counselling 1995.
 Report on PGD and Germ-Line Intervention 2003.
The IBC reached the following conclusions on PGD and
Germ-Line Intervention in its latest report of 2003: Germ-
Line Intervention is strongly discouraged or legally
banned. PGD may be an additional option for parents at
increased risk of having a child with a genetically caused
disease or malformation. PGD is still considered an
experimental procedure requiring highly specialised skills
and a multidisciplinary approach. IBC does not make a
general statement about the moral acceptability of PGD. It
is recommended that PGD be limited to medical indica-
tions. Embryonic HLA typing to save a sibling with a
genetic blood disease or leukaemia is considered ethically
acceptable only if carried out simultaneously with PGD for
the disease concerned and if mismatching of the HLA type
is not considered in itself as a basis for selecting against the
embryo unaffected by the disease concerned. PGD to select
and implant embryos with a similar genetic disease or
condition as one of the parents is considered unethical.
Aneuploidy testing is considered ethically acceptable. PGD
for DNA sequences should be restricted to cases involving
high genetic risk and clinically severe diseases. PGD for
normal physical and mental characteristics is rejected.
The IGBC (Inter-Governmental Bioethics Committee) was
created in 1998, under Article 11 of the Statutes of the IBC.
The IGBC is comprised of 36 Member States whose
representatives meet at least once every 2 years to examine
the advice and recommendations of the IBC. It informs the
IBC of its opinions and submits these opinions along with
proposals for follow-up of the IBC’s work to the Director-
General for transmission to Member States, the Executive
Board and the General Conference.
UNESCO has been drafting an International declaration on
Universal Norms on Bioethics, which is aimed at being
finalised in the General Conference in October 2005
(www.unesco.org/bioethics).
2. Council of Europe The Council of Europe, a body set
up in 1949 and now composed of 46 Member States,
considers ethical issues in the field of biomedicine through
a Steering Committee on Bioethics (CDBI). Its Working Party
on the Protection of the Human Embryo and Foetus has
published a report on 19 June 2003 of the protection of the
human embryo in vitro. The report aimed to reflection on
ART and PGD in particular, by outlining the various
existing positions in Europe, without taking a stance on
the issues raised. It shows a broad consensus on the need
for the protection of the embryo in vitro. However, the
definition of the status of the embryo remains an area
where fundamental differences are encountered, based on
strong arguments. These differences largely form the basis
of most divergences around the other issues related to the
protection of the embryo in vitro. Common approaches
were desired to ensure proper conditions for the applica-
tion of procedures involving the creation and use of
embryos in vitro.
Convention for the Protection of Human Rights and Funda-
mental Freedoms (1950), Article 8 addresses the right to
respect for private and family life, personal identity, the
home and correspondence. Article 12 declares that ‘Men
and women of marriageable age have the right to marry
and to found a family, according to the national laws
governing the exercise of this right.’ Some have argued
referring to these articles and to Article 14 that prohibits
discrimination, that infertility treatments should be avail-
able to everyone disregarding marital status, sex, age, etc.
Case law of the European Court of Human Rights is
limited, but in some cases other than ART, the court has
ruled that countries can allocate limited health care
resources, for instance, based on medical reasons, which
would hence leave nonmedical purposes of ART outside
this right (eg, single women, lesbian couples). This
convention is very significant in practice because indivi-
duals can bring cases to the European Court of Human
Rights in case they feel their rights have been breached by
their governments.
Assisted reproductive technologies and genetics
S Soini et al
630
European Journal of Human Genetics
Convention for the Protection of Human Rights and
Dignity of The Human Being with regard to the Applica-
tion of Biology and Medicine (Convention on Human Rights
and Biomedicine Oviedo 4.4.1997) is significant in the field
of biomedicine, even though not so many countries have
ratified it yet. (When a country ratifies certain convention,
it assumes a legal obligation to implement the rights
recognised in the treaty.) Biomedical convention does not
constitute individual rights, but in cases pending in the
European Court of Justice, also the provisions of the
Biomedical convention can be appealed to. The conven-
tion of biomedicine addresses among other things the
following:
Article 4, Professional Standards: Any intervention in the
health field, including research, must be carried out in
accordance with relevant professional obligations and
standards.
Article 12, Predictive genetic tests: Tests that are predictive
of genetic diseases or which serve either to identify the
subject as a carrier of a gene responsible for a disease or to
detect a genetic predisposition or susceptibility to a disease
may be performed only for health purposes or for scientific
research linked to health purposes, and subject to appro-
priate genetic counselling.
Article 13, Interventions on the human genome: An inter-
vention seeking to modify the human genome may only be
undertaken for preventive, diagnostic or therapeutic
purposes, and only if its aim is not to introduce any
modification in the genome of any descendants.
Article 14, Nonselection of sex: The use of techniques
of medically assisted procreation shall not be allowed
for the purpose of choosing a future child’s sex, except
where serious hereditary sex-related disease is to be
avoided.
Article 21, Prohibition of financial gain: The human body
and its parts shall not, as such, give rise to financial gain.
A new additional protocol to the Convention on Human
Rights and Biomedicine concerning biomedical research
was introduced in June 2004. The protocol covers full
range of research activities in the health field involving
interventions on human beings. It does not apply to
research on embryos in vitro, but it does apply to research
on foetuses and embryos in vivo. General provisions
include that research may only be undertaken if there is
no alternative of comparable effectiveness. Article 18 sets
conditions on research during pregnancy or breastfeeding:
research on a pregnant woman, of which she or her
embryo, foetus or future child do not have direct benefit,
may only be undertaken, (1) if the research has the aim of
contributing benefit to other women in relation to
reproduction or to other embryos, foetuses and children;
(2) research of comparable effectiveness cannot be carried
out on women who are not pregnant, and the research
entails only minimal risk and minimal burden. New
developments are addressed in Article 24.
Working Party on Human Genetics has made a working
paper, under the responsibility of CDBI, with a view to the
elaboration of an additional Protocol concerning genetics
to the convention on Human Rights and Biomedicine. It
was open for comments till 30 April 2003. According to the
information received form the Treaty Office, CDBI started,
at its plenary meeting in October 2004, the examination of
the first part of the draft Protocol, which concerns general
provisions and the health field, prepared by the Working
Party taking into account the comments received on the
working document. It agreed to focus the Protocol on
genetic tests. According to the document, however, the
protocol is not supposed to extend to the applications of
genetics to the human embryo and foetus or any biological
material derived from them. In 2005, discussion on this
part of the draft Protocol will continue at the level of the
CBDI with view to its finalisation.
3. European Union Charter of Fundamental rights of the
European Union, approved by the member states in 2000
was further accepted as a part of the EU Constitutional
Convention in June 2004. It is not yet in force. The Charter
has provisions applicable to biomedicine and research,
such as personal integrity; informed consent requirement;
prohibitions against the use of methods for genetic
enhancement and selection of people; and ban on deriving
economical beneficence from human body or its parts and
reproductive cloning.
European Union has not adopted directive or other
regulation on particularly applicable to ART. Some parts of
the following directives shall be applied also when using
ART with respect to safety of the use of gametes and
performance of tests.
(1) ‘Tissue Directive’
Directive 2004/23/EC of the European Parliament and of
the Council of 31 March 2004 on setting standards of
quality and safety for the donation, procurement, testing,
processing, preservation, storage and distribution of hu-
man tissues and cells, ‘the Tissue Directive’, entered into
force on 7 April 2004. The member countries shall
implement it by 7 April 2006. The objective of the directive
is namely to ensure high level of health protection and to
prevent transmission of diseases by human cells and
tissues. According to its Recital 7, the Directive is also,
among other things, applied to reproductive cells, foetal
tissues and cells as well as adult and embryonic stem cells.
Recital 12 allows Member States make own decisions
concerning the use or nonuse of any specific type of
human cells. According to Recital 18, tissue and cell
application should be founded on the philosophy of
voluntary and unpaid donation, anonymity of both donor
and recipient. However, in Recital 29 is stated that Member
States could legislate otherwise in exceptional cases,
notably regarding donation of gametes. Recital 22 refers
to the Charter of Fundamental Rights of the European
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Union and Convention on Human Rights and Biomedicine
and claims to respect them.
Article 8 sets a requirement that all tissues and cells
meant by the Directive shall be traceable. The data shall be
coded and kept for a minimum of 30 years after clinical
use. Article 14 concerns data protection and confidentiality
and states that all data, including genetic information,
collated within the scope of the Directive and to which
third party have access, shall be rendered anonymous so
that neither donors nor recipients remain identifiable.
Article 9 stipulates the import and export of tissues and
cells. Only licensed establishments can be used, traceability
shall be ensured and equal standards of quality and safety
requirements shall be met as in the Directive. According to
Article 19, all donations of tissues and cells shall be tested
in accordance with the requirements referred to in Article
28(e) and selection and acceptance of tissues and cells shall
comply with the requirements referred to in Article 28(f).
An annex of the Directive sets following requirements
for information to be given to the donor:
1. The person in charge of the donation process shall
ensure that the donor has been properly informed of at
least those aspects relating to the donation and
procurement process outlined in paragraph 3 of the
Directive. Information must be given before the pro-
curement.
2. The information must be given by a trained person able
to transmit it in an appropriate and clear manner, using
terms that are easily understood by the donor.
3. The information must cover the purpose and nature of
the procurement, its consequences and risks; analytical
tests, if they are performed; recording and protection of
donor data, medical confidentiality; therapeutic pur-
pose and potential benefits; and information on the
applicable safeguards intended to protect the donor.
4. The donor must be informed that he/she has the right
to receive the confirmed results of the analytical tests,
clearly explained.
5. Information must be given on the necessity for requir-
ing the applicable mandatory consent, certification and
authorisation in order that the tissue and/or cell
procurement can be carried out.
The Tissue Directive requires establishment of special
authority for inspection, licensing and accreditation; a
quality system approach, proper expertise and a monitor-
ing system for adverse incidents and reactions. The criteria
for these will be set in the following documents:
(2) ‘Technical Documents’
The Tissue Directive empowers the Commission to
establish and update technical requirements in relation
to quality and safety of human tissues and cells. The
Commission conducted an open consultation for this and
has prepared two documents, which have not been
adopted yet. The latest outline of the first document dates
from November 2004. Both documents are still in a
consultation phase. The Council of Europe and WHO were
consulted to ensure coherence between guidelines.
The first document aims to cover all human cells and
tissues and all manufactured products derived from them,
which are used for application to the human body, during
the first phases of the process – donation, procurement and
testing – in order to ensure their quality and safety.
A second document will address the technical require-
ments for processing, preservation, storage and distribu-
tion of human tissues and cells and will incorporate the
criteria for accreditation/designation/authorisation/licen-
sing of tissue establishments, the quality system require-
ments, the tissue coding requirements and the
requirements for adverse event reporting.
The future Directive will introduce definitions of repro-
ductive cells, partner donation and direct use and set
technical criteria for the assessment of donor eligibility. It
contains minimum testing levels to be carried out on
potential donors and requires thorough examination of the
health and background of potential donors of reproductive
cells. The testing device has to be CE marked. In the case of
partner donation for direct use, selection criteria and tests
are not applied, whereas if the cells are not to be used
directly, several serology tests must be carried out. Accord-
ing to Section ‘The main indications of PGD’ of the
outlined draft, the use of reproductive cells from third
party requires immense testing and genetic screening
depending on the donor’s medical, familial or ethnical
background. For instance, genetic screening for autosomal
recessive genes known to be prevalent in the donor’s ethnic
background and an assessment of the risk of transmission
of inherited conditions known to be present in the family
shall be carried out, after obtaining consent and providing
complete information, in accordance with the require-
ments in force in Member States. Complete information on
the associated risk and on the measures undertook to its
prevention shall be communicated and clearly explained
to the recipient.
(3) In vitro diagnostic directive 98/79/EC aims at protecting
safety of the in vitro medical devices and obliges mainly the
manufacturers by setting the essential requirements de-
vices must meet before being placed on the market. The
directive refers to ethical provisions of Biomedical conven-
tion by stating in the Article: ‘For the purposes of this
Directive, the removal, collection and use of tissues, cells
and substances of human origin shall be governed, in
relation to ethics, by the principles laid down in the
Convention of the Council of Europe for the protection of
human rights and dignity of the human being with regard
to the application of biology and medicine and by any
Member States’ regulations on this matter’.
(4) Proposal of Directive on Services (COM (2004) 2) is at
present largely debated among the member states (Spring
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2005). First drafts aimed at ruling also of the free move-
ment of healthcare services and reimbursement issues, but
a suggestion has been made to remove healthcare services
from the scope of application. The patient mobility and the
access to health care within EU have been addressed in
Chapter 11 of the background document.
The issues of assisted reproduction have not been much
addressed to within the European Union. Several commit-
tees under the European Commission and the European
Parliament have taken following initiatives in reports and
opinions, which might have certain impact indirectly in
the field of ART and genetics as well:
 European Parliament Temporary Committee on Human
Genetics and Other New Technologies in Modern
Medicine (November 2001) identified certain questions
relating to PGD and other testing, but did not end up in
any conclusion. (Report on the ethical, legal, economic
and social implications of human genetics http://
europa.eu.int/comm/research/biosociety/pdf/pe_genetics.
pdf)
 A multidisciplinary expert group in the field of law,
philosophy, ethics and medicine, invited by the Eur-
opean Commission, has released a set of 25 recommen-
dations on human genetic testing for medical purposes
in 2004. http://europa.eu.int/comm/research/conferences/
2004/genetic/pdf/recommendations_en.pdf
 Commissioner David Byrne launched a reflection pro-
cess for a new EU Health Strategy in July 2004 ‘Enabling
Good Health for all’.
The Joint Research Centre (JRC) is a body of the European
Commission providing scientific and technical advice to
support EU policies and the Institute for Prospective
Technological Studies (IPTS) is one of its seven scientific
institutes. JCR/IPTS has released a report on quality
standards of genetic testing in Europe in 2003 (Report:
Towards quality assurance and harmonisation of genetic
testing services in the EU).
European Group on Ethics in Science and New Technologies
(EGE) is an independent, pluralist and multidisciplinary
body which advices the European Commission on ethical
aspects of science and new technologies in connection
with the preparation and implementation of Community
legislation or policies.
National regulation
European countries
Austria
Austrian Federal Law of 1992 (Serial 275) regulating
Medically Assisted Procreation (The Reproductive Medicine
Law), and Amending the General Civil Code, is restrictive.
Its central principle is that reproductive medicine is
acceptable only within a stable heterosexual relationship
for the purpose of reproduction. The law provides that
embryos can be used only for implantation in the woman
whose oocytes are being used and cannot be used for other
purposes. The donation of embryos or gametes is explicitly
prohibited, excluding semen donation in partner IVF. PGD
is not allowed currently. Two alternative approaches to
allow the use of PGD were presented in an opinion of
Bioethics committee in July 2004: the other would limit
the use of PGD only for testing of nonviability of an
embryo when treating infertility, and the other testing of
severe genetic illnesses on a case-by-case consideration of
an authority. Austria has not signed the Convention on
Human Rights and Biomedicine.
Belgium
In Belgium, the professional codes of conduct and
ethical principles of hospitals and clinics have for long
time ruled the practise. The law on embryo research was
adopted in 2003, but ART remained unregulated excluding
PGD which is allowed for therapeutic purposes.244 Most
ART are being practised.
According to Article 3 of the Law on embryo research,
research on embryos is allowed if following conditions are
met: (1) research has to have a therapeutic aim or has to
increase knowledge about reproductive fertility, transplan-
tation, disease treatment, (2) is based on recent research
findings and fulfils demands of correct methodology of
medical research, (3) is performed in an accredited lab
associated to a university care unit, (4) is carried out under
the supervision of a specialist medical doctor or scientist,
(5) is performed before day 14 and (6) there are no other
methods of research. Article 4 states that (1) creating
embryos for research (surnumerary embryos) is forbidden,
unless the aim of the research cannot be reached by other
means, (2) ovarian stimulation is allowed if the woman is
of age, has given written consent and the stimulation is
performed as scientifically justified. Under Article 5, it is
forbidden (1) to implant human embryos in animals or to
create chimera or hybrids, (2) to replace embryos that have
been used for research in humans, unless the research was
performed with a therapeutic aim for the embryo or when
an observation method that does not harm the embryo has
been used, (3) to use embryos, gametes or embryonic stem
cells for commercial ends, (4) to perform research or
treatment with a eugenic aim and (5) to perform research
or treatment aimed at sex selection, unless it is for sex-
linked diseases. Reproductive cloning is forbidden. Re-
search on embryos is subject to approval of local ethical
committees and the Federal Commission for medical and
scientific research. The contents and procedures of in-
formed consent are described in the law. The law also
established a Federal Commission for medical and scien-
tific research, consisting of four MDs, four PhDs, two
lawyers, four experts in ethical and social sciences, to
which every researcher must send an annual report.
Violations of the law are subject to penalty.
Belgium has not signed the Convention on Human
Rights and Biomedicine.
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Denmark
The Danish rules governing ART are laid down in the Act
on Assisted Reproduction of 1997 (Lov om kunstig
befrugtning) as well as various guidelines and executive
orders, primarily the National Board of Health’s guideline
from September 1997, the Guideline on assisted reproduction
and other reproduction-promoting treatment – for Danish
doctors. The legislation applies solely to the treatment
provided by a doctor or under the responsibility of a
doctor. In addition, the Children Act of 2002 contains some
relevant provisions regarding the assignment of paternity
in the case of assisted reproduction.
Most ART is allowed in Denmark at present. Never-
theless, surrogacy and ART after the age of 45 in the woman
is not allowed. Doctors are not allowed to perform
insemination of lesbian couples. Oocyte donation is
restricted to women undergoing IVF owing to their own
infertility. Gamete donors are guaranteed anonymity, if
insemination or oocyte donation is provided by profes-
sional medical services. The issue of whether a child has a
right to know its genetic parents has been actually debated
also in Denmark. The Danish Council of Ethics has
published several reports on issues relating to ART and
genetics, inter alia, it has addressed thoroughly the issue of
anonymity and selection in the context of sperm donation
in its report of 2002.234
The National Board of Health has issued guidelines of the
tests a donor has to undergo before use of his sperm (tests
include HIV, syphilis and gonorrhoea, and hereditary
disorders that can be detected). Donor’s phenotype can
be considered when choosing sperm for recipient to allow
preferences of ethnic and familial similarity. Private sperm
banks have also used other personal counter-selection
criteria, such as personality, motives and physical appear-
ance, which are not supported by legislation, though.
A Health Technology Assessment report, covering tech-
nological, patient-related, ethical and health economic
aspects of PGD was published in 2002 under the auspices of
the National Board of Health.10 After law amendment in
2004, the National Board of Health can give a license to use
PGD for HLA matching upon consideration case by case.
PGD for severe inherited diseases and for aneuploidy
screening is allowed within the framework of a research
protocol, approved by the research ethics committee
system. A more general allowance is presently under
consideration.
Embryonic stem cell research is allowed, and stem cell
lines may be produced from excess embryos from IVF
treatments, after ethical permission and informed consent
from the couple.
Denmark has ratified the Convention on Human Rights
and Biomedicine in 1999.
Finland
In the absence of legislation on ART, Finland has until
now offered a very high level and broad access to ART
subject to professional ethical standards, under license of
the National Authority for Medicolegal Affairs (TEO).
However, the new public healthcare project will bring
some limitations to the access in the public sector or to
reimbursement in the private sector (prognosis, age of
woman, number of cycles), as all the treatments are as of
March 2005 subject to a specific relevance criteria (point
award system). Similar system is used at least in the New
Zealand. Moreover, the largely debated governmental
proposition of 2002 for legislation on assisted reproduction
will be presented again to the Parliament during 2006. The
proposal was withdrawn after the first presentation, as
certain controversial issues could not be resolved, mainly
the right of homosexuals and single women to get fertility
treatment, and donor identity. Under the proposal access
to treatments are targeted for involuntary childlessness
owing to medical reasons and prevention of certain severe
hereditary illnesses (PGD). Also, single women and lesbian
couples are suggested to have a right to ART. Donor
anonymity will be abolished. The law would not rule of the
techniques as such. Basically all the treatments would be
allowed, as long they are scientifically justified. Same
donor could be used five times plus siblings.
Finland has signed, but not ratified, the Convention on
Human Rights and Biomedicine.
France
In France le code civil and le code de la sante´ publique
contain provisions of the bioethical issues. ART-related
issues became regulated by the Laws on Bioethics passed in
1994. Legal framework in France is considered to be
situated in the middle course among other European laws.
A recent large amendment to the current law (Loi n1 2004–
800 du 6 aouˆt 2004 relative a` la bioe´thique) stipulates very
thoroughly on ART. The authorities under this law are
Comite´ consultatif national d’e´thique pour les sciences de
la vie et de la sante´ (CCNE) and a new ‘Agence de
Biomedicine’ that substitutes the former ‘Etablissement
francais des greffes’. Annual reports from centres are
required to be submitted to the Agency, which has at its
aim to oversee ART issues. CCNE has issued several relevant
opinions on the subject matter.
The law permits many forms of ART and related
techniques, but under the surveillance of Agence de
Biomedicine and only to heterosexual couples on ther-
apeutical medical grounds. The law can be considered a
predecessor in an ethically difficult situation of PGD-HLA,
as it enables ‘saviour sibling’ with a consent of l’Agence de
Biomedicine (Article L. 2131-4-1). PGS, however, is not
allowed. The new law allows furthermore research on
surplus embryos with no implantation potential under the
consent of the parents. Both therapeutic and reproductive
cloning remained prohibited. Surrogacy is forbidden as
well. Gamete and embryo donations are allowed. Social
security policy covers the main costs of the necessary ART
treatments.
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France has signed, but not ratified, the Convention on
Human Rights and Biomedicine in 1997.
Germany
In Germany ART are governed by the Embryo Protection
Act of 1990 (Embryonenschutzgesetz, EschG). This law
declares different types and uses of ART to be criminal and
thereby formulates very restrictive policies. EschG fully
prohibits oocyte donation, embryo donation and declares
the transfer of more than three embryos to a woman
within a cycle to be a punishable offence. It also prohibits
the creation of an embryo for any other purpose than
transferring it to a woman from whom the oocyte comes in
order to induce pregnancy. Any research on embryos and
totipotent cells is criminalised. Deriving stem cells from
embryos for research purposes is forbidden by EschG.
The Stem Cell Act (Stammzellengesetz, StZG) was
adopted in 2002. Regulation is somewhat controversial,
as EschG forbids deriving the stem cells from embryos, but
StZG allows their import in certain conditions for research
purposes.
The German Medical Chamber has given the Guidelines
on Assisted Reproduction, which have legally binding
character.
Consequently, the German regime regarding ART can be
considered very restrictive. The protection of the embryo is
emphasised. The access to ART is limited to marital status
and sexual orientation, on a case-by-case basis, to stable
unmarried couples. Insurance coverage for married couples
is relatively broad, but denied for unmarried couples, if
granted access.245
Manipulation of the embryo after syngamy of the two
pronuclei is not allowed in Germany. The law as such does
not forbid PGD, but the way it is interpreted at the
moment prevents performance of PGD on cleavage stage
embryos and blastocysts, whereas PGD on polar bodies is
applied in Germany. Whether polar body biopsy violates
the meaning of the law is debated.83 The German National
Ethics Committee has addressed the issue of PGD
in its opinion of 2003.84 Recent surveillance indicates that
the public opinion is in favour of allowing PGD in
Germany.125
Germany has not signed the Convention on Human
Rights and Biomedicine.
Greece
Greece has since 2002 a legal framework on ART. The first
law (Law 3089/23-12-2002) provides broad framework,
wheres the latest one (Law 3305/27-1-2005) provides for
more detailed framework: ART should be applied taking
into account mainly the best interests of the child to be
born; the upper age limit for the woman is 50 years;
informed consent is mandatory after providing detailed
information on all aspect of treatment; the number of
embryos to be transferred is limited: in women up to 40
years up to three embryos and over 40 years up to four
embryos. Furthermore, the law allows PGD, PGS and
emrbryo research after the approval from the Authority.
An independent ART authority is established to oversee the
whole field. It audits and licences the ART Centres and
Cryobanks, renews the licences, gives permission for
specific techniques and research, etc. For violations of the
two laws, there are specific penalties. ART will be covered
by the state insurances.
Greece has ratified the Convention on Human Rights
and Biomedicine in 1998.
Italy
ART procedures have experienced 20 years of activity in
this field, with more than 10 000 couples who have been
treated. Although a wide debate in the field was present
from long time no specific law was present and only in
2004, the first law on medically assisted reproduction has
been approved by the Italian parliament. This law is said to
be the most restrictive in Europe. The law has been
criticised both in and outside of the country because of
its excessive concern with the status of embryos in
comparison to the interests of women and infertile
couples.246 Donation of embryos and gametes is banned,
as well as cryopreservation. A maximum of three oocytes
can be fertilised and every embryo, without testing, has to
be transferred into uterus regardless of the quality of the
embryo. PGD is absolutely prohibited. In this new situa-
tion, nonsterile couples at high genetic risk have started to
seek PGD abroad.126,220 The ART procedures performed
within public hospitals follow the same rules of the other
medical treatments within the National Health System.
The centres needs to fulfil the accreditation criteria
according to the national law, but are more specifically
regulated by Guidelines on Assisted Reproduction ap-
proved by each regional government.
The existing IVF embryos in frozen storage in Italy will
be put up ‘for adoption’ if unclaimed, and a storage facility
has been set up as a national centre in Milan.
A complete change of the law was asked in the spring
2005, but the national consultation ‘referendum’ did not
reach the number of votes needed, and therefore the
request has been rejected. A national debate is still present
and there is quite a wide opinion than less radical changes
could improve the present law.
Italy has signed, but not ratified, the Convention on
Human Rights and Biomedicine in 1997.
The Netherlands
The Netherlands has several laws and decrees to rule ART
issues: Law on special medical acts (Wet op Bijzondere
Medische Verrichtingen WBMV) rules that certain medical
acts are forbidden, unless the Minister of Public Health,
Welfare and Sports granted a licence. IVF, for instance, is
subject to a licence (Decision specifying WBMV). Planning
Decree on In Vitro Fertilisation of 1998, based on WBMV,
set the maximum of 13 IVF centres in the country and
determines that IVF should be performed according to the
Guideline ‘indication IVF’ of the Dutch Association of
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Obstetrics and Gynaecology of 1998. Moreover, IVF should
follow the protocol as referred to in Article 2 of the Embryo
Act of 2002. The Embryo Act sets rules for embryos/
gametes used for own pregnancies and addresses the
question what can be carried out with gametes and
embryos when these are not used for own pregnancies
(donation, scientific research, property and rights on
gametes and embryos). Some acts are specifically forbid-
den, for instance, reproductive cloning, the creation of
chimeras, sex selection in the absence of medical indica-
tion and changing the nucleus of germ cells, which will be
used to establish a pregnancy (germline gene therapy). The
Embryo Act only specifically prohibits changing the
nucleus of germ cells, therefore leaving open the possibility
of changing DNA outside the nucleus (mitochondria).
The Embryo Act prohibits the creation of embryos for the
sole purpose of research (Article 24a). However, this
prohibition may be temporary because Article 33 states
that Article 24a will expire on a date which will be set by
Royal Decree. At the time Article 24a expires, Article 11 will
automatically enter into force, which would prohibit
research on embryos specifically created for research,
except in cases where research is intended to increase
knowledge on infertility, ART, genetic diseases or trans-
plantation (thus a limited prohibition). Within 5 years of
entering into force of the Embryo Act, a proposal for the
above-mentioned Royal Decree will be made. At the
moment, such proposal has not yet been made, and it is
not to be expected to be made in the very near future
owing to arrangements made between the coalition
partners of the current government. Therefore at the
moment a full prohibition is in force.
Planning Decree on Clinical Genetic Investigation and
Genetic Counselling is also based on the WBMV and
determines that PGD can only be performed with licence of
the Minister. For the time being, the University Hospital
Maastricht is the only centre that is allowed to perform
PGD. The Decree contains specific procedural instructions.
The Central Committee on Research involving Human
Subjects (CCMO) provides advice on procedures and acts as
a monitoring authority. A positive judgement of the
CCMO is needed for PGD, subject to conditions set by
Embryo Act.
As of June 2004, the Netherlands deserted donor
anonymity and AID children will at the age of 16 have
the possibility to find out who their donors are. With
regard to how many children can be conceived by one
donor, the decision is left for donors. Most donors tend to
prefer to donate to four or five women plus siblings.
Medical autonomy is limited through licensing, mon-
itoring and reporting. The ART policy is considered at a
medium position on the dimensions of autonomy and
access.247 The Dutch Association of Obstetrics and Gynae-
cology provides guidelines to be followed. The Minister of
Public Health, Welfare and Sports, the Central Committee
on Research involving Human Subjects (CCMO) and the
Health Council are authoritative bodies advising, licensing
and monitoring medical professionals and institutions
operating in the field, for example, by annual reports and
other procedures. Varying arrangements have been drawn
up concerning the financial aspects of IVF treatment.
The Netherlands has signed the Convention on Human
Rights and Biomedicine in 1997.
Norway
Law on Medical Application of Biotechnology of 1994,
revised in 2003 (Lov om humanmedisinsk bruk av
bioteknologi m. m), is considered rather restrictive. This
law also regulates gene therapy and reproductive technol-
ogy. The access to treatments is limited to medical reasons
and prevention of severe diseases. Marital status or stable
heterosexual relationship is required. Embryos and oocytes
cannot be donated, but sperm donations are allowed.
Surrogates are not allowed. PGD is only allowed in cases of
serious hereditary sex-linked disease with no available
treatment. However, there is a possibility to apply for
exception from the law and recently a couple was allowed
treatment including both PGD and tissue matching in
order to have matching stem cells for a seriously sick
sibling.
The Norwegian Biotechnology Advisory Board
(www.bion.no) has evaluative and advisory role to the
government on all cases involving use of biotechnology.
ICSI has in 2003 been permitted by law and MESA/TESE is
permitted on a temporary basis after application to the
Health Authority. Research on embryos or embryonic stem
cells is not allowed. As of January 2005, donor anonymity
is abolished and the child has a right to know the identity
of the donor when he/she reaches the age of 18. Each
donor can give rise to six children.
Norway has signed the Convention on Human Rights
and Biomedicine in 1997.
Portugal
ART issues in Portugal are regulated by professional
standards, but a law proposal for a broad legislation is
planned, which would include a creation of a technical
Authority on Human Reproduction and Embryology.
At the moment, ART treatments are offered to any adult
(X18 years), heterosexual and stable (economically, so-
cially and psychiatrically) couple, independently of the
legal marriage status. All main central public hospitals offer
ART treatments (five in Porto, one in Coimbra and two in
Lisbon), which are covered by public funds up to four trials.
Public funds, however, do not cover medication used for
ovarian controlled hyperstimulation. Public hospitals
refuse access to women with 439 years. There is no
insurance covering of ART in Portugal.
All centres, public and private, are requested to comply
with ESHRE Guidelines of good medical and laboratory
ART practices. All centres, public and private, are requested
to send each year a full report on procedures, patients,
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cycles of treatments, laboratory results and clinical out-
comes. These data are published each year and sent to
ESHRE.
Provided services compose a broad assortment, including
ICSI and PGD/PGS and also ooplasm transplantation for
mitochondrial diseases. All couples will have a full
diagnostic procedure before a treatment cycle is initiated.
These include the determination of the infertility causes
and all infectious transmissible agents. Karyotypes of the
couples will be detected before ICSI cycles. Y-microdele-
tions are screened in case of severe oligozoospermia or
secretory azoospermia. In case of CBAVD, CFTR screening
is performed and, if positive, the wife is also tested, and if
both positive PGD is offered. In special cases, sperm is
studied for screening aneuploidy (FISH), apoptosis, im-
printing defects and CAG repeats, whereas transmission
electron microscopy is performed if 490% immobility.
Genetic testing is performed under patient-informed
consent. Genetic testing procedures are annually licensed
by the European Molecular Genetic Quality Network
(EMQN).
Portugal provides with oocyte, sperm and embryo
cryopreservation, but also long-term embryo culture in
order to enable blastocyst transfer, which is reported to
decrease the number of frozen embryos, increase the
pregnancy rate and decrease multiple pregnancies (70%
single, 20% double).
Ovary and testicle tissue cryopreservation is offered
before malignancy treatments or in case of TESE.
The rules for embryo transfer are the following: In the
last 4 years (2000–2003), only 7% of the cycles had
cryopreserved surplus embryos. This low number is
owing to a soft ovary hyperstimulation (mean: 6–8
oocytes/cycle). All embryos were later requested for
replacement.
Even though sperm and oocyte donations belong to both
public and private current practice, couples have went to
Spain for DI, because the Portuguese state has not yet
released the necessary funds for building a Portuguese
tissue bank. General rules follow matching based on skin
colour, height, hair, eyes and blood ABO/Rh typing.
Donors are checked by a full personal and family history
(absence of all main known diseases, including oncologist
and psychiatric), absent history of alcohol, tobacco and
drug abuse, and absence of infectious transmissible agents.
In general, the same donor can be used between five to 10
times.
Embryo donation is not accepted in the guidelines, but
in the future law it will be allowed. Surrogacy is not
accepted in the guidelines, but in the future law it may be
allowed for women with congenital malformations and
hysterectomy.
Treatment of single parents and homosexuals (men and
women) and posthumous or postmenopausal conception
are presently not accepted in the guidelines, and there has
been no consensus to accept these couples in the next law
either.
Pregnancy termination is allowed by law if the fetus has
confirmed anatomic or genetic anomalies, or in case of
violation.
It is agreed that creation of human embryos for research
purposes is forbidden.
Research on unviable embryos is authorised, under
patient informed consent.
It is agreed that reproductive cloning should continue to
be forbidden.
Therapeutic cloning and the use of surplus blastocysts to
derive embryonic stem cells for transplantation will be
allowed in the next law.
All centres have closed to access to data bases, with full
protection of personal data. All products, materials and
cells have a traceable system.
Portugal has ratified the Convention on Human Rights
and Biomedicine in 2001.
Spain
Spain was one of the first countries to adapt a law on ART
and on the donation and use of human embryos and
foetuses or their cells, tissue and organs in 1988, which was
also rather liberal despite a strong catholic tradition (Ley
sobre Te´cnicas de Reproduccio´n Asistida: LTRA). The law
was revised in 2003 (45/2003). Basically, any woman can
have access to treatments and a variety of techniques are
available.248 Reimbursement is limited to fertility criteria,
however. Public hospitals have ART units, although a big
amount of services are provided by private clinics. Spain
has been target to reproductive tourism owing to its liberal
policy.126 However, difficulties of integrating new technol-
ogies limit the available treatments in practise. Spain along
with Belgium and Greece are the only European countries
to allow posthumous insemination. PGD is allowed.
The Spanish legislation authorises research using unvi-
able embryos, so that the main problem regards the
concept of viability. The discussion focuses on whether
surplus cryopreserved embryos should be considered
unviable or not, when they have passed their legal date
for use and have been discarded for any parental project, as
their chances of developing in a liquid nitrogen tank are
nil. The National Commission on Assisted Reproduction
and the Observatory of Bioethics and Law, as well as many
scientific groups, have all declared themselves in favour of
this option. The Spanish government has in 2004 formally
approved a decree clarifying the country’s laws on human
embryonic stem (ES) cell research.
The government of Spain will try to approve before the
end of 2005 a new law on assisted reproduction in which
PGD for tissue typing, late-onset diseases and susceptibility
genes would be accepted, as well as research with spare
embryos.
Spain has ratified the Convention on Human Rights and
Biomedicine in 1999.
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Sweden
There is no special licensing body of IVF clinics in
Sweden. Half of the clinics are private, and half officially
funded.
Sweden has several laws regulating ART: the Act on
Insemination of 1984 (Lag om insemination), the Act on
IVF of 1988 (Lag om befrukting untanfo¨r kroppen) and the
Act on procedures in research and use of fertilised human
ova of 1991 (Lag om a˚tga¨rder i forsknings – eller
behandlingssyfte med befruktade a¨gg fra˚n ma¨nniska).
Another law that influences ART is the law from 2003
about tissue banks, stating that all cells, tissue, etc that are
traceable and kept for more than 2 months, must be
registered in a national register. The Swedish National
Board of Health and Welfare (Socialstyrelsen) has also
issued several guidelines concerning assisted reproduction
and genetics. For instance, only one embryo shall be
implanted, in ‘special circumstances’ two (eg, older
women, several cycles performed without pregnancy).
Since 2003 oocytes and sperm may be donated to be used
in IVF treatment, although only at University Hospital-
based clinics (ie, not at private). Embryo donation is not
allowed. Since 1985, the donors are identifiable to children
when they reach maturity. This has caused a variable
shortage of donors. Each donor may give rise to six
children plus siblings. Some patients still seek treatments
abroad, mainly in the Denmark and also in Finland. A law
amendment in summer of 2005 allows DI also to lesbian
couples. Until that, access to ART treatments was limited to
stable heterosexual couples.
The Swedish National Council on Medical Ethics (SMER)
issued an opinion of PGD in The Swedish national council
on medical ethics,249 when new indications for PGD kept
on appearing. PGD has been performed in two clinics, one
in Stockholm and one in Gothenburg. The Swedish
Parliament set rather restrictive guidelines on PGD in
1995, which since then has ruled the practise. The
indication criteria have been limited to serious, life
threatening and incurable diseases. The Council now
proposes a framework law governing PGD, which would
follow the existing guidelines of the Parliament. This
proposal suggests a more liberal use of PGD for medical
purposes, but PGS only for research purposes, after
permission from an ethical committee.
Embryonic stem cell research is allowed, and stem cell
lines may be produced from excess embryos from IVF
treatments, after ethical permission and informed consent
from the couple.
Sweden has signed, but not ratified, the Convention on
Human Rights and Biomedicine in 1997.
Switzerland
The Swiss Reproductive Medicine Act of 1998, in force
since January 2001 (Fortpflanzungsmedizingesetz
(FmedG)/Loi fe´de´rale sur la procre´ation me´dicalement
assiste´e (LPMA)/Legge sulla medicina della procreazione
(LPAM) of and Reproductive Medicine Ordinance
of 2000, in force since January 2001 (Fortpflanzungsmedi-
zinverordnung/Ordonnance sur la procre´ation me´dicale-
ment assiste´e/Ordinanza sulla medicina della
procreazione), govern the conditions under which medi-
cally assisted human reproduction is permissible in
Switzerland. The Act declares the welfare of the child to
be its primary principle, and requires every couple seeking
treatment to undergo a comprehensive counselling
process.
The fertilisation of an oocyte outside the female body is
used extensively to start pregnancy. No more than three
embryos may be produced per treatment cycle in order to
prevent large-scale multiple pregnancies and the creation
of surplus embryos. Data on the sperm donor are held at
the Federal Civil Registry Office and must be made
available to children conceived using this process.
The practice of medically assisted reproductive techni-
ques requires a licence, as does the conservation of gametes
and fertilised ova. Persons holding a licence are subject to a
reporting obligation and the cantons must also maintain
constant supervision over their activities.
The law prohibits preservation of embryos, oocyte
donation, surrogacy and in vitro genetic testing of embryos
(PGD). Polar body diagnosis is not forbidden, though, and
a parliamentary committee has mandated the Swiss
government to examine whether the interdiction of PGD
should be changed. The improper collection of embryos
and their development outside the female body beyond the
time at which they can become attached to the uterus
lining, as well as germ gene therapy (intervention to alter
the genetic composition of gamete and embryos) and
cloning are also punishable.
A recent amendment in the law allows stem cell research
with surplus embryos.
A National Ethics Commission, appointed by the Federal
Council, monitors scientific developments in the field of
human medicine and draws up recommendations for
medical practice. The commission exists in a purely
advisory capacity. Its secretariat is attached to the Swiss
Federal Office for Public Health.
Switzerland has signed, but not ratified, the Convention
on Human Rights and Biomedicine in 1999.
The United Kingdom
The Human Fertilisation and Embryology Act of 1990
regulates some reproductive issues, such as donation and
storage of gametes and embryos as well as creation and use
of embryos outside the woman’s body for both treatment
and research purposes. Any use or storage of embryos and
gametes conducted outside the terms of a licence is
criminalised. The Act stipulated of the formation of the
Human Fertilisation and Embryology Authority (HFEA),
which is a statutory regulatory and licensing body. HFEA
has published the 6th edition of very specific Code of
Practise regarding the practise of ART (http://www.hfea.gov.
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uk/HFEAPublications/CodeofPractice). The Act will be
reviewed by the Government in order to bring it up to
date with the new techniques (Hansard Society’s report
2004/UK House of Commons/Science and Technologies
Committee).
The HFE Act has initiated the HFEA to take into the Code
of Practice provisions on how to consider the welfare of the
child, for example, parental capacity to bring up a child
and social and psychological environment, etc. The United
Kingdom removed the anonymity of the donor in April
2005, allowing thus a child to know its biological parent
when reaching maturity. Semen donated before April 2005
from anonymous donors may be used for treatment until
April 2006. This has caused a lot of concern as is feared it
will lead to a shortage of sperm. As of April 2006, treatment
with anonymous sperm is no longer allowed.
In the UK, for instance, only minority of the IVF clinics
are licensed to freeze oocytes, because few requests have
been received.
The HFEA has in November 2004 launched a public
consultation on sperm, egg and embryo donation. The
online web consultation (www.hfea.gov.uk), entitled ‘The
Regulation of Donor Assisted Conception’, is seeking views
on issues such as limits on the number of children per
donor, how donor’s characteristics should be matched with
patients, and how much compensation donors should be
paid. One proposal outlined in the document is to increase
the compensation payment made to oocyte donors, up to
as much as d1000. At the moment they receive d15, plus
‘reasonable expenses’, the same amount as sperm donors.
The consultation forms part of the HFEA’s ongoing SEED
(sperm, egg and embryo donation) review, which includes
a survey of UK clinics and a review of current scientific and
clinical evidence in this area. Over 37 000 children have
now been born in the UK following donor-assisted
conception.
Any clinic wishing to carry out PGD must first obtain a
licence from the HFEA. The HFEA issues licences for PGD
where the embryo is at significant risk of developing a
serious condition. All PGD applications are sent out to a
minimum of two peer reviewers and decisions are taken by
HFEA licence committees who consider all the scientific,
legal, ethical and medical information. On July 2004, HFEA
decided to extend the rules allowing embryos to be tested
in order for families to have a child who could be a tissue
match for a seriously ill brother or sister. According to Suzi
Leather, HFEA Chair ‘Our review of the evidence available
does not indicate that the embryo biopsy procedure
disadvantages resulting babies compared to other IVF
babies. It also shows that the risks associated with sibling
to sibling stem cell donation are low and that this
treatment can benefit the whole family.’
HFEA has issued a preimplantation genetic diagnosis
(PGD) licence for Familial Adenomatous Polyposis Coli
(FAP) to the Assisted Conception Unit at University College
Hospital, London. HFEA has informed of the fresh report
Assisted reproduction: a safe, sound future issued on 23
November 2004 by the Medical Research Council (MRC).
The HFEA approached the MRC in 2002 to review the
current knowledge of IVF and its possible health effects and
provide advice on what further research is necessary.
Human Genetics Commission (HGC) has in 2004 started
preparing a report to the UK Government and arranged an
open consultation on genetics and reproductive decision-
making (Human Genetics Commission: Chooosing the
future, 2004). The discussion paper summarised informa-
tion and views so far considered, and was a base for public
discussion and comments. Questions asked concern pre-
natal screening; counselling; risk of disrespect towards
disabled owing to option to prevent birth of affected
children; and PGD and its indications and choosing
characteristics of a donor for a child. People were also
encouraged to freely present issues and concerns of ART
and genetics (www.hgc.gov.uk).
United Kingdom has not signed the Convention on
Human Rights and Biomedicine.
TRANS-ATLANTIC
Canada
Canada’s new Assisted Human Reproduction Act (AHRA)
of 2004 has been considered as to constitute a successful
legislation on human genetic and reproductive technolo-
gies. As Canada is said to have a tradition of consensus
politics, the new law required hard work and political
sophistication. The AHRA will review the law after
3 years experience, which enabled many who were
not completely satisfied with the law to support it none-
theless. (Source: the website of the Center for Genetics and
Society).
The new law set clear lines between beneficial applica-
tions subject to development, and prohibited unacceptable
applications of new human genetic and reproductive
technologies. The prohibited practices include: The crea-
tion of human embryos solely for research; germline
engineering (ie, inheritable genetic modification); the
creation of human/non-human hybrids and chimeras; all
use of somatic cell nuclear transfer (cloning), whether for
research or reproduction; sex selection except to prevent,
diagnose or treat a sex-linked disorder or disease; and
commercial surrogate motherhood contracts and the sale
of sperm, eggs and embryos.
Research involving human embryos, including embryo-
nic stem cell research, is permitted using embryos created
but not used during in vitro fertilization procedures. The
AHRA establishes the Assisted Human Reproduction
Agency of Canada (AHRAC) to develop and oversee
regulations covering these and other permitted activities.
The AHRAC is to license and monitor all private and public
fertility clinics, research facilities and other institutions
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whose research or commercial activity involves human
gametes or embryos.
USA
There is only one federal statute that aims at the
regulation of assisted reproduction: the Fertility Clinic
Success Rate and Certification Act of 1992. The purposes of
the statute and its related regulations are two-fold: (1) to
provide consumers with reliable and useful information
about the efficacy of ART services offered by fertility clinics,
and (2) to provide states with a model certification process
for embryo laboratories. The clinics should give annul
reports to the Society for Assisted Reproductive Technology
(SART), but no penalties are set for the breach. Unlike the
reporting system, adoption of the model programme is
entirely voluntary.203
There is now no direct federal or state regulation of
either PGD or sperm sorting as such. Three federal agencies
within the US Department of Health and Human Services
oversee areas related to PGD: the Centers for Disease
Control and Prevention (CDC), the Food and Drug
Administration (FDA) and the Center for Medicare and
Medicaid Services (CMS, formerly known as the Health
Care Financing Administration).
In 2003, two relevant Bills were introduced in the House
of Representatives: a bill as to the Family Building Act (HR
3014 IH) and the Medicare Infertility Coverage Act (HR 969
IH). However, these were not yet approved in December
2004. The Family Building Act aims to amend the Public
Health Service Act and some other statutes in order to
require coverage for the treatment of infertility, as the
majority of the present group health plans do not provide
coverage. One requirement is that the treatment is
performed at a medical facility that conforms to the
standards of ASRM. Under the Medicare Infertility Cover-
age Act, the approved technology procedures would be
artificial insemination, IVF, embryo transfer, GIFT, intra-
vaginal, intracervical and intrauterine inseminations, any
other ART procedure identified by the Secretary as well as
services and supplies related to such procedures.
The President’s Council on Bioethics (PCBE) has on March
2004 published a report ‘Reproduction and responsibility:
the regulation of new biotechnologies’, which provides
with the following information: there are a variety of state
laws that bear directly on the clinical practice of assisted
reproduction. The vast majority of state statutes directly
concerned with assisted reproduction, however, are con-
cerned mostly with the question of access to such services.
These states have legislative directives as to whether and to
what extent assisted reproduction services will be covered
as insurance benefits. Other state statutes regarding
assisted reproduction aim to prevent the malfeasance of
rogue practitioners (eg, California criminalises un-
authorised use of sperm, ova and embryos). Still others
focus on the regulation of gamete and embryo donation
(eg, California sets forth screening requirements for
donated sperm). Many of the state laws dictate parental
rights and obligations in the context of assisted reproduc-
tion. There are a number of state and federal governmental
authorities that do not explicitly aim at the regulation of
ART, but indirectly and incidentally provide some measure
of oversight and direction.
American Association of Reproductive Medicine (ASRM) is an
organisation of close to 9000 physicians, researchers,
nurses, technicians and other professionals dedicated to
advancing knowledge and expertise in reproductive biol-
ogy. Affiliated societies include the Society for Assisted
Reproductive Technology (SART), The Society for Male
Reproduction and Urology, the Society for Reproductive
Endocrinology and Infertility, and the Society of Repro-
ductive Surgeons.
The key sources of nongovernmental guidance and
oversight for the practice of assisted reproduction are the
standards propounded by ASRM, published in conjunction
with its sister organization, SART. SART clinics must agree
to adhere to these guidelines as a condition of the
membership. SART additionally requires certification of
its members’ embryo labs by the College of American
Pathologists, JCAHO, or the New York State Tissue Bank
program. Moreover, SART requires its members to comply
with the reporting provisions of the federal Fertility Clinic
Success Rate and Certification Act. According to SART’s
website, 95% of the nation’s assisted reproduction clinics
are SART members. The practice guidance documents
provide direction as to minimal standards for IVF (such
as personnel requirements, laboratory requirements, qual-
ity assurance and control standards). Specific examples of
subjects covered by such documents include guidelines for
gamete and embryo donation (ASRM 2002), ICSI, informed
consent, induction of ovarian follicle development and
ovulation with exogenous gonadotropins, number of
embryos transferred and preimplantation genetic diagno-
sis. Practice committees also evaluate novel procedures.
These committees review the existing literature on rando-
mised clinical trials. If two peer-reviewed published studies
show that the risk–benefit ratio is acceptable, the proce-
dure is elevated from ‘experimental’ to ‘practice’. ICSI has
been elevated to practice status in this way, as have PGD
and blastocyst transfer. ASRM ‘actively discourages’ some
procedures on ethical grounds, for example, PGD for
elective sex selection, oocyte donation after natural
menopause, posthumous reproduction in the absence of
advance directives and cloning for reproduction.203
ASRM Ethics Committee supports disclosure from
parents to their offspring about the use of donor gametes
in their conception (Fertility and Sterility 2004; 81:
527–531).
The Hastings Centre’s report discusses how new techniques
at the intersection of reproductive medicine and genetics
raise complex ethical questions that should not be resolved
by a largely unregulated market. Rather, they demand
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policies that have been publicly and transparently devel-
oped.19
RELIGIOUS PERSPECTIVES
In a pluralistic Europe, it is important to recognise different
religious approaches to ART issues. Even the Christian
world does not share same opinions. For instance, the
Vatican does not approve assisted reproduction, whereas
Protestant and Anglican churches accept many forms of
ART.250
Islamic world
A Muslim woman is entitled, and even expected, to seek
medical fertility treatment and use new technologies in
case she is childless. However, third-party assistance shall
not be used and therefore donations of germ cells or
surrogacy are not allowed in Islam. Embryos can be
preserved, but they may be used only for the same couple.
The basic concept of Islam is to avoid mixing genes, as
Islam enjoins the purity of genes and heredity. It deems that
each child should relate to a known father and mother.
Multifetal pregnancy reduction is allowed, if it would
endanger the pregnancy or if the life or health of the
mother is jeopardy. Pregnancy in the postmenopause using
donated oocytes is ethically unacceptable and is in general
prohibited unless very exceptional reasons.
Islamic opinions vary as to whether elective abortion is
allowed or not. In most cases, however, a pregnancy can be
terminated if the foetus is found affected before 120 days of
pregnancy.251 PGD for medical indications is allowed.
A former head of the Al-Azhar Mosque and University,
Shaykh Mahmud Shaltut as cited by Abul Fadl Mohsin
Ebrahim (1988) released a fatwa (religious decree) that
condemns the act of DI and equates it to committing
adultery. This fatwa is still in force.
The Fatwas from Al-Azhar, the Islamic Fikh Council in
Mecca and the Church of Alexandria issued guidelines,
which were adopted by the National Medical Councils and
Ministries of Health in the various countries in the 1980s.
The guidelines controlled the practices of ART centres and
encouraged couples to seek infertility treatment if there
was a medical indication.252 Recent debates and confer-
ence addressed new practices of ART in 2004, which were
basically consistent with the previous guidelines
International Islamic Centre for Population Studies and
Research, Al-Azhar University, Cairo, organised a workshop
in November 2000 to consider use of assisted reproduction
technologies (ART) in the Islamic world. The ‘Cairo
workshop’ reinforced a 1997 recommendation that a
Standing Committee for Shari’s Medical Ethics be con-
stituted to monitor and assess developments in ART
practice. Among issues the workshop addressed were
equitable access to services for infertile couples of modest
means, and regulation of standards of equipment and
personnel that ART centres should satisfy to gain approval
to offer services. Acceptable uses of PGD were proposed,
and follicular maturation research in animals, including in
vitro maturation and in vitro growth of oocytes, was
encouraged, leading to human applications. Embryo
implantation after the death of the husband, postmeno-
pausal pregnancy, uterine transplantation and gene ther-
apy were addressed and human reproductive cloning
condemned, but cloning human embryos for stem cell
research was considered acceptable.252
Israel
Israel has the world’s highest per capita rate of IVF
clinics. Diverse cultural values affect fertility rates among
the population and attitudes towards assisted conception.
The duty of procreation, ‘be fruitful and multiply’, is the
first commandment of the Jewish Torah. Many forms of
ART are available,253 including PGD, even though many
rabbinical authorities disapprove the use of donor gametes.
In the Jewish Law, interruption of pregnancy is forbidden
after the 40th day of pregnancy and therefore the ultra-
Orthodox community only rarely use the prenatal tests.251
PGD is allowed.
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Glossary and abbreviations
1. Glossary and definitions
ART: Assisted Reproductive Technology.
Treatments or procedures with the
aim at helping to establish a preg-
nancy by in vitro handling of
human oocytes, sperm and embryos.
This includes: in vitro fertilization
(IVF), gamete intrafallopian trans-
fer (GIFT), zygote intrafallopian
transfer (ZIFT), gamete and embryo
donation, cryopreservation and
gestational surrogacy. ART does
not include assisted/artificial inse-
mination (AI) using sperm from
either a woman’s partner or a
sperm donor (WHO18, Glossary).
Assisted hatching: In vitro micromanipulation
procedure in which the zona
pellucida of an embryo (usually at
eight-cell stage or a blastocyst) is
perforated by chemical, mechani-
cal or laser-assisted methods to
assist separation (‘hatching’) of
the blastocyst from the zona
pellucida.5
CGH: Comparative genome hybridisa-
tion, an analysing method to de-
tect genomic imbalances.
Cryopreservation: Freezing the gametes or the embryo
has helped to make the IVF treat-
ment more flexible. However, in
particular, oocytes suffer from this
procedure. All stages of an embryo
from the zygote (two pronucleate)
stage to the blastocyst stage can be
cryopreserved.
DI: Donor insemination.
FISH: Fluorescence in situ hybridisation,
an analysing method to detect
chromosomal anomalies.
GIFT: Gamete intrafallopian transfer.
Both types of gametes (sperm and
oocytes) are transferred to the
fallopian tubes.
HLA: Human leukocyte antigen.
ICSI: Intracytoplasmic sperm injection.
Method to assist fertilisation, var-
iant of IVF. A single spermatozoon
is injected through the zona
pellucida into the ooplasm of the
oocyte. ICSI is indicated in cases of
severe male-factor infertility, in
which male patients have either
malformed sperm or an abnormally
low sperm count, and in cases of
previous failed fertilisation with
conventional IVF.
IVF: In vitro fertilization. Method used
to assist fertilisation and help a
couple achieve a pregnancy. The
woman is superovulated to pro-
duce multiple oocytes, which are
collected and mixed with sperm.
After fertilisation, the oocytes are
kept in culture. Usually, one to two
resulting embryos are transferred to
the uterus between days 2 and 5 of
development. Indications include
blocked fallopian tubes, infertility
of unknown cause, etc.
MESA: Microscopic epididymal sperm as-
piration, a procedure in which
spermatozoa is obtained from the
epididymis by surgical excision.
PCR: Polymerase chain reaction (a
method that can be used in PGD
for analysing genes in cases of
monogenic diseases).
PESA: Percutaneous epididymal sperm as-
piration, where sperm are aspirated
from the epididymis using needle
biopsy.
PGD: Preimplantation genetic diagnosis.
Method used to determine a specific
abnormality in embryos generated
by parents carrying that abnorma-
lity. Indications include patients
carrying X-linked disease, monogenic
disorders and chromosomal abnorm-
alities such as translocations, etc.
PGS: Preimplantation genetic screening
(for aneuploidy). Method used to
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identify the most chromosomally
normal embryo for transfer in an
IVF/ICSI cycle. Usually, between
five and nine chromosomes are
examined.
PND: Prenatal diagnosis is a (molecular,
cytogenetic, biochemical) diagnos-
tic test carried out on a developing
foetus after amniocentesis, chorio-
nic villus sampling or foetal blood
sampling.
SET: Single embryo transfer (eSET elec-
tive SET).
TESA: Testicular sperm aspiration. Sper-
matozoa is obtained directly from
the testicle, by needle aspiration of
testicular tissue.
TESE: Testicular sperm extraction, where
spermatozoa is obtained from the
testicle by use of surgical excision.
TVOD: Transvaginal ovarian drilling, a
surgical treatment for polycystic
ovary syndrome to improve the
clinical outcome in ART.
ZIFT: Zygote intrafallopian transfer. The
zygote is transferred into the fallo-
pian tube in its pronuclear stage of
development. In ZIFT, the embryo
is placed (via laparoscopy) directly
into the fallopian tube, rather than
into the uterus. In this way, it is
similar to the transfer of gametes in
GIFT. Some opt for ZIFT on the
theory that it enhances the like-
lihood of implantation, given that
the embryo matures on its way to
the uterus, presumably as it would
in natural conception and implan-
tation. Additionally, many patients
prefer ZIFT to GIFT because the
process of fertilization and early
development of the embryo may be
monitored.
ZP: Zona pellucida.
2. Institutions and organisations and their
websites
ASRM: American Society for Reproductive Medi-
cine, www.asrm.org
CCNE: Comite´ counsultatif national d’e´thique
pour les sciences de la vie et de la sante´,
www.ccne-ethique.fr
CIOMS: Council for International Organizations
of Medical Sciences, www.cioms.ch
COE: Council of Europe, www.coe.int
EDDNAL: European Directory of DNA Diagnostic
Laboratories, www.eddnal.com
EGE: European Group on Ethics in Science and
New Developments, http://europa.eu.int/
comm/european_group_ethics/index_en.
htm
EMQN: European Molecular Genetics Quality
Network, www.emgn.org/emgn.php
ESHG: European Society of Human Genetics
www.eshg.org
ESHRE: European Society of Human Reproduc-
tion and Embryology www.eshre.com
Ethikrat: German National Ethics Council,
www.ethikat.org
EUROCAT: European Registration of Congenital
Anomalies, www.eurocat.ulster.ac.uk
EURORDIS: European Organisation of Rare Diseases,
www.eurordis.com
GIG: Genetic Interest Group, www.gig.org.uk
HGC: Human Genetics Commission,
www.hgc.gov.uk
HFEA: Human Fertilisation and Embryology
Authority, www.hfea.gov.uk
IBC: International Bioethics Committee,
www.unesco.org/shs/bioethics
ICBDSR: International Clearinghouse for Birth
Defects Research and Surveillance,
www.icbd.org
IFFS: International Federation of Fertility So-
cieties, www.iffs-reproduction.org
IPTS: Institute for Prospective Technological
Studies, www.jrc.es
JCR: Joint Research Center, www.jcr.coe.eu.int
PCBE: President’s Council on Bioethics,
www.bioethics.gov
PGDIS: Preimplantation Genetic Diagnosis Inter-
national Society, www.pgdis.org
WHO: World Health Organisation, www.who.
int
WMA: World Medical Association, www.wma.
net
UNESCO: United Nations Educational, Scientific
and Cultural Organisation, www.portal.
unesco.org
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